EP2513066A1 - Sphingosine kinase inhibitors - Google Patents

Abstract

The invention relates to compounds of formula (I), where R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, M_1, M₂, M₃, M₄, Y₁, Y₂, V, W, n, m and o have the meanings specified herein, and to the physiologically compatible salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including the mixtures thereof in all ratios, for use in the treatment of diseases that are influenced by inhibiting sphingosine kinase 1.

Description

 Inhibitors of sphingosine kinase

description

Technical area

 The present invention relates to inhibitors of sphingosine kinase and their physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, including mixtures thereof in all ratios

Use in the treatment of diseases that are affected by inhibition of Sph kinase 1.

Background of the invention

 The invention was based on the object, new compounds with valuable

Find properties, especially those that can be used for the production of medicines.

The present invention relates to compounds and the use of

Compounds for the treatment of diseases associated with an increase in

Sphingosinphosphatspiegels go, also pharmaceutical

Compositions containing these compounds.

In particular, the present invention relates to compounds of formula (I) which preferentially inhibit the enzyme sphingosine kinase 1, which regulates sphingosine phosphate levels by phosphorylation of sphingosine, compositions containing these compounds, and methods for their use in the treatment of diseases and conditions such as cancer, tumorigenesis, growth and spread, arteriosclerosis, eye diseases, choroidal neovascularization and diabetic retinopathy, inflammatory diseases, arthritis, neurodegeneration, restenosis, heart disease, wound healing or graft rejection.

In particular, the compounds according to the invention are suitable for the therapy of cancerous diseases. Sphingosine phosphate belongs to the family of sphingolipids which, in addition to their role as structural building blocks of cell membranes, also perform important functions as extracellular and intracellular signaling molecules. Sphingosine phosphate (S1P) is produced in the cell from sphingomyelin, which is first degraded to ceramide and sphingosine and the latter is phosphorylated by sphingosine kinases. Of the two previously identified sphingosine kinases, sphingosine kinase 1 (SphK1) becomes the larger

Significance attributed to the formation of S1P in serum (Zemann et al., 2006 Blood Vol. 107, page 1454). While ceramide and sphingosine induce cell death and cell growth inhibition (Kolesnick 2002, J Clin Invest Vol 110, page 3;

Ogretmen et al. 2004 Nat Rev Cancer Vol 4, page 604), sphingosine phosphate has an adverse effect on the cell and increases the resistance to apoptosis, cell growth and the release of messengers that increase blood flow

Tissue and thus also of tumors (Cuvilier et al., 1996, Nature Vol 381, page 800, Perez et al., 1997, Nat Med Vol 3, page 1228). The ratio of ceramide and sphingosine on the one hand and S1P on the other, therefore, governs cell growth, and thus inhibiting SphK 1 can not only inhibit the formation of the growth-promoting sphingosine phosphate, but also increase the cellular concentration of the growth-inhibiting molecules ceramide and sphingosine ,

 A variety of cellular effects, which are triggered by S1 P, by

Secretion of S1 P and its binding to previously 5 different G protein-coupled receptors (termed S1P _-5 ) mediated. The signal forwarding takes place again over different G proteins (Gj, G _q , G ₁₂ 13), so that a row

different cellular signaling pathways, such as ERK or PI3K are activated, which are particularly important in carcinogenesis and growth. An increasing number of publications also shows that S1P is an important factor in tumor angiogenesis. Angiogenesis is an important process in tumor growth, from which new blood vessels are formed from existing blood vessels, thus ensuring the supply of nutrients to the tumor. For this reason, the inhibition of angiogenesis is an important starting point for cancer and tumor therapy. (Folkman, 2007, Nature Reviews Drug Discovery Vol. 6, pages 273-286). S1P stimulates chemotactic movement of endothelial cells and induces differentiation into multicellular structures, both early steps in the formation of new blood vessels (Lee et al., 1999 Biochem Biophys Res Commun Vol 264 page 325, Argraves et al., 2004 J Biol Chem Vol 279, page 50580 ). In addition, S1 P promotes the migration of bone marrow-derived endothelial progenitor cells to neovascular initiation sites (Annabi et al., 2003, 2003, Hematology Vol 31, 640), and transactivates the receptor of VEGF, one of the most important pro-angiogenic factors, in particular in the

Tumor Biology (Tanimoto et al., 2002 J Biol Chem Vol 277, page 42997, Endo et al., 2002 J Biol Chem Vol 277, page 23747). Direct evidence of the activity of S1 P in tumor angiogenesis could be provided by experiments with an antibody that specifically binds to S1P. The S1P antibody inhibited the migration and vascularization of endothelial cells in vitro, blocked S1P-dependent secretion of pro-angiogenic factors such as VEGF, IL-8, and IL-6 in vitro and in vivo, and significantly reduced the growth of breast, lung, and tumor models and ovaries in mouse xenograft experiments (Visentin 2006 Cancer Cell Vol 9, p. 225).

 In addition, S1P also has intracellular functions, such as the activation of the transcription factor NF-κΒ, which plays a major role in the apoptosis resistance of cancer cells (Xia et al., 2002 J Biol Chem Vol 277, page 7996). However, the intracellular interaction partners of S1P have not yet been identified.

 It concludes that in contrast to an equally conceivable intervention with the carcinogenic effect of S1P by pharmacological blockade of extracellular receptors, inhibition of the enzyme responsible for S1 P formation SphK1 has the advantage, thus also to inhibit the intracellular activities of S1 P. This approach is supported by studies by Xia et al.

(2000 Curr Biol Vol 10, page 1527), showing that non-tumor fibroblasts are transformed by ectopic expression of SphK1 and can form tumors in mice. SphK1 can thus be classified as an oncogene. In different

Expression studies have shown increased levels of SphK1 mRNA in tumor tissues of the brain, breast, lung, ovaries, stomach, uterus, kidneys, and small and large intestines to healthy tissue (French et al., 2003 Cancer Research Vol. 63, page 5962, Johnson et al., 2005, J Histochem Cytochem Vol 53, page 1159, Van Brocklyn, et al., 2005 J Neuropathol Exp Neural Vol 64, page 695). In addition, increased expression of SphK1 correlates with poorer prognosis in patients with glioblastoma multiform (Van Brocklyn et al., 2005 J Neuropathol Exp Neural vol 64 page 695).

 SphK1 plays an important role in the modulation of chemotherapeutic induced apoptosis of cancer cells. So increases through

Overexpression of SphK1 the resistance of breast cancer, prostate cancer and leukemia cells to chemotherapeutic agents such as anthracyclines, docetaxel, Camptothecin or doxorubicin (Nava et al 2002 Exp Cell Res Vol 281 page 115; Pchejetski 2005 Cancer Res Vol 65 p 11667; Bonhoure 2006 Leukemia Vol 20 p 95). It could be shown that the increased presence of SphK1 leads to a shift of the ceramide / S1 P equilibrium in the direction of the

apoptosis resistance-promoting S1 P leads. One possible mechanism is the inhibition of mitochondrial cytochrome C ejection by SphK1, which is usually an early event in programmed cell death (Cuvilier et al 2001 Blood Vol 98 page 2828, Bonhoure 2006 Leukemia Vol 20 page 95).

 Conversely, by targeted blockade of SphK1 expression by siRIMA in tumor cell models of various indications such as leukemia,

 Breast cancer, glioblastoma or prostate cancer trigger apoptosis or increase the efficacy of chemotherapeutic agents (Bonhoure 2006 Leukemia Vol 20 page 95, Taha et al 2004 J Biol Chem Vol 279 page 20546; Taha et al 2006 FASEB J Vol 20 Page 482; Van Brocklyn et al., 2005 J Neuropathol Exp Neural Vol. 64, page 695; Pchejetski, 2005 Cancer Res Vol 65, page 11667).

 In a mouse model it could be shown that overexpression of SphK1 causes degenerative changes of cardiomyocytes and myocardial fibrosis, which increased with increasing age of the experimental animals.

A function of the S1 P signaling pathway in heart diseases is also supported by the fact that in mice in which the expression of the S1 P3 receptor was deliberately suppressed, the formation of cardiovascular fibroses is strongly inhibited (Takuwa 2008 Biochimica and Biophysica Acta in press). In other organs, such as the lungs, S1P also plays a role in the differentiation of fibroblasts into myofibroblasts and thus in the development and progression of fibrous diseases (Kono et al., 2007, J J Respir Cell Mol Biol, page 395).

It has been found that the compounds according to the invention cause specific inhibition of sphingosine kinase 1, but not sphingosine kinase 2. The compounds of the invention preferably exhibit a beneficial biological activity that is detectable in the assays described, for example, herein. In such assays, the compounds of the present invention exhibit and effect an inhibiting effect, usually documented by IC ₅₀ values in a suitable range, preferably in the micromolar range, and more preferably in the nanomolar range. In general, all solid and non-solid tumors can be treated with the compounds of formula (I), such as monocytic leukemia, brain, urogenital, lymphatic, gastric, laryngeal, ovarian, and lung carcinoma, among them

Lung adenocarcinoma and small cell lung carcinoma. Other examples include prostate, pancreatic and breast carcinoma.

 As discussed herein, effects of the compound of the invention are relevant to various diseases. Accordingly, the compounds of the invention are useful in the prophylaxis and / or treatment of diseases that are affected by inhibition of SphK1.

 The subject of the present invention is therefore inventive

 Compounds as medicaments and / or active pharmaceutical ingredients in the treatment and / or prophylaxis of said diseases and the use of

Compounds according to the invention for the preparation of a pharmaceutical for the treatment and / or prophylaxis of said diseases, as well as a method for the treatment of said diseases comprising the administration of one or more compounds of the invention to a patient in need of such administration.

 The host or patient may belong to any mammalian species, e.g. one

Primate species, especially humans; Rodents, including mice, rats and hamsters, rabbits, horses, cattle, dogs, cats, etc. Animal models are of interest for experimental studies, representing a model for the treatment of human disease.

 The sensitivity of a particular cell to treatment with the compounds of the invention can be determined by testing in vitro.

Typically, a culture of the cell is combined with a compound of the invention at various concentrations for a time sufficient to allow the active agents to lower the intracellular S1P concentration and, in addition, to block the secretion of angiogenesis promoting substances or to induce cell death , For testing in vitro, cultured cells from a biopsy specimen or established cancer cell lines expressing SphK1 can be used.

 The dose varies depending on the specific compound used, the specific disease, the patient status, etc. Typically, one

therapeutic dose sufficient to substantially reduce the undesired cell population in the target tissue while maintaining the viability of the patient becomes. The treatment is generally continued until there is a significant reduction, eg, at least about 50% reduction in cell load and can be continued until essentially no more unwanted cells can be detected in the body.

use

As described in the introduction, SphK1, S1P and its

Cell surface receptors S1P _1-5 in a variety of physiological and

pathophysiological processes involved. For this reason, it is expected that the inhibition of SphK1 by the substances described here

various diseases can be used for therapeutic purposes.

 The formation of S1P by SphK1 and the consequent shift in the ceramide / S1P equilibrium, as stated above, result in the cells proliferating more and becoming more resistant to apoptotic stimuli. From this a general function of SphK1 in hyperproliferative diseases such as cancer, psoriasis, restenosis and atherosclerosis can be deduced. The compounds of the formula I underlying this invention which inhibit SphK1 and thus regulate and / or modulate the S1P level, compositions containing these compounds and the processes described can thus be employed for the treatment of these diseases. In general, all solid and non-solid tumors can be treated with the compounds of formula X, e.g. monocytic leukemia, brain, urogenital,

Lymphatic, gastric, laryngeal, ovarian and lung carcinoma, including

Lung adenocarcinoma and small cell lung carcinoma. Other examples include colon, prostate, pancreas and breast carcinoma.

 In addition to the function of cell growth, S1 P also plays a role in the formation of new blood vessels (angiogenesis). In many disease processes, angiogenesis is either causally at the heart of the disease or worsens the progression of the disease. For example, in

In cancer, angiogenesis causes the tumor to enlarge and spread to other organs. Other diseases in which angiogenesis plays an important role are psoriasis, arthrosis, arteriosclerosis and eye diseases such as diabetic retinopathy, age-related macular degeneration, rubeosis iridis or neovascular glaucoma. The basis of this invention compounds of the formula I which inhibit SphK1 and thus regulate and / or modulate the S1P level, compositions containing them

Contain compounds, and the methods described can thus be used for the treatment of these diseases.

Furthermore, SphK1 and S1P influence the proliferation, differentiation, migration and secretion of immune cells (Rosen and Goetzl 2005 Nat Rev Immunol Vol. 5 page 560) and are thus involved in various functions of the immune system

Immune system and involved in inflammatory processes. Stimulation of the

Immune System Enhances S1P Formation and Output in Mast Cells

Platelet cells and some mononuclear phagocytes (Stunff et al 2004 J Cell Biochem Vol 92 p 882, Olivera and Rivera 2005 j Immunol Vol 174 p 1153). The activity of SphK1 is greatly enhanced, in particular, by factors such as tumor necrosis factor (TNF) and cross-linking of IgG receptors (Stunff et al., 2004 J Cell Biochem Vol. 92, page 882, Delon et al., 2004 J Biol Chem Vol 279 page 44763). It has also been shown that SphK1 and S1P are important for the TNF-dependent production of proinflammatory enzymes such as cyclooxygenase-2 (COX-2) and nitric oxide synthase (NOS) (Pettus et al., 2003 FASEB J Vol 17, 1411; et al., 2001 J Biol Chem Vol. 276, pages 10627-33). The compounds of the formula I underlying this invention, which inhibit SphK1 and thus regulate and / or modulate the S1P level,

Compositions containing these compounds as well as the methods described can thus be used for the treatment of inflammatory diseases such as arthrosis, arteriosclerosis, psoriasis, multiple sclerosis, chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis), asthma and other allergic diseases.

Furthermore, the compounds of formula (I) can be used to isolate and study the activity or expression of Sph kinase. In addition, they are particularly suitable for use in diagnostic

Methods of disorders associated with unregulated or impaired Sph kinase activity.

It can be shown that the compounds according to the invention have an in vivo antiproliferative action in a xenograft tumor model. The Compounds of the invention are administered to a patient with a

hyperproliferative disease, e.g. for the inhibition of

Tumor growth, to reduce inflammation associated with a lymphoproliferative disorder, to inhibit graft rejection or neurological damage due to tissue repair, etc. The present compounds are useful for prophylactic or therapeutic purposes. As used herein, the term "treating" is used to refer to both the prevention of disease and the treatment of pre-existing conditions The prevention of proliferation is prevented by the administration of the compounds of the invention against the development of obvious disease, for example to prevent tumor growth, prevent metastasis Growth, the reduction of cardiovascular surgery-related restenosis, etc. Alternatively, the compounds are treated

ongoing diseases used by stabilization or improvement of the clinical symptoms of the patient.

The host or patient may belong to any mammalian species, e.g. a primate species, especially humans; Rodents, including mice, rats and hamsters; Rabbits; Horses, cattle, dogs, cats, etc. Animal models are of interest for experimental investigations, where they are a model for

Provide treatment for a human disease.

The susceptibility of a particular cell to treatment with the compounds of the invention can be determined by testing in vitro. Typically, a culture of the cell is combined with a compound of the invention at various concentrations for a period of time sufficient to allow the active agents to induce cell death or inhibit migration, usually between about one hour and one week. For testing in vitro, cultured cells from a biopsy sample can be used. The viable cells remaining after treatment are then counted.

 The dose will vary depending on the specific compound used, the specific disease, the patient status, etc. Typically, one therapeutic dose will be sufficient to treat the undesired cell population in the human body

Target tissues decrease significantly while the patient's viability is maintained. The treatment is generally continued until there is a significant reduction, eg, at least about 50% reduction in cell load and can be continued until essentially no more unwanted cells are detected in the body.

To identify a signal transduction pathway and to detect interactions between different signal transduction pathways, appropriate models or model systems have been developed by various scientists, e.g. Cell culture models (e.g., Khwaja et al., EMBO, 1997, 16, 2783-93) and models of transgenic animals (e.g., White et al., Oncogene, 2001, 20, 7064-7072). to

Determining particular levels in the signal transduction cascade, interacting compounds can be used to modulate the signal (e.g., Stephens et al., Biochemical J., 2000, 351, 95-105). The compounds according to the invention can also be used as reagents for testing kinase-dependent

Signaling pathways in animals and / or cell culture models or in the clinical diseases mentioned in this application can be used.

To identify a signal transduction pathway and to detect interactions between different signal transduction pathways, appropriate models or model systems have been developed by various scientists, e.g. Cell culture models (e.g., Khwaja et al., EMBO, 1997, 16, 2783-93) and models of transgenic animals (e.g., White et al., Oncogene, 2001, 20, 7064-7072). to

Determining particular levels in the signal transduction cascade, interacting compounds can be used to modulate the signal (e.g., Stephens et al., Biochemical J., 2000, 351, 95-105). The compounds according to the invention can also be used as reagents for testing kinase-dependent

Signaling pathways in animals and / or cell culture models or in the clinical diseases mentioned in this application can be used. The measurement of kinase activity is a technique well known to those skilled in the art.

Generic test systems for the determination of kinase activity with substrates, eg histone (eg Alessi et al., FEBS Lett. 1996, 399, 3, pages 333-338) or the basic myelin protein are described in the literature (eg Campos-Gonzalez, R. and Glenney, Jr., JR 1992, J. Biol. Chem. 267, page 14535). Various assay systems are available for the identification of kinase inhibitors. In the Scintillation Proximity Assay (Sorg et al., J. of Biomolecular Screening, 2002, 7, 11-19) and the FlashPlate assay, the radioactive

Phosphorylation of a protein, peptide or in the case of SphK1 a lipid as a substrate with gamma-ATP measured. In the presence of an inhibitory compound, no or a reduced radioactive signal is detectable. Further, homogenous time-resolved fluorescence resonance energy transfer (HTR-FRET) and fluorescence polarization (FP) technologies are useful as assay methods (Sills et al., J. of Biomolecular Screening, 2002, 191-214).

 Another non-radioactive ELISA assay method uses a specific antibody against S1 P to quantify S1 P (Assay System from Echelon).

There are many diseases associated with deregulation of cell proliferation and cell death (apoptosis). The ailments of interest include, but are not limited to, the following conditions. The compounds of the invention are useful in the treatment of a variety of conditions involving smooth muscle cell proliferation and / or migration and / or

Inflammatory cells in the intimal layer of a vessel is present, resulting in limited blood flow to this vessel, e.g. in neointimal occlusive lesions. Occlusive transplant vascular diseases of interest include atherosclerosis, coronary vascular disease after transplantation,

Venous graft stenosis, peri-anastomotic prosthetic restenosis, restenosis after angioplasty or stent placement, and the like.

State of the art

WO 2005/103022 describes substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators.

 WO 2006/73167 describes pyrrolidine derivatives.

 In WO 2007/100610 pyridine, pyrimidine and pyrazine derivatives are described as CXCR3 receptor modulators.

In US 2007/043083 Thiazolylpiperidine derivatives are described. Summary of the invention

The invention relates to compounds of the formula (I)

 in which, independently of one another, mean:

R ¹ , R ³ , R ⁴ , R ⁵ , R ⁶ R ⁷ , R ⁸ , R ⁹ , R ¹⁰ , R ¹¹ , R ¹² , R ¹³ , R ¹⁴ , R ¹⁵ , R ¹⁶ , R ⁷ H, D (deuterium), A, OR ¹⁸ , CN, F, Cl and NR ¹⁸ R ¹⁸ ;

where R ¹ and R ² , R ³ and R ⁴ , R ⁵ and R ⁶ , R ¹⁰ and R ¹¹ , R ¹² and R ¹³ , R ⁴ and R ⁵ , R ⁶ and R ¹⁷ together are each also = 0 (carbonyl oxygen) can form;

wherein R ⁹ and R ¹ , R ¹ and R ² , R ² and R ³ , R ³ and R ⁴ , R ⁴ and R ⁵ , R ⁵ and R ⁶ , R ⁶ and R ⁷ , R ⁷ and R ⁸ , R ¹⁰ and R ¹¹ , R ¹¹ and R ¹² , R ² and R ¹³ , R ¹⁴ and R ¹⁵ , R ¹⁵ and R ¹⁶ , R ¹⁶ and R ¹⁷ together are each also cyclic alkyl with 3,

4, 5, 6 or 7 carbon atoms or Het with 3, 4, 5, 6 or 7 ring atoms can form;

wherein R ¹⁰ and R ¹⁹ when = CR ¹⁹ , R ¹ and R ¹² , R ¹³ and R ¹⁹ when Y ₂ = CR ¹⁹ , R ¹⁴ and R ⁹ when V = CR ¹⁹ , R ¹⁵ and R ¹⁶ , R ¹⁷ and R ¹⁹ when Y ₂ = CR ¹⁹ together can also form a C = C double bond with the single bond and the carbon atoms to which they are attached;

R ¹⁸ , R ^{18 '} H. D or A;

R ¹⁹ , R ^{19 '} H, D, A, OR ¹⁸ , NR ¹⁸ R ¹⁸ , C (O) OR ¹⁸ , C (O) NR ¹⁸ R ^18' , F, Cl, Br, CN, Het or A-Het ;

ML M ₂ , M ₃ , CR ¹⁹ , N, S or O;

VC (R ¹⁹ ) (R ^{19 '} ), NR ¹⁹ or missing;

WC (R ¹⁹ ) (R ^{19 '} )] _p Z, CO- [C (R ¹⁹ ) (R ^19' )] _p Z, [C (R ¹⁹ ) (R ^{19 '} )] _P N (R ¹⁹ ) Z, CO-N (R ¹⁹ ) - [C (R ⁹ ) (R ^{19 '} )] _p Z, N (R ¹⁹ ) -CO- [C (R ¹⁹ ) (R ^19' )] _p Z, CO- 0- [C (R ¹⁹ ) (R ^{19 '} )] _p Z, C (0) OR ¹⁹ , OR ¹⁹ , H or D; where V, W and Y ₂ together are each also cyclic alkyl having 3, 4, 5, 6 or 7 C atoms, wherein preferably 1, 2, 3, 4, 5, 6 or 7 H atoms by F, Cl, Br , CN and / or OH, OR ¹⁹ , OC (O) R ¹⁹ , NR ¹⁹ C (O) OZ, C (O) OR ¹⁹ ,

C (O) N (R ¹⁹ ) (R ^{19 '} ) or N (R ¹⁹ ) (R ^19' ) may be replaced, or Het with 3, 4, 5, 6 or 7 ring atoms can form, wherein Het preferably a saturated , unsaturated or aromatic heterocycle having 1 to 4 N, O and / or S atoms, which is unsubstituted or mono-, di- or trisubstituted by Hal, F, Cl, Br, CN, A, OR ¹⁸ , W, SR ¹⁸ , N0 ₂ ,

N (R ¹⁹ ) (R ^{19 '} ), NR ¹⁸ COOZ, OCONHZ, NR ¹⁸ S0 ₂ Z, S0 ₂ N (R ¹⁸ ) Z, S (0) _m Z, COZ, CHO, COZ, = S, = NH , = NA, Oxy (-0) and / or = 0

 (Carbonyl oxygen) may be substituted;

 Z Het, Ar or A;

A is unbranched or branched alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, wherein 1, 2, 3, 4, 5, 6 or 7 H atoms by F, Cl , Br, CN and / or OH, OR ¹⁹ , OC (O) R ¹⁹ , NR ¹⁹ C (O) OZ, C (O) OR ¹⁹ ,

C (O) N (R ¹⁹ ) (R ^{19 '} ) or N (R ¹⁹ ) (R ^19' ) may be replaced;

and / or wherein one or two CH ₂ groups are represented by O, S, SO, SO ₂ , CO, COO, NR ¹⁸ , NR ¹⁸ CO, CONR ¹⁸ , cyclic alkyl having 3, 4, 5, 6 or 7 C atoms , CH = CH and / or CH ^ CH groups may be replaced;

or cyclic alkyl having 3, 4, 5, 6 or 7 C atoms, in which 1, 2, 3, 4, 5, 6 or 7 H atoms are represented by F, Cl, Br, CN and / or OH, OR ¹⁹ , OC (O) R ¹⁹ , NR ⁹ C (O) OZ, C (O) OR ¹⁹ , C (O) N (R ¹⁹ ) (R ^{19 '} ) or N (R ¹⁹ ) (R ^19' ) may be replaced ;

Ar is mono-, di- or trisubstituted by Hal, F, Cl, Br, CN, A, OR ¹⁸ , W, SR ¹⁸ , NO ₂ , N (R ¹⁹ ) (R ¹⁹ ), NR ¹⁸ COOZ, OCONHZ, NR ¹⁸ S0 ₂ Z, S0 ₂ N (R ¹⁸⁾ Z, S (0) _m Z, COZ, CHO, COZ substituted phenyl, naphthyl or biphenyl,

Each independently represents a mono-, di- or trinuclear saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and / or S atoms, which is unsubstituted or mono-, di- or trisubstituted by Hal, F, Cl , Br, CN, A, OR ¹⁸ , W, SR ¹⁸ , NO ₂ , N (R ¹⁹ ) (R ^{19 '} ), NR ¹⁸ COOZ, OCONHZ, NR ¹⁸ S0 ₂ Z, S0 ₂ N (R ¹⁸ ) Z, S (0) _m Z, COZ, CHO, COZ, = S, = NH, = NA, Oxy (-0) and / or = 0 (carbonyl oxygen) may be substituted,

m 1, 2 or 3,

n, o is 0, 1 or 2,

p is 0, 1, 2, 3 or 4

with the proviso that compounds of formula (I) are excluded, wherein (a) M ₁ = N, M ₂ = CR ¹⁹ , M ₃ = S, and

(b) Y ₁ = CH and Y ₂ = N, and

 (c) n = 1 and o = 1;

 and their physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, including mixtures thereof in all ratios.

The invention further relates to preferred independent embodiments of compounds according to formula (I), wherein each independently of one another means:

Preferred embodiment (A): R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ R ⁷ , R ⁸ , R ⁹ , R ¹⁰ , R ¹¹ , R ¹² ,

_R 13 _R 14 _R 15 _R 16 _R 17, _, Q p _QR 18 _{or |} - _A;

where R ¹ and R ² , R ³ and R ⁴ , R ⁵ and R ⁶ , R ¹⁰ and R ¹¹ , R ² and R ¹³ , R ¹⁴ and R ¹⁵ , R ¹⁶ and R ¹⁷ together are each also = 0 (carbonyl oxygen) can form;

wherein R ⁹ and R ¹ , R ¹ and R ² , R ² and R ³ , R ³ and R ⁴ , R ⁴ and R ⁵ , R ⁵ and R ⁶ , R ⁶ and R ⁷ , R ⁷ and R ⁸ , R ¹⁰ and R ¹¹ , R ¹¹ and R ¹² , R ¹² and R ¹³ , R ¹⁴ and R ⁵ , R ¹⁵ and R ¹⁶ , R ¹⁶ and R ¹⁷ together are each also cyclic alkyl having 3, 4, 5, 6 or 7 C. Atoms or Het with 3, 4, 5, 6 or 7 ring atoms can form;

Preferred embodiment (B): R ⁹ , R ⁹ H, A, OR ¹⁸ , C (0) OR ¹⁸ ,

C (O) NR ¹⁸ R ^{18 '} , A-Het;

Preferred Embodiment (C): N, and M _{2 is} CR ¹⁹ and M _{3 is} S;

Preferred embodiment (D): ΜN, and M ₂ S and M ₃ CR ¹⁹

Preferred Embodiment (E): Mi O, and M ₂ N and M ₃ CR ¹⁹

Preferred embodiment (F): N, and M ₂ O and M ₃ CR ¹⁹

Preferred Embodiment (G): Mi S, and M ₂ N and M ₃ N;

Preferred Embodiment (H): S, and M ₂ N and M ₃ CR ¹⁹

Preferred Embodiment (I): Mi O, and M ₂ N and M ₃ N;

Preferred Embodiment (J): N, and M ₂ N and M ₃ O;

Preferred embodiment (K): N, and M ₂ N and M ₃ S;

Preferred Embodiment (L): CR ¹⁹ , and M ₂ N and M ₃ O;

Preferred Embodiment (M): CR ¹⁹ , and M ₂ O and M ₃ N;

Preferred Embodiment (N): N, and Y ₂ CR ¹⁹ ;

Preferred Embodiment (O): YN, and Y ₂ N; Preferred Embodiment (P): CR ¹⁹ , and Y ₂ N;

Preferred Embodiment (Q): Y, CR ¹⁹ , and Y ₂ CR ¹⁹ ;

Preferred Embodiment (R): VC (R ¹⁹ ) (R ^{19 '} ), NR ¹⁹ or Missing;

Preferred Embodiment (S): W [C (R ¹⁹ ) (R ^{19 '} )] _p Z, CO- [C (R ¹⁹ ) (R ^19' )] pZ, CO-O- [C (R ⁹ ) (R ^{19 '} )] _p Z, CO-N (R ¹⁹ ) - [C (R ¹⁹ ) (R ^9, )] _p Z, [C (R ¹⁹ ) (R ^9' )] _P N (R ¹⁹ ) -Z , N (R ¹⁹ ) -

CO- [C (R ¹⁹ ) (R ^{19 '} )] _p Z, C (O) OR ¹⁹ , OR ¹⁹ or H; where V, W and Y ₂ together are each also cyclic alkyl having 3, 4, 5, 6 or 7 C atoms, wherein preferably 1, 2, 3, 4, 5, 6 or 7 H atoms by F, Cl, Br , CN and / or OH, OR ¹⁹ , OC (O) R ¹⁹ , NR ¹⁹ C (O) OZ, C (O) OR ¹⁹ , C (O) N (R ¹⁹ ) (R ^{19 '} ) or N (R ¹⁹ ) (R ^{19 '} ) may be replaced, or Het with 3, 4, 5, 6 or 7 ring atoms can form, wherein Het preferably a saturated, unsaturated or aromatic heterocycle having 1 to 4 N-, O- and / or S Represents atoms which is unsubstituted or mono-, di- or trisubstituted by Hal, F, Cl, Br, CN, A, OR ¹⁸ , W, SR ¹⁸ , NO ₂ , N (R ⁹ ) (R ^{19 '} ), NR ¹⁸ COOZ, OCONHZ, NR ¹⁸ S0 ₂ Z, S0 ₂ N (R ¹⁸ ) Z, S (0) _m Z, COZ, CHO, COZ, = S, = NH, = NA, Oxy (-O) and / or = 0 (carbonyl oxygen) may be substituted;

 Preferred Embodiment (T): Z is Het or A;

 Preferred embodiment (U): m 1 or 2;

 Preferred embodiment (V): p 0, 1, 2 or 3;

 and in each case their physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, including mixtures thereof in all ratios.

The invention further relates in a preferred embodiment

Compounds according to formula (I) and preferred illustrated here

Embodiments in which each independently of one another means:

 r »

F, OR ¹⁸ or A;

where R ¹ and R ² , R ³ and R ⁴ , R ⁵ and R ⁶ , R ¹⁰ and R ¹¹ , R ¹² and R ¹³ , R ¹⁴ and R ¹⁵ , R ¹⁶ and R ¹⁷ together are each also = 0 (carbonyl oxygen) can form;

wherein R ⁹ and R ¹ , R ¹ and R ² , R ² and R ³ , R ³ and R ⁴ , R ⁴ and R ⁵ , R ⁵ and R ⁶ , R ⁶ and R ⁷ , R ⁷ and R ⁸ , R ⁰ and R ¹ , R ¹¹ and R ¹² , R ¹² and R ¹³ , R ¹⁴ and R ¹⁵ , R ¹⁵ and R ¹⁶ , R ¹⁶ and R ¹⁷ together are each also cyclic alkyl having 3, 4, 5, 6 or 7 C. Atoms or Het with 3, 4, 5, 6 or 7 ring atoms can form;

R ¹⁹ , R ^{19 '} H, A, OR ¹⁸ , C (O) OR ¹⁸ , C (O) NR ¹⁸ R ^18' , A-Het; M, N, and M _{2 are} CR ¹⁹ and M ₃ S; or

N, and M ₂ S and M ₃ CR ¹⁹ ; or

Mi O, and M ₂ N and M ₃ CR ¹⁹ ; or

M, N, and M ₂ O and M ₃ CR ¹⁹ ; or

Μ _Ί S, and M ₂ N and M ₃ N; or

Mn S, and M ₂ N and M ₃ CR ¹⁹ ; or

Mi O, and M ₂ N and M ₃ N; or

Mi N, and M ₂ N and M ₃ O; or

Mi N, and M ₂ N and M ₃ S; or

Mi CR ¹⁹ , and M ₂ N and M ₃ 0; or

Y ₁ CR ¹⁹ , and Y ₂ N; or

VC (R ¹⁹ ) (R ^{19 '} ), NR ¹⁹ or missing;

W [C (R ¹⁹ ) (R ^{19 '} )] _p Z, CO- [C (R ¹⁹ ) (R ^19' )] _p Z, CO-O- [C (R ¹⁹ ) (R ^{19 '} )] pZ , CO-N (R ¹⁹ ) - [C (R ⁹ ) (R ^{19 '} )] _p Z, [C (R ⁹ ) (R ^19' )] _P N (R ¹⁹ ) -Z, N (R ¹⁹ ) -CO- [C (R ¹⁹ ) (R ^{19 '} )] pZ,

C (0) OR ¹⁹ , OR ⁹ or H;

where V, W and Y ₂ together are each also cyclic alkyl having 3, 4, 5, 6 or 7 C atoms, wherein preferably 1, 2, 3, 4, 5, 6 or 7 H atoms by F, Cl, Br , CN and / or OH, OR ¹⁹ , OC (O) R ¹⁹ , NR ¹⁹ C (O) OZ, C (O) OR ¹⁹ ,

C (O) N (R ¹⁹ ) (R ^{19 '} ) or N (R ¹⁹ ) (R ^19' ) may be replaced, or Het with 3, 4, 5, 6 or 7 ring atoms can form, wherein Het preferably a saturated , unsaturated or aromatic heterocycle having 1 to 4 N, O and / or S atoms, which is unsubstituted or mono-, di- or trisubstituted by Hal, F, Cl, Br, CN, A, OR ¹⁸ , W, SR ¹⁸ , N0 ₂ ,

N (R ¹⁹ ) (R ^{19 '} ), NR ¹⁸ COOZ, OCONHZ, NR ¹⁸ S0 ₂ Z, S0 ₂ N (R ¹⁸ ) Z, S (0) _m Z, COZ, CHO, COZ, = S, = NH , = NA, Oxy (-0) and / or = 0

 (Carbonyl oxygen) may be substituted;

Z Het or A; m is 1 or 2;

 p is 0, 1, 2 or 3;

 and their physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, including mixtures thereof in all

Conditions.

The invention further relates to compounds selected from the group consisting of:

35 





20



and their physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, including mixtures thereof in all

 Conditions.

The invention also provides the precursors of the compounds of the formula (I), medicaments containing these compounds and their use for the treatment of diseases, as described for the compounds of the formula (I).

Compounds of the formula (I) are also understood as meaning the hydrates and solvates of these compounds, and also pharmaceutically usable derivatives.

 The invention also relates to the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds. Solvates of the compounds are understood to mean additions of inert solvent molecules to the compounds which form due to their mutual attraction. Solvates are e.g. Mono or dihydrate or alcoholates.

 Pharmaceutically usable derivatives are understood, for example, as so-called prodrug compounds. Under prodrug derivatives is understood with z. As alkyl or acyl groups, amino acids, sugars or oligopeptides modified compounds of formula (I), which are rapidly cleaved in the organism to the active compounds of the invention. These include biodegradable polymer derivatives of the compounds of the invention, as z. In Int. J. Pharm. 115, 61-67 (1995).

The term "effective amount" means the amount of a drug or pharmaceutical agent that has a biological or medical response in it a tissue, system, animal or human being, for example, sought or sought by a researcher or physician.

 In addition, the term "therapeutically effective amount" means an amount that, as compared to a corresponding subject who has not received that amount, results in:

 improved curative treatment, cure, prevention or elimination of a disease, a clinical picture, a disease state, a condition, a disorder or side effects or even a reduction in the progression of a disease, a condition or a disorder.

 The term "therapeutically effective amount" also includes the amounts effective to increase normal physiological function.

The invention also provides the use of mixtures of

Compounds of the formula I, e.g. Mixtures of two diastereomers, e.g. in the ratio 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1:10, 1: 100 or 1: 1000. These are particularly preferably mixtures of stereoisomeric compounds.

The invention further relates to a process for the preparation of compounds according to the formula (I) and the preferred embodiments and disclosed compounds shown here, as well as their physiologically acceptable salts,

Derivatives, prodrugs, solvates, tautomers and stereoisomers thereof

marked that one

 (a) a compound of the formula (II)

wherein R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ R ⁷ , R ⁸ , R ⁹ and m are those given herein

 Have meanings and meanings given below,

with a compound of the formula (III)

wherein R ¹⁰ , R ¹¹ , R ¹² , R ¹³ , R ⁴ , R ¹⁵ , R ¹⁶ , R ¹⁷ , Y _{1 t} Y ₂ , V, n, and o have the meanings given herein, L _{2 is} the meaning given below has "VH" possibly provided with a protective group ("V-protection group"), and if necessary still below specified connection steps are carried out,

O

implements,

and

(b) the compound of formula (IV) resulting from step (a)

wherein R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ R ⁷ , R ⁸ , R ⁹ , R ¹⁰ , R ¹ , R ² , R ¹³ , R ¹⁴ , R ¹⁵ , R ¹⁶ , R ¹⁷ , M ¹ , M ² , M ³ , Y _{1 (} Y ₂ , V, m, n, and o and m are those given herein

 meanings

 if necessary freed from the protective group ("V-protective group") and with a

 Compound of the formula (V)

 L-W (V)

 wherein W has the meaning given herein and L is Cl, Br, I or a free or reactively functionally modified OH group,

implements,

or

(c) releasing them from one of their functional derivatives (e.g., with protecting groups) by treatment with an acidic, basic, solvolyzing or hydrogenolysing agent,

and / or converting a base or acid of formula (I) into one of its salts. The term "carbamoyl" means "aminocarbonyloxy" and vice versa.

A is alkyl, is unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. A is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1, 1, 1, 2 or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4- Methylpentyl, 1-, 1-, 1-, 2-, 1-, 3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1- Ethyl 2-methylpropyl, 1,1,2 or 1,2,2-trimethylpropyl, more preferably, for example, trifluoromethyl.

 A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl , Pentafluoroethyl or 1,1,1-trifluoroethyl.

 Cyclic alkyl (cycloalkyl) is preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. Ar means e.g. Phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p- tert-butylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p- (N-methylamino) -phenyl , o-, m- or p- (N-methylaminocarbonyl) -phenyl, o-, m- or p-acetamidophenyl, o-, m- or p-methoxyphenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m- or p- (N, N-dimethylamino) -phenyl, o-, m- or p- (N, N-dimethylaminocarbonyl) -phenyl, o-, m- or p - (N-ethylamino) -phenyl, o-, m- or p- (N, N-diethylamino) -phenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o -, m- or p-chlorophenyl, o-, m- or p- (methylsulfonamido) -phenyl, o-, m- or p- (methylsulfonyl) -phenyl, o-, m- or p-methylsulfanylphenyl, o-, m- or p-cyanophenyl, o-, m- or p-carboxyphenyl, o-, m- or p-methoxycarbonylphenyl, o-, m- or p-formylphenyl, o-, m- or p-acetylphenyl, o-, m- or p-aminosulfonylphenyl, o-, m- or p- (morpholin-4-ylcarbonyl) -phenyl, o-, m- or p- (morpholin-4-ylcarbonyl) -phenyl, o-, m- or p- (3-oxomorpholin-4-yl) -phenyl, o-, m- or p- (piperidinylcarbonyl) -phenyl, o-, m- or p- [2- (morpholin-4-yl) ethoxy] -phenyl, o-, m- or p- [3- (N, N-diethylamino) propoxy] -phenyl, o-, m- or p- [3- (3-diethylaminopropyl) -ureido] -phenyl, o-, m- or p- (3-diethylaminopropoxy) carbonylamino) -phenyl, more preferably 2,3-,

2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3 , 5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,4- or 2,5-dinitrophenyl,

2,5- or 3,4-dimethoxyphenyl, 3-nitro-4-chlorophenyl, 3-amino-4-chloro, 2-amino-3-chloro, 2-amino-4-chloro, 2-amino-5 chloro or 2-amino-6-chlorophenyl, 2-nitro-4-N, N-dimethylamino or 3-nitro-4-N, N-dimethylaminophenyl, 2,3-diaminophenyl, 2,3,4-, 2 , 3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-dichloro-4-aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl, 2,5-difluoro-4-bromophenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6- methoxy- phenyl, 3-chloro-4-acetamidophenyl, 3-fluoro-4-methoxyphenyl, 3-amino-6-methylphenyl,

3-chloro-4-acetamidophenyl or 2,5-dimethyl-4-chlorophenyl.

Het, irrespective of further substitutions, e.g. 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2 -

4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, more preferably 1, 2,3-triazole-1, -4- or -5-yl, 1, 2,4-triazole-1, -3- or 5-yl , 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4 or -5-yl, 1, 2,4-oxadiazol-3 or -5-yl, 1,3,4-thiadiazol-2 or -5-yl, 1, 2,4-thiadiazol-3 or -5-yl, 1, 2,3-thiadiazol-4 or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, indazolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7- benzoxazolyl, 3-, 4-, 5-, 6- or 7- benzisoxazolyl, 2-, 4-, 5- , 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3- , 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6- , 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3- , 5-, 6-, 7- or 8-2H-benzo [1,4] oxazinyl, more preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3 Benzothiadiazol-4 or 5-yl, 2,1,3-benzoxadiazol-5-yl or dibenzofuranyl.

 The heterocyclic radicals may also be partially or completely hydrogenated. Regardless of other substitutions Het can thus z. B. also mean 2,3-dihydro

2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or -3-furyl,

1,3-dioxolan-4-yl, tetrahydro-2- or 3-thienyl, 2,3-dihydro-1-, 2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro- 1-, 2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl,

Tetrahydro-1-, 2- or -4-imidazolyl, 2,3-dihydro-1-, 2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or - 4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1, 2,3,4-

Tetrahydro-1-, 2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro -2-, -3- or -4-pyranyl, 1, 4-dioxanyl, 1, 3-dioxane-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl , Hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolyl, 1, 2,3,4-tetrahydro-1 -, -2 -, -3-, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8-

3,4-dihydro-2H-benzo [1,4] oxazinyl, more preferably 2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4- (difluoromethylenedioxy) phenyl, 2 , 3-dihydrobenzofuran-5- or 6-yl, 2,3- (2-oxomethylenedioxy) -phenyl or also 3,4-dihydro-2H-1,5-benzodioxepin-6 or -7-yl preferably 2,3-dihydrobenzofuranyl, 2,3-dihydro-2-oxofuranyl, 3,4-dihydro-2- oxo-1 / - / - quinazolinyl, 2,3-dihydrobenzoxazolyl, 2-oxo-2,3-dihydrobenzoxazolyl, 2,3-dihydrobenzimidazolyl, 1,3-dihydroindole, 2-oxo-1,3 dihydro-indole or 2-oxo-2,3-dihydro-benzimidazolyl. Hai is preferably F, Cl or Br, but also I, more preferably F or

Cl.

For the entire invention, all residues that occur multiple times may be the same or different, i. are independent of each other.

 The compounds of formula (I) may possess one or more chiral centers and therefore exist in different stereoisomeric forms. Formula (I) encompasses all these forms.

Accordingly, the invention is particularly those

Compounds of the formula (I) and their use in which at least one of the radicals mentioned has one of the preferred meanings given above.

The compounds of formula (I) and also the starting materials for their preparation are otherwise prepared by methods known per se, as described in the literature (eg in the standard works such as Houben-Weyl, methods of organic chemistry, Georg-Thieme-Verlag, Stuttgart) are described, under

Reaction conditions which are known and suitable for the said reactions. One can also make use of known per se, not mentioned here variants.

The starting compounds of the formulas (II), (III), (IV) and (V) are generally known. If they are new, they can be produced by methods known per se. The conversion to the compounds of the formula (I) is generally carried out in

 Presence of an acid-binding agent, preferably an organic base such as DIPEA, triethylamine, dimethylaniline, pyridine or quinoline.

Also, the addition of an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali or Alkaline earth metals, preferably potassium, sodium, calcium or cesium may be beneficial.

 Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature between about -30 ° and 140 °, normally between -10 ° and 90 °, in particular between about 0 ° and about 70 °.

 Suitable inert solvents are e.g. Hydrocarbons such as hexane,

Petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as

Trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane;

 Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides such as acetamide, dimethylacetamide or dimethylformamide (DMF); Nitriles such as acetonitrile; Sulfoxides such as dimethylsulfoxide (DMSO); Carbon disulphide; Carboxylic acids such as formic acid or acetic acid; Nitro compounds such as nitromethane or

 nitrobenzene; Esters such as ethyl acetate or mixtures of said solvents.

 Particularly preferred is acetonitrile, dichloromethane and / or DMF.

Furthermore, one can acylate free amino groups in the usual way with an acid chloride or anhydride or with an unsubstituted or substituted

Alkylate alkyl halide, suitably in an inert solvent such as

Dichloromethane or THF and / or in the presence of a base such as triethylamine or pyridine at temperatures between -60 and + 30 °. The compounds of the formula (I) can be further obtained by reacting them with their functional derivatives (for example with protective groups) by solvolysis,

in particular hydrolysis, or freed by hydrogenolysis.

Preferred starting materials for the solvolysis or hydrogenolysis are those which contain, instead of one or more free amino and / or hydroxyl groups, corresponding protected amino and / or hydroxyl groups, preferably those which, instead of an H atom, are bonded to an N atom is to carry an amino protecting group, for. For example, those corresponding to formula (I) but containing, instead of an NH ₂ group, an NHR 'group (wherein R' represents an amino-protecting group, eg BOC or CBZ). Furthermore, starting materials are preferred, which instead of the H atom of a

Hydroxy group carry a hydroxy protecting group, for. Those corresponding to formula (I) but containing, instead of a hydroxyalkyl group, a R'O-alkyl group (wherein R "represents a hydroxy-protecting group).

There may also be several - same or different - protected amino and / or hydroxy groups present in the molecule of the starting material. if the

existing protecting groups are different from each other, they can be selectively cleaved in many cases.

The term "amino protecting group" is well known and refers to groups which are capable of protecting (blocking) an amino group from chemical reactions, but which are readily removable after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are in particular unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups. Since the amino protecting groups after the

the desired reaction (or reaction sequence) are removed, their nature and size is otherwise not critical; however, preference is given to those having 1-20, in particular 1-8 C atoms. The term "acyl group" is to be understood in the broadest sense in the context of the present process. It encloses of aliphatic,

Acyl groups derived from araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and in particular alkoxycarbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups. Examples of such acyl groups are alkanoyl such as acetyl, propionyl, butyryl; Aralkanoyl such as phenylacetyl; Aroyl such as benzoyl or toluyl;

Aryloxyalkanoyl such as POA; Alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC, 2-iodoethoxycarbonyl; Aralkyloxycarbonyl, such as CBZ

("Carbobenzoxy"), 4-methoxybenzyloxycarbonyl, FMOC; Arylsulfonyl such as Mtr, Pbf or Pmc. Preferred amino protecting groups are BOC and Mtr, furthermore CBZ, Fmoc, benzyl and acetyl.

The term "hydroxy protecting group" is also well known and refers to groups which are suitable for protecting a hydroxy group from chemical reactions, but which are readily removable after the desired chemical reaction has been carried out at other sites on the molecule. Typical for such Groups are the abovementioned unsubstituted or substituted aryl, aralkyl or acyl groups, and also alkyl groups. The nature and size of the hydroxy-protecting groups is not critical since they are removed after the desired chemical reaction or reaction sequence; preferred are groups having 1-20, in particular 1-10 C-atoms. Examples of hydroxy protecting groups include tert.

Butoxycarbonyl, benzyl, p-nitrobenzoyl, p-toluenesulfonyl, tert-butyl and acetyl, with benzyl and tert-butyl being particularly preferred. The COOH groups in

Aspartic acid and glutamic acid are preferably protected in the form of their tert-butyl esters (eg Asp (OBut)).

The in-freedom setting of the compounds of formula (I) from their functional derivatives succeed - depending on the protecting group used - z. B. with strong acids, useful with TFA or perchloric acid, but also with other strong

inorganic acids such as hydrochloric acid or sulfuric acid, strong organic carboxylic acids such as trichloroacetic acid or sulfonic acids such as benzene or

Toluene sulfonic acid. The presence of an additional inert solvent is possible, but not always necessary. Suitable inert solvents are

preferably organic, for example carboxylic acids such as acetic acid, ethers such as tetrahydrofuran or dioxane, amides such as DMF, halogenated hydrocarbons such as dichloromethane, and also alcohols such as methanol, ethanol or isopropanol, and

Water. Also suitable are mixtures of the abovementioned solvents. TFA is preferably used in excess without the addition of another solvent, perchloric acid in the form of a mixture of acetic acid and 70% perchloric acid in the ratio 9: 1. The reaction temperatures for the cleavage are suitably between about 0 and about 50 °, preferably between 15 and 30 ° (room temperature).

The groups BOC, OBut, Pbf, Pmc and Mtr can, for. B. preferably cleaved with TFA in dichloromethane or with about 3 to 5N HCl in dioxane at 15-30 °, the FMOC group with an about 5 to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-30 °.

Hydrogenolytically removable protecting groups (eg CBZ or benzyl) may e.g. By treating with hydrogen in the presence of a catalyst (e.g.

Noble metal catalyst such as palladium, conveniently on a support such as carbon) be split off. Suitable solvents are those given above, in particular z. For example, alcohols such as methanol or ethanol or ethers such as THF. The hydrogenolysis is usually carried out at temperatures between about 0 and 100 ° and pressures between about 1 and 200 bar, preferably at 20-30 ° and 1-10 bar. Hydrogenolysis of the CBZ group succeeds z. B. good at 5 to 10% Pd / C in

Methanol or THF or with ammonium formate (instead of hydrogen) on Pd / C in methanol / DMF at 20-30 °.

Pharmaceutical salts and other forms

The abovementioned compounds according to the invention can be used in their final non-salt form. On the other hand, the present invention also encompasses the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases according to procedures known in the art. Pharmaceutically acceptable salt forms of the compounds of formula (I) are for the most part prepared conventionally. If the compound of the formula (I) contains a carboxylic acid group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base addition salt. Such bases include, for example, alkali metal hydroxides, including potassium hydroxide,

 Sodium hydroxide and lithium hydroxide; Alkaline earth metal hydroxides such as barium hydroxide and calcium hydroxide; Alkali metal alcoholates, e.g. Potassium ethanolate and sodium propanolate; and various organic bases such as piperidine, diethanolamine and

N-methyl-glutamine. The aluminum salts of the compounds of formula (I) are also included. For certain compounds of formula (I) can be

 Forming acid addition salts by reacting these compounds with pharmaceutically acceptable organic and inorganic acids, e.g. Hydrogen halides such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and their corresponding salts such as sulfate, nitrate or phosphate and the like, and alkyl and monoarylsulfonates such as ethanesulfonate, toluenesulfonate and

 Benzenesulfonate, and other organic acids and their corresponding salts such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like. Accordingly, too pharmaceutical

acceptable acid addition salts of the compounds of the formula (I) the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, Bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentaneproprionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, Hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2-naphthalenesulphonate, Nicotinate, nitrate, oxalate, oleate, pamoate, pectinate, persulfate, phenyl acetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this is not limiting.

Furthermore, the base salts of the compounds according to the invention include aluminum, ammonium, calcium, copper, iron (III), iron (II), lithium, magnesium, manganese (III), manganese (II), potassium -, sodium and zinc salts, but no

To represent restriction. Preferred among the above-mentioned salts

Ammonium; the alkali metal salts sodium and potassium, and the alkaline earth metal salts calcium and magnesium. Salts of compounds of formula I derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, e.g. Arginine, betaine, caffeine, chloroprocaine, choline, Ν, Ν'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, Histidine, hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris- (hydroxymethyl) - methylamine (tromethamine), which is not intended to be limiting. Compounds of the present invention containing basic nitrogen-containing groups can be reacted with agents such as (C 1 -C 4) alkyl halides, e.g. Methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; Di-1-alkylsulfates, e.g.

Dimethyl, diethyl and diamyl sulfate; (C ₁₀ -C ₁₈ ) alkyl halides, eg decyl, dodecyl, lauryl, myristyl and stearyl chloride,

bromide and iodide; and AryHC! -C ^ alkyl halides, eg benzyl chloride and Phenethylbromide, quaternization. With such salts, both water- and oil-soluble compounds of the invention can be prepared.

The above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate,

Hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, phosphate, stearate, sulphate, sulphosalicylate, tartrate, thiomalate, tosylate and

Tromethamine, which is not intended to be limiting. Particularly preferred are hydrochloride, dihydrochloride, hydrobromide, maleate,

Mesylate, phosphate, sulfate and succinate.

The acid addition salts of basic compounds of formula (I) are prepared by contacting the free base form with a sufficient amount of the desired acid to form the salt in a conventional manner. The free base can be regenerated by contacting the salt form with a base and isolating the free base in a conventional manner. The free base forms in some sense differ from their corresponding salt forms in terms of certain physical properties such as solubility in polar solvents; however, in the context of the invention, the salts otherwise correspond to their respective free base forms.

As mentioned, the pharmaceutically acceptable base addition salts of the compounds of formula (I) with metals or amines such as alkali metals and

Alkaline earth metals or organic amines formed. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are Ν, Ν'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine. The base addition salts of acidic compounds of the invention are prepared by contacting the free acid form with a sufficient amount of the desired base to form the salt in a conventional manner. The free acid can be regenerated by contacting the salt form with an acid and isolating the free acid in a conventional manner. The free acid forms differ in some sense from their corresponding salt forms in relation to certain physical properties such as solubility in polar solvents; However, in the context of the invention, the salts otherwise correspond to their respective free acid forms. If a compound according to the invention contains more than one group which can form such pharmaceutically acceptable salts, the invention also encompasses multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium and trihydrochloride, but this is not intended to be limiting.

In view of the above, one sees that under the expression

"pharmaceutically acceptable salt" as used herein means an active ingredient containing a compound of formula (I) in the form of one of its salts, particularly when that salt form is the active ingredient compared to the free form of the active ingredient or any other salt form of the drug that has been used previously confers improved pharmacokinetic properties. The pharmaceutically acceptable salt form of the active substance may also first impart a desired pharmacokinetic property to this active ingredient which it has not previously possessed, and may even positively influence the pharmacodynamics of this active ingredient in terms of its therapeutic activity in the body.

The invention furthermore relates to medicaments comprising one or more compounds of the formula (I) and the preferred embodiments and disclosed compounds shown below, wherein compounds of the formula (I) in which (a) = N, M ₂ = CR ¹⁹ , M ₃ S are, and (b) = CH and Y ₂ = N, and (c) n = 1 and o = 1, are not excluded, as well as their physiological

non-hazardous salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, including mixtures thereof in all proportions, for use in the treatment of diseases resulting from the inhibition of Sph kinase 1 by the compounds of formula (I) and the embodiments illustrated herein and disclosed compounds. A corresponding use for the manufacture of a medicament for the treatment and / or prophylaxis of the aforementioned conditions is intended to be included.

In a preferred embodiment, further claimed are pharmaceutical compositions comprising one or more compounds according to the formula (I) and here preferred compounds and compounds disclosed wherein compounds of formula (I) wherein (a) is Mi = N, M ₂ = CR ¹⁹ , M ₃ = S, and (b) = CH and Y ₂ = N, and ( c) n = 1 and o = 1 are excluded, and their physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, including mixtures thereof in all proportions, to

Use in the treatment of diseases which are affected by inhibition of Sph kinase 1 by the compounds of formula (I) and the embodiments and disclosed compounds presented herein. A corresponding use for the manufacture of a medicament for the treatment and / or prophylaxis of the aforementioned conditions is intended to be included.

Pharmaceutical formulations may be presented in the form of dosage units containing a predetermined amount of active ingredient per unit dose. Such a unit may, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, more preferably 5 mg to 100 mg of a novel

Depending on the disease state treated, the route of administration and the age, weight and condition of the patient, or

Pharmaceutical formulations may be presented in the form of dosage units containing a predetermined amount of active ingredient per unit dose. Preferred unit dosage formulations are those containing a daily or partial dose as indicated above or a corresponding fraction thereof, of an active ingredient. Furthermore, such pharmaceutical

Make formulations by any of the methods well known in the pharmaceutical art.

Pharmaceutical formulations may be administered by any suitable route, for example, oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) Ways, adapt. Such formulations can be prepared by any method known in the pharmaceutical art, for example, by bringing the active ingredient together with the carrier (s) or excipient (s). Pharmaceutical formulations adapted for oral administration may be presented as separate entities, such as capsules or tablets; Powder or granules;

Solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active ingredient component can be mixed with an oral, non-toxic and

pharmaceutically acceptable inert carrier, e.g. Ethanol, glycerin, water and the like combine. Powders are prepared by comminuting the compound to a suitable fine size and comminuting it in a similar manner

pharmaceutical carrier, e.g. an edible carbohydrate such as starch or annit. A flavor, preservative, dispersant and dye may also be present.

Capsules are made by preparing a powder mix as described above and filling shaped gelatin casings therewith. Lubricants such as e.g. fumed silica, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form can be added to the powder mixture before the filling process. A disintegrants or solubilizers, e.g. Agar-agar, calcium carbonate or sodium carbonate may also be added to improve the availability of the drug after ingestion of the capsule.

In addition, if desired or necessary, suitable binding, lubricating and disintegrants as well as dyes can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars, e.g. Glucose or beta-lactose, corn sweeteners, natural and synthetic gums, e.g. Acacia, tragacanth or sodium alginate, carboxymethylcellulose,

Polyethylene glycol, waxes, etc. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. The disintegrating agents include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. The tablets are formulated by, for example, preparing a powder mixture, granulating or dry pressing, adding a lubricant and a disintegrating agent and pressing the whole into tablets. A powder mixture is produced, by suitably comminuting the compound with a diluent or a base as described above, and optionally with a binder such as carboxymethyl cellulose, an alginate, gelatin or polyvinylpyrrolidone, a dissolution reducer such as paraffin, a resorption accelerator such as a quaternary salt and / or an absorbent, such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder such as syrup, starch paste, Acadia slime or solutions of cellulosic or polymeric materials and pressing through a sieve. As an alternative to granulation, the powder mixture by a

Run tableting machine, resulting in irregularly shaped lumps, which are broken up into granules. The granules may be greased by the addition of stearic acid, a stearate salt, talc or mineral oil to prevent sticking to the tablet molds. The greased mixture is then compressed into tablets. The compounds according to the invention can also be combined with a free-flowing inert carrier and then without carrying out the

 Granulation or Trockenverpressungsschritte be pressed directly into tablets. A transparent or opaque protective layer, consisting of a

Shellac sealant, a layer of sugar or polymeric material and a glossy layer of wax may be present. Dyes can be added to these coatings in order to differentiate between different dosage units.

Oral fluids, e.g. Solution, syrups and elixirs may be prepared in unit dosage form such that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in an appropriate taste aqueous solution while preparing elixirs using a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers, e.g. ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavoring additives such as e.g. Peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, etc. can also be added.

The unit dosage formulations for oral administration may optionally be encapsulated in microcapsules. The formulation can be also prepare so that the release is prolonged or retarded, such as

for example, by coating or embedding particulate material in polymers, wax and the like. The compounds of formula (I) as well as salts, solvates and physiologically functional derivatives thereof can also be administered in the form of liposome delivery systems, e.g. small unilamellar vesicles, large unilamellar vesicles and

multilamellar vesicles. Liposomes can be different

Phospholipids, e.g. Cholesterol, stearylamine or phosphatidylcholines.

The compounds of formula (I) as well as the salts, solvates and physiologically functional derivatives thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds can also be coupled with soluble polymers as targeted drug carriers. Such polymers may include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol or polyethyleneoxidepolylysine substituted with palmitoyl radicals. Furthermore, the compounds can be attached to a class of biodegradable

Polymers suitable for the controlled release of a drug, e.g. Polylactic acid, polyepsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates, and crosslinked or amphipathic block copolymers of hydrogels. Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches for prolonged, intimate contact with the epidermis of the recipient. For example, the drug may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3 (6), 318 (1986).

Pharmaceutical compounds adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. For treatments of the eye or other external tissues, eg mouth and skin, the formulations are preferably applied as a topical ointment or cream. When formulated into an ointment, the active ingredient can be used with either a paraffinic or water miscible cream base. Alternatively, the active ingredient can be formulated into a cream with an oil-in-water cream base or a water-in-oil base.

The pharmaceutical formulations adapted for topical application to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.

Pharmaceutical formulations adapted for topical application in the mouth include lozenges, troches and mouthwashes.

Pharmaceutical formulations adapted for rectal administration may be presented in the form of suppositories or enemas.

Pharmaceutical formulations adapted for nasal administration in which the vehicle is a solid contain a coarse powder having a particle size, for example, in the range of 20-500 microns, which is administered in the manner in which snuff is received, i. by

Quick inhalation via the nasal passages from a close to the nose held

Container with the powder. Suitable formulations for administration as a nasal spray or nasal drops with a liquid carrier include drug solutions in water or oil.

For administration by inhalation adapted pharmaceutical

Formulations include fine particulate dusts or mists that can be generated by various types of pressurized dosing dispensers with aerosols, nebulizers or insufflators.

Pharmaceutical formulations adapted for vaginal administration may be used as pessaries, tampons, creams, gels, pastes, foams or

Spray formulations are presented. Among the adapted for parenteral administration pharmaceutical

Formulations include aqueous and non-aqueous sterile injection solutions containing antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions which may contain suspending agents and thickeners. The formulations may be administered in single or multi-dose containers, e.g. sealed ampoules and vials, presented and freeze-dried

(lyophilized) state, so that only the addition of the sterile

Carrier liquid, e.g. Water for injections, needed immediately before use. Injection solutions and suspensions prepared by formulation can be prepared from sterile powders, granules and tablets.

It will be understood that in addition to the above particularly mentioned ingredients, the formulations may include other means conventional in the art with respect to the particular type of formulation; for example, formulations suitable for oral administration may contain flavorings.

A therapeutically effective amount of a compound of formula (I) will depend on a number of factors, including e.g. the age and weight, the exact state of the disease requiring treatment, and the severity of the disease

The nature of the formulation and the route of administration, and is ultimately determined by the attending physician or veterinarian. However, an effective amount of a compound of the invention is for the treatment of neoplastic

Growth, eg, colon or breast carcinoma, generally in the range of 0.1 to 100 mg / kg body weight of the recipient (mammal) per day, and more typically in the range of 1 to 10 mg / kg body weight per day. Thus, for a 70 kg adult mammal, the actual amount per day would usually be between 70 and 700 mg, this amount as a single dose per day or more commonly in a number of divided doses (such as two, three, four, five or six) per Day can be given so that the total daily dose is the same. An effective amount of a salt or solvate or a physiologically functional derivative thereof can be determined as a proportion of the effective amount of the compound of the invention per se. It can be assumed that similar dosages are suitable for the treatment of the other, above-mentioned disease states. The invention further relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one compound according to the formula (I) and the preferred embodiments and disclosed compounds illustrated herein.

 In a preferred embodiment, a pharmaceutical

A composition as claimed herein containing at least one additional compound selected from the group consisting of physiologically acceptable extenders, excipients, additives, diluents, carriers and / or additional pharmaceutically active substance other than the compounds according to formula (I) and the preferred embodiments shown herein and disclosed compounds.

The invention also provides a kit comprising a therapeutically effective amount of at least one compound according to formula (I) and the preferred embodiments and disclosed compounds and / or at least one pharmaceutical composition as shown herein and a therapeutically effective amount of at least one other pharmacologically active Substance other than the compounds of formula (I) and the preferred embodiments and disclosed compounds illustrated herein.

 The kit contains suitable containers, such as boxes or boxes, individual bottles, bags or ampoules. The set may e.g. containing separate ampoules, in each of which an effective amount of a compound of formula (I) and / or its pharmaceutically acceptable derivatives, solvates, tautomers and stereoisomers, including mixtures thereof in all proportions, and an effective amount of another drug substance are dissolved or lyophilized Form is present.

use

The instant compounds are useful as pharmaceutical agents for mammals, particularly for humans, in the treatment of sphingosine kinase-related diseases. These diseases include the proliferation of tumor cells, the pathological neovascularization (or angiogenesis) that causes the

Growth of solid tumors promotes neovascularization in the eye (diabetic

Retinopathy, age-related macular degeneration and the like) as well as inflammation (psoriasis, rheumatoid arthritis and the like). The present invention comprises the use of the compounds of formula (I) and / or their physiologically acceptable salts and solvates for the manufacture of a medicament for the treatment or prevention of cancer. Preferred carcinomas for the treatment are from the group of brain carcinoma, genitourinary tract carcinoma, carcinoma of the lymphatic system, gastric carcinoma, laryngeal carcinoma and lung carcinoma. Another group of preferred forms of cancer are monocytic leukemia, lung adenocarcinoma, small cell lung carcinoma, prostate cancer, colon cancer, pancreatic cancer, ovarian cancer, kidney cancer, liver carcinoma,

Glioblastomas and breast carcinoma.

 Also included is the use of the compounds of the invention and / or their physiologically acceptable salts and solvates for the manufacture of a medicament for the treatment or prevention of a disease in which angiogenesis is involved.

 One such disease involving angiogenesis is an eye disease such as retinal vascularization, diabetic retinopathy, age-related macular degeneration, and the like.

 The use of compounds of formula (I) and / or their physiologically acceptable salts and solvates for the manufacture of a medicament for the treatment or prevention of inflammatory diseases is also within the scope of the present invention. Such inflammatory diseases include, for example, rheumatoid arthritis, psoriasis, contact dermatitis, late-type hypersensitivity reaction, and the like.

 Also included is the use of the compounds of the formula (I) and / or their physiologically acceptable salts and solvates for the preparation of a

A medicament for treating or preventing a disease or a disease in a mammal, which method comprises treating a diseased mammal in need of such treatment with a therapeutically effective amount of a mammal

administered compound of the invention. The therapeutic amount depends on the particular disease and can be determined by the skilled person without too much effort.

 The present invention also encompasses the use of compounds of the formula (I) and / or their physiologically acceptable salts and solvates

Preparation of a medicament for the treatment or prevention of retinal vascularization. Method of treatment or prevention of eye diseases such as

Diabetic retinopathy and age-related macular degeneration are also part of the invention. The use for the treatment or prevention of inflammatory diseases such as rheumatoid arthritis, psoriasis, contact dermatitis and late-type hypersensitivity reactions, as well as the treatment or

 Prevention of bone pathologies from the group of osteosarcoma, osteoarthritis and rickets also falls within the scope of the present invention.

 In addition to the compounds of formula (I) and their precursors for

Treatment of these diseases are used.

The compounds of formula (I) may be administered to patients for the treatment of cancer, especially fast growing tumors.

The invention thus relates to the use of compounds of the formula I, and their pharmaceutically usable derivatives, solvates, tautomers and stereoisomers, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and / or Modulation of signal transduction of kinases plays a role. Preference is given here to the Sph kinase.

Preference is given to the use of compounds of the formula (I), and of their pharmaceutically usable derivatives, solvates, tautomers and stereoisomers, including mixtures thereof in all ratios,

 for the manufacture of a medicament for the treatment of diseases caused by

Inhibition of SphK 1 can be influenced by the compounds according to formula (I) and the preferred embodiments and disclosed compounds illustrated herein. The diseases to be treated are preferably selected from the group hyperproliferative disease, inflammatory disease, angiogenic

Illness.

The hyperproliferative disease is preferably selected from the group Cancer (tumor disease), atherosclerosis, restenosis, proliferative disease of the mesangial cells, psoriasis.

The tumor disease is preferably selected from the group

 Tumor of squamous epithelium, bladder, stomach, kidneys, head and neck, esophagus, cervix, thyroid, intestine, liver, brain, prostate, genitourinary tract, lymphatic system, stomach, stomach Larynx, lungs, skin, monocytic leukemia, lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma, breast carcinoma, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma.

The proliferative disease of the mesangial cells is preferably selected from the group

 Glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndrome, graft rejection, glomerulopathy.

The inflammatory disease is preferably selected from the group of inflammatory bowel disease, arthritis, atherosclerosis, asthma, allergies, inflammatory kidney disease, multiple sclerosis, chronic obstructive

Pulmonary disease, inflammatory skin diseases, Pardontal diseases, psoriasis, T cell-mediated immune disease.

Inflammatory bowel disease is preferably selected from the group ulcerative colitis, Crohn's disease, undetermined colitis.

The T-cell mediated immune disease is preferably selected from the group

 allergic encephalomyelitis, allergic neuritis, transplant rejection, graft-versus-host reaction, myocarditis, thyroiditis, nephritis, systemic lupus erythematosus, insulin-dependent diabetes mellitus.

The arthritis disorder is preferably selected from the group Rheumatoid arthritis, osteoarthritis, Caplan syndrome, Felty syndrome, Sjögren syndrome, ankylosing spondylitis, Still's disease, chondrocalcinosis, metabolic arthritis, rheumatic fever, Reiter's disease, Wissler syndrome. The inflammatory kidney disease is preferably selected from the group

Glomerulonephritis, glomerular injury, nephrotic syndrome, interstitial nephritis, lupus nephritis, Goodpasture syndrome, Wegener's granulomatosis,

Renal vasculitis, IgA nephropathy, idiopathic glomerular disease. The inflammatory skin disease is preferably selected from the group

Psoriasis, atopic dermatitis, contact sensitivity, acne.

The angiogenic disorder is preferably selected from the group of diabetic retinopathy, arthritis, cancer, psoriasis, Kaposi's sarcoma, hemangioma, myocardial angiogenesis, atherosclerotic plaque neovascularization, angiogenic eye diseases, choroidal neovascularization, retrolental fibroplasia, macular degeneration, corneal graft rejection, rubeosis iridis, neurosculares Glaucoma, Oster Webber syndrome. The invention furthermore relates to medicaments comprising one or more

Compounds according to the formula (I) and preferred illustrated here

Embodiments and disclosed compounds and their physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, including mixtures thereof in all ratios,

The invention furthermore relates to medicaments comprising one or more compounds of the formula (I) and preferred embodiments and disclosed compounds as well as their physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, including mixtures thereof in all ratios, for use in the treatment of diseases which are affected by inhibition of Sph kinase 1 by the compounds according to formula (I) and and the embodiments and disclosed compounds presented herein, which are to be treated

Diseases selected from the group consisting of: "hyperproliferative disease, inflammatory disease, angiogenic disease, fibrotic Lung, kidney, liver and heart disease, cancer (tumor disease), atherosclerosis, restenosis, mesangial cell proliferative disease,

Psoriasis, tumor of the squamous epithelium, bladder, stomach, kidneys, head and neck, esophagus, cervix, thyroid, intestine, liver, brain, prostate, genitourinary tract, lymphatic system, stomach , larynx, lungs, skin, monocytic leukemia,

Lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma, breast carcinoma, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, glomerulonephritis, diabetic

Nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndrome, graft rejection, glomerulopathy, inflammatory bowel disease, arthritis, asthma, allergies, inflammatory kidney disease, multiple sclerosis, chronic obstructive pulmonary disease, inflammatory skin diseases,

Pardontal diseases, T cell-mediated immune disease, ulcerative colitis, Crohn's disease, indeterminate colitis, allergic encephalomyelitis, allergic neuritis, graft rejection, graft-versus-host disease,

Myocarditis, thyroiditis, nephritis, systemic lupus erythematosus,

insulin dependent diabetes mellitus, rheumatoid arthritis, osteoarthritis, Caplan syndrome, Felty syndrome, Sjögren syndrome, ankylosing spondylitis, Still's disease, chondrocalcinosis, metabolic arthritis, rheumatic fever, Reiter's disease, Wissler syndrome, glomerulonephritis, glomerular injury, nephrotic syndrome, interstitial nephritis, lupus nephritis, Goodpasture syndrome, Wegener's granulomatosis, renal vasculitis, IgA nephropathy, idiopathic glomerular disease, atopic dermatitis, contact sensitivity, acne, diabetic

Retinopathy, Kaposi's sarcoma, hemangioma, myocardial angiogenesis,

Atherosclerotic plaque neovascularization, angiogenic eye diseases, choroidal neovascularization, retrolental fibroplasia, macular degeneration, corneal graft rejection, rubeosis iridis, neuroscular glaucoma, Oster Webber syndrome

A medicament for the treatment and / or prophylaxis of the aforementioned conditions as well as a method for the treatment of said diseases comprising the administration of one or more compounds of the invention to a patient in need of such administration. should be included here. In a preferred embodiment, further claimed are medicaments comprising one or more compounds of the formula (I) and the preferred embodiments and disclosed compounds illustrated herein and their physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, including mixtures thereof in all ratios, for use in the treatment of diseases which are affected by inhibition of Sph kinase 1 by the compounds according to formula (I) and the embodiments and compounds disclosed herein, wherein the diseases to be treated are selected from the group consisting of:

"Hyperproliferative disease, inflammatory disease, angiogenic

 Disease, fibrotic disease of the lung, kidney, liver and heart, cancer (tumor disease), atherosclerosis, restenosis, proliferative disease of the mesangial cells, psoriasis, squamous cell tumor, bladder, stomach, kidney, head and neck, esophagus , the cervix, the

Thyroid, intestine, liver, brain, prostate, genitourinary tract, lymphatic system, stomach, larynx, lungs, skin, monocytic leukemia, lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma, breast carcinoma, acute myeloid

Leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis,

thrombotic microangiopathy syndrome, graft rejection,

Glomerulopathy, inflammatory bowel disease, arthritis, asthma, allergies, inflammatory kidney disease, multiple sclerosis, chronic obstructive

Lung disease, inflammatory skin diseases, Pardontal diseases, T-cell mediated immune disease, ulcerative colitis, Crohn's disease, indefinite colitis, allergic encephalomyelitis, allergic neuritis,

Graft-versus-host reaction, myocarditis, thyroiditis, nephritis, systemic lupus erythematosus, insulin-dependent diabetes mellitus, rheumatoid arthritis, osteoarthritis, Caplan syndrome, Felty syndrome, Sjögren syndrome, ankylosing spondylitis, Still's disease, chondrocalcinosis, metabolic arthritis, rheumatoid arthritis Fever, Reiter's disease, Wissler syndrome,

Glomerulonephritis, glomerular injury, nephrotic syndrome, interstitial nephritis, lupus nephritis, Goodpasture syndrome, Wegener's granulomatosis, renal vascular tis, IgA nephropathy, idiopathic glomerular disease, atopic Dermatitis, contact sensitivity, acne, diabetic retinopathy, Kaposi's sarcoma, hemangioma, myocardial angiogenesis, atherosclerotic plaque neovascularization, angiogenic eye disease, choroidal neovascularization, retrolental fibroplasia, macular degeneration, corneal graft rejection, rubeosis iridis, neuroscular glaucoma, Oster Webber syndrome

corresponding use for the manufacture of a medicament for the treatment and / or prophylaxis of the aforementioned conditions as well as a method for

Treatment of said disorders comprising administering one or more of the compounds of the invention to a patient in need of such administration. should be included here.

In a preferred embodiment, such a drug contains at least one additional pharmacologically active substance (therapeutic agent, medicament, ingredient).

 In a further preferred embodiment, the drug is applied before and / or during and / or after treatment with at least one additional pharmacologically active substance.

The disclosed compounds of formula (I) may be administered in conjunction with other therapeutics (pharmacologically active substances), including anticancer agents. As used herein, the term "anticancer agent" refers to any agent that is administered to a patient with cancer for the purpose of treating the cancer. The anticancer treatment as defined herein may be used as a sole therapy or may include conventional surgery or radiation therapy or chemotherapy in addition to the compound of the present invention. Such chemotherapy may include one or more of the following categories of anti-tumor agents:

 (i) antiproliferative / antineoplastic / DNA damaging agents and combinations thereof as used in medical oncology, such as alkylating agents (for example cisplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); Antimetabolites (e.g., antifolates such as fluoropyrimidines such as 5-fluorouracil and tegafur, raltitrexed, methotrexate,

Cytosine arabinoside, hydroxyurea and gemcitabine); Anti-tumor antibiotics (e.g.

Anthracyclines, such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, Idarubicin, mitomycin C, dactinomycin and ithramycin); antimitotic agents (for example vinca alkaloids, such as vincristine, vinblastine, vindesine and vinorelbine, and

Taxoids, such as Taxol and Taxoter); Topoisomerase inhibitors (for example

Epipodophyllotoxins such as etoposide and teniposide, amsacrine, topotecan, irinotecan and camptothecin) and cell differentiating agents (for example, alkrans-retinoic acid, 13-cis-retinoic acid and fenretinide);

 (ii) cytostatic agents such as anti-estrogens (eg tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfen), the estrogen receptor downregulating agents (eg fulvestrant), anti-androgens (eg bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH Antagonists or LHRH agonists (for example

Goserelin, leuprorelin and buserelin), progesterone (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5a-reductase, such as finasteride;

 (iii) agents that inhibit the invasion of cancer cells (for example, metalloproteinase inhibitors such as marimastat and inhibitors of urokinase plasminogen activator receptor function);

 (iv) inhibitors of growth factor function, for example, such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example, the anti-erbb2 antibody trastuzumab [Herceptin ™] and the anti-erbb1 antibody cetuximab [C225]), Farnesyltransferase inhibitors, tyrosine kinase inhibitors and serine / threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example inhibitors of the tyrosine kinases of the EGFR family, such as N- (3-chloro-4-fluorophenyl) -7- methoxy-6- (3-morpholinopropoxy) quinazolin-4-amine (gefitinib, AZD1839), N- (3-ethynylphenyl) -6,7-bis (2-methoxyethoxy) quinazolin-4-amine (erlotinib, OSI-774 ) and 6-acrylamido - (3-chloro-4-fluorophenyl) -7- (3-morpholinopropoxy) quinazolin-4-amine (Cl 1033)), for example, platelet-derived growth factor family inhibitors and, for example, inhibitors of the hepatocyte growth factor family;

(v) antiangiogenic agents, such as those which inhibit the effects of vascular endothelial growth factor (for example, the vascular endothelial cell growth factor bevacizumab antibody [Avastin ™], compounds such as those disclosed in published international patent applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds which act by other mechanisms (for example, linomide, inhibitors of integrin-avβ3 function and angiostatin); (vi) vascular damaging agents such as combretastatin A4 and in the

international patent applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213;

 (vii) antisense therapies, for example, those directed against the targets listed above, such as ISIS 2503, an anti-Ras antisense;

 (viii) gene therapy approaches, including, for example, approaches to

Replacement of altered genes, such as altered p53 or altered BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches using those that use cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme, as well as approaches to increase the Patient tolerance

 Chemotherapy or radiation therapy, such as multi-drug resistance gene therapy; and

(ix) immunotherapy approaches including, for example, ex vivo and in vivo approaches to increase the immunogenicity of patient tumor cells such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte macrophage colony stimulating factor, approaches to reducing T Cell anergy, batches using transfected immune cells such as cytokine-transfected dendritic cells, batches using cytokine-transfected tumor cell lines, and anti-idiotypic antibody approaches. Preferably, but not exclusively, the drugs of the following

Table 1 combined with the compounds of formula (I).

Table 1.

 Alkylating agent Cyclophosphamide Lomustine

 Busulfan procarbazine

 Ifosfamide altretamine

 Melphalan estramustin phosphate

 Hexamethylmelamine mechlorethamine

 Thiotepa streptozocin

 Chlorambucil Temozolomide

 Dacarbazine Semustin

 carmustine

 Platinum agent cisplatin carboplatin

 Oxaliplatin ZD-0473 (AnorMED)

 Spiroplatin Lobaplatin (Aetema)

 Carboxyphthalatoplatinum Satraplatin (Johnson Matthey)

Tetraplatinum BBR-3464 (Hoffmann-La Roer

Ormiplatin SM-11355 (Sumitomo)

Iproplatin AP-5280 (Access) Antimetabolite azacytidine Tomudex

 Gemcitabine trimetrexate

 Capecitabine deoxycoformycin

 5-fluorouracil fludarabine

 Floxuridine pentostatin

2-chlorodeoxyadenosine Raltitrexed

 6-mercaptopurine hydroxyurea

 6-thioguanine decitabine (SuperGen)

 Cytarabine Clofarabine (Bioenvision)

2-Fluorodeoxycytidine Irofulvene (MGI Pharma)

Methotrexate DMDC (Hoffmann-La Roche)

Idatrexate Ethinylcytidine (Taiho)

 Topoisomerase Amsacrine Rubitecane (SuperGen)

Inhibitors Epirubicin Exatecan Mesylate (Daiichi)

 Etoposide Quinamed (ChemGenex)

Teniposide or Mitoxantrone Gimatecan (Sigma-Tau)

Irinotecan (CPT-11) Diflomotecan (Beaufour-Ipsen)

7-Ethyl-10-hydroxycamptothec TAS-103 (Taiho)

 Topotecan Elsamitrucin (Spectrum)

Dexrazoxanet (TopoTarget) J-107088 (Merck & Co)

Pixantron (Novuspharrna) BNP-1350 (BioNumerik)

Rebeccamycin analog CKD-602 (Chong Kun Dang)

(Exelixis) KW-2170 (Kyowa Hakko)

BBR-3576 (Novuspharrna)

 Antitumor antibiotics Dactinomycin (Actinomycin D) Amonafide

 Doxorubicin (Adriamycin) Azonafide

 Deoxyrubicin anthrapyrazole

 Valrubicin oxantrazole

 Daunorubicin (Daunomycin) Losoxantrone

 Epirubicin bleomycin sulfate (blenoxan)

Therarubicin bleomycinic acid

 Idarubicin bleomycin A

 Rubidazone bleomycin B

 Plicamycin mitomycin C

 Porfiromycin MEN-10755 (Menarini)

Cyanomorpholinodoxorubicin GPX-100 (Gern Pharmaceutic.

Mitoxantrone (Novantrone)

 Antimitotic agent Paclitaxel SB 408075 (GlaxoSmithKline)

 Docetaxel E7010 (Abbott)

 Colchicine PG-TXL (Cell Therapeutics)

Vinblastine IDN 5109 (Bayer)

 Vincristine A 105972 (Abbott)

 Vinorelbine A 204197 (Abbott)

 Vindesin LU 223651 (BASF)

 Dolastatin 10 (NCI) D 24851 (ASTA Medica)

Rhizoxin (Fujisawa) ER-86526 (Eisai)

 Mivobulin (Warner-Lambert) Combretastatin A4 (BMS)

Cemadotin (BASF) isohomohalichondrin-B

RPR 109881 A (Aventis) (PharmaMar) TXD 258 (Aventis) ZD 6126 (AstraZeneca) Epothilone B (Novartis) PEG Paclitaxel (Enzone) T 900607 (Tularik) AZ10992 (Asahi)

 T 138067 (Tularik)! DN-5109 (Indena)

 Cryptophycin 52 (Eli Lilly) AVLB (Prescient NeuroPharm; Vinflunin (Fabre) Azaepothilone B (BMS) Auristatin PE (Teikoku Hormor BNP-7787 (BioNumerik) BMS 247550 (BMS) CA-4 prodrug (OXiGENE) BMS 184476 (BMS) Dolastatin -10 (NrH)

 BMS 188797 (BMS) CA-4 (OXiGENE)

 Taxoprexin (Protarga)

 Aromatase Inhibitors Aminoglutethimide Exemestane

 Letrozole Atamestane (BioMedicines)

Anastrazole YM-511 (Yamanouchi)

formestane

 Thymidylate Synthase- Pemetrexed (Eli Lilly) Nolatrexed (Eximias)

Inhibitors ZD-9331 (BTG) CoFactor ™ (BioKeys)

 DNA antagonists Trabectedin (PharmaMar) Mafosfamide (Baxter Internatior

 Glufosfamide (Baxter Apaziquon (Spectrum

 International) Pharmaceuticals)

 Albumin + 32P (isotopes 06-benzylguanine (Paligent) Solutions)

 Thymectacin (NewBiotics)

 Edotreotide (Novartis)

 Farnesyltransferase Arglabine (NuOncology Labs) Tipifarnib (Johnson & Johnson Inhibitors lonafarnib (Schering-Plow) Perillyl Alcohol (DOR BioPharrr

 BAY-43-9006 (Bayer)

 Pump inhibitors CBT-1 (CBA Pharma) Zosuquidar trihydrochloride (El

 Tariquidar (Xenova) Lilly)

 MS-209 (Schering AG) Biricodar dicitrate (vertex)

Histone acetyl trans-Tacedinalin (Pfizer) pivaloyloxymethyl butyrate (Titai ferase inhibitors SAHA (Aton Pharma) depsipeptide (Fujisawa)

 MS-275 (Schering AG)

 Metalloproteinase neovastate (Aeterna Laboratorii CMT -3 (CollaGenex)

Inhibitors Marimastat (British Biotech) BMS-275291 (Celltech)

Ribonucleosidredukt; Gallium maltolate (titanium) tezacitabine (Aventis)

 Triapine (Vion) Didox (Molecules for Health) Inhibitors

 TNF-alpha virulizine (Lorus Therapeutics) Revimid (Celgene)

Agonists / AntaCDC-394 (Celgene)

gonisten

Endothelin A Prescription Atrasentan (Abbot) YM-598 (Yamanouchi) Antagonists ZD-4054 (AstraZeneca)

 Retinoic Acid Fenretinide (Johnson & Johnsor Alitretinoin (Ligand)

Agonists LGD-1550 (Ligand)

 Immunomodulators Interferon Dexosome Therapy (Anosys)

 Oncophage (Antigenics) Pentrix (Australian Cancer GMK (Progenics) Technology)

 Adenocarcinoma vaccine JSF-154 (Carrying)

 (Biomira) cancer vaccine (Intercell) CTP-37 (AVI BioPharma) Norelin (Biostar)

 JRX-2 (Immuno-Rx) BLP-25 (Biomira)

 PEP-005 (Peplin Biotech) MGV (Progenics)

 Synchrovax vaccines (CTL! 3-alethine (Dovetail)

 Immuno) CLL-Thera (Vasogen) Melanoma vaccine (CTL

 Immuno)

 p21 RAS vaccine (GemVax)

 Hormonal and estrogenic prednisone

antihormonal agents conjugated estrogens methylprednisolone

 Ethinyl Estradiol Prednisolone

 Chlorotrienes Aminoglutethimide

 Idenestrol Leuprolide

 Hydroxyprogesterone caproate goserelin

 Medroxyprogesterone Leuporelin

 Testosterone Bicalutamide

 Testosterone Propionate Flutamide

 Fluoxymesterone octreotide

 Methyltestosterone Nilutamide

 Diethylstilbestrol Mitotane

 Megestrol P-04 (Novogen)

 Tamoxifen 2-Methoxyestradiol (EntreMed Toremofin Arzoxifen (Eli Lilly)

 dexamethasone

 Photodynamic Mi Talaporfin (Light Sciences) Pd-Bacteriopheophorbide (Yedc

 Theralux (Theratechnologies) Lutetium Texaphyrin

 Motexafin Gadolinium (Pharmacyclics)

 (Pharmacyclics) Hypericin

 Tyrosine Kinase Imatinib (Novartis) Kahalid F (PharmaMar) Inhibitors Leflunomide (Sugen / Pharmacia CEP-701 (Cephalon)

 ZDI839 (AstraZeneca) CEP-751 (Cephalon)

 Erlotinib (Oncogene Science) MLN518 (Millenium)

 Canertjnib (Pfizer) PKC412 (Novartis)

 Squalamine (Genaera) Phenoxodiol 0

 SU5416 (Pharmacia) trastuzumab (Genentech) SU6668 (Pharmacia) C225 (ImClone)

 ZD4190 (AstraZeneca) rhu-Mab (Genentech)

ZD6474 (AstraZeneca) MDX-H210 (Medarex) Vatalanib (Novartis) 2C4 (Genentech)

Midostaurin (PKC inhibitor, MAXIA)

 Novartis) apomin (Apoptosis promoter,

Bryostatin-1 (PKC stimulant, ILEX Oncology)

 GPC Biotech) Urocidin (apoptosis promoter,

CDA-II (Apoptosis promoter, Bioniche)

 Everlife) Ro-31-7453 (apoptosis promoter

SDX-101 (apoptosis promoter, La Roche)

 Salmedix) Brostallicin (Apoptosis-Fördere

Ceflatonin (apoptosis promoter Pharmacia)

 ChemGenex)

 Alkylating agent Cyclophosphamide Lomustine

 Busulfan procarbazine

m ifosfamide altretamine

 I u

 Melphalan estramustin phosphate

 Hexamethylmelamine mechlorethamine

 Thiotepa streptozocin

 Chlorambucil Temozolomide

 Dacarbazine Semustin

 carmustine

 15 platinum agent cisplatin carboplatin

 Oxaliplatin ZD-0473 (AnorMED)

 Spiroplatin Lobaplatin (Aetema)

 Carboxyphthalatoplatinum Satraplatin (Johnson Matthey)

Tetraplatinum BBR-3464 (Hoffrnann-La Roch

Ormiplatin SM-11355 (Sumitomo)

Iproplatin AP-5280 (Access)

 20

 Antimetabolite azacytidine Tomudex

 Gemcitabine trimetrexate

 Capecitabine deoxycoformycin

 5-fluorouracil fludarabine

 Floxuridine pentostatin

 2-chlorodeoxyadenosine Raltitrexed

 6-mercaptopurine hydroxyurea

 25 6-thioguanine decitabine (SuperGen)

 Cytarabine Clofarabine (Bioenvision)

2-Fluorodeoxycytidine Irofulvene (MGI Pharma)

Methotrexate DMDC (Hoffmann-La Roche)

Idatrexate Ethinylcytidine (Taiho)

 Topoisomerase Amsacrine Rubitecane (SuperGen)

30 inhibitors epirubicin exatecan mesylate (Daiichi)

 Etoposide Quinamed (ChemGenex)

Teniposide or Mitoxantrone Gimatecan (Sigma-Tau)

Irinotecan (CPT-11) Diflomotecan (Beaufour-Ipsen)

7-Ethyl-10-hydroxycamptothec TAS-103 (Taiho)

 Topotecan Elsamitrucin (Spectrum)

Dexrazoxanet (TopoTarget) J-107088 (Merck & Co)

Pixantron (Novuspharrna) BNP-1350 (BioNumerik)

35 Rebeccamycin Analog CKD-602 (Chong Kun Dang) (Exelixis) KW-2170 (Kyowa Hakko)

BBR-3576 (Novuspharrna)

Antitumor antibiotics Dactinomycin (Actinomycin D) Amonafide

 Doxorubicin (Adriamycin) Azonafide

 Deoxyrubicin anthrapyrazole

 Valrubicin oxantrazole

 Daunorubicin (Daunomycin) Losoxantrone

 Epirubicin bleomycin sulfate (blenoxan)

Therarubicin bleomycinic acid

 Idarubicin bleomycin A

 Rubidazone bleomycin B

 Plicamycin mitomycin C

 Porfiromycin MEN-10755 (Menarini)

Cyanomorpholinodoxorubicin GPX-100 (Gern Pharmaceutic Mitoxantrone (Novantron)

 Antimitotic agent Paclitaxel SB 408075 (GlaxoSmithKline)

 Docetaxel E7010 (Abbott)

 Colchicine PG-TXL (Cell Therapeutics)

Vinblastine IDN 5109 (Bayer)

 Vincristine A 105972 (Abbott)

 Vinorelbine A 204197 (Abbott)

 Vindesin LU 223651 (BASF)

 Dolastatin 10 (NCI) D 24851 (ASTA Medica) Rhizoxin (Fujisawa) ER-86526 (Eisai)

 Mivobulin (Warner-Lambert) Combretastatin A4 (BMS) Cemadotin (BASF) Isohomohalichondrin-B RPR 109881 A (Aventis) (PharmaMar)

 TXD 258 (Aventis) ZD 6126 (AstraZeneca) Epothilone B (Novartis) PEG Paclitaxel (Enzone) T 900607 (Tularik) AZ10992 (Asahi)

 T 138067 (Tularik)! DN-5109 (Indena)

 Cryptophycin 52 (Eli Lilly) AVLB (Prescient NeuroPharm Vinflunin (Fabre) Azaepothilone B (BMS) Auristatin PE (Teikoku Hormor BNP-7787 (BioNumerik) BMS 247550 (BMS) CA-4 prodrug (OXiGENE) BMS 184476 (BMS) Dolastatin 10 (NrH)

 BMS 188797 (BMS) CA-4 (OXiGENE)

 Taxoprexin (Protarga)

 Aromatase Inhibitors Aminoglutethimide Exemestane

Letrozole Atamestane (BioMedicines) Anastrazole YM-511 (Yamanouchi) Formestan Thymidylate Synthase- Pemetrexed (Eli Lilly) Nolatrexed (Eximias)

Inhibitors ZD-9331 (BTG) CoFactor ™ (BioKeys)

 DNA antagonists Trabectedin (Pharma ar) Mafosfamide (Baxter Internatior

 Glufosfamide (Baxter Apaziquon (Spectrum

 International) Pharmaceuticals)

 Albumin + 32P (isotopes 06-benzylguanine (Paligent) Solutions)

 Thymectacin (NewBiotics)

 Edotreotide (Novartis)

 Farnesyltransferase Arglabine (NuOncology Labs) Tipifarnib (Johnson & Johnson Inhibitors lonafarnib (Schering-Plow) Perillyl Alcohol (DOR BioPharrr

 BAY-43-9006 (Bayer)

 Pump inhibitors CBT-1 (CBA Pharma) Zosuquidar trihydrochloride (El

 Tariquidar (Xenova) Lilly)

 MS-209 (Schering AG) Biricodar dicitrate (vertex)

Histone acetyltransfera tacedinalin (Pfizer) pivaloyloxymethyl butyrate (Titai

 SAHA (Aton Pharma) Depsipeptide (Fujisawa) Inhibitors MS-275 (Schering AG)

 Metalloproteinase neovastate (Aeterna Laboratory CMT -3 (CollaGenex)

Inhibitors Marimastat (British Biotech) BMS-275291 (Celltech)

Ribonucleosidredukt; Gallium maltolate (titanium) tezacitabine (Aventis)

 Triapine (Vion) Didox (Molecules for Health) Inhibitors

 TNF-alpha virulizine (Lorus Therapeutics) Revimid (Celgene)

Agonists / Antagonis CDC-394 (Celgene)

 Endothelin A Prescription Atrasentan (Abbot) YM-598 (Yamanouchi) Antagonist ZD-4054 (AstraZeneca)

 Retinoic Acid Fenretinide (Johnson & Johnsor Alitretinoin (Ligand)

Agonists LGD-1550 (Ligand)

Immunomodulators Interferon Dexosome Therapy (Anosys)

 Oncophage (Antigenics) Pentrix (Australian Cancer GMK (Progenics) Technology)

 Adenocarcinoma vaccine JSF-154 (Carrying)

 (Biomira) cancer vaccine (Intercell) CTP-37 (AVI BioPharma) Norelin (Biostar)

 JRX-2 (Immuno-Rx) BLP-25 (Biomira)

 PEP-005 (Peplin Biotech) MGV (Progenics)

 Synchrovax vaccines (CTL! 3-alethine (Dovetail)

 Immuno) CLL-Thera (Vasogen)

Melanoma vaccine (CTL Immuno)

 p21 RAS vaccine (GemVax)

Hormonal and estrogenic prednisone

antihormonal agents conjugated estrogens methylprednisolone

 Ethinyl Estradiol Prednisolone

 Chlorotrienes Aminoglutethimide

 Idenestrol Leuprolide

 Hydroxyprogesterone caproate goserelin

 Medroxyprogesterone Leuporelin Testosterone Bicalutamide

 Testosterone Propionate Flutamide

 Fluoxymesterone octreotide

 Methyltestosterone Nilutamide

 Diethylstilbestrol Mitotane

 Megestrol P-04 (Novogen)

 Tamoxifen 2-Methoxyestradiol (EntreMed Toremofin Arzoxifen (Eli Lilly)

 dexamethasone

 Photodynamic Mi Talaporfin (Light Sciences) Pd-Bacteriopheophorbide (Yed <

 Theralux (Theratechnologies) Lutetium Texaphyrin

 Motexafin Gadolinium (Pharmacyclics)

 (Pharmacyclics) Hypericin

 Tyrosine Kinase Imatinib (Novartis) Kahalid F (PharmaMar) Inhibitors Leflunomide (Sugen / Pharmacia CEP-701 (Cephalon)

 ZDI839 (AstraZeneca) CEP-751 (Cephalon)

 Erlotinib (Oncogene Science) MLN518 (Millenium)

 Canertjnib (Pfizer) PKC412 (Novartis)

 Squalamine (Genaera) phenoxodiol O

 SU5416 (Pharmacia) trastuzumab (Genentech) SU6668 (Pharmacia) C225 (ImClone)

 ZD4190 (AstraZeneca) rhu-Mab (Genentech)

 ZD6474 (AstraZeneca) MDX-H210 (Medarex) Vatalanib (Novartis) 2C4 (Genentech)

 PKI166 (Novartis) MDX-447 (Medarex)

 GW2016 (GlaxoSmithKline) ABX-EGF (Abgenix)

 EKB-509 (Wyeth) IMC-1 C11 (ImClone)

 EKB-569 (Wyeth)

 Various agents SR-27897 (CCK-A inhibitor, BCX-1777 (PNP inhibitor,

 Sanofi-Synthelabo) BioCryst)

Tocladesin (cyclic AMP ranibirnase (ribonuclease)

CDA-II (apoptosis promoter, brostallicin (apoptosis promoter) Everlife) Pharmacia)

 SDX-101 (apoptosis promoter,

 Salmedix)

 Ceflatonin (apoptosis promotion

 ChemGenex)

Such joint treatment can be achieved by simultaneously, sequentially or separately dosing the individual components of the treatment. Such combination products employ the compounds of the invention.

Furthermore, the invention relates to compounds selected from the group consisting of:

Even without further statements, it is assumed that a person skilled in the art can use the above description to the greatest extent. The preferred embodiments are therefore to be considered as merely a descriptive disclosure, which by no means is limiting in any way.

Above and below, all temperatures are given in ° C. In the examples below, "usual work up" means: if necessary, remove the solvent, add water if necessary, adjust to pH values between 2 and 10, if necessary, to the final product, extracted with ethyl acetate or dichloromethane, separated, the organic phase is washed with saturated NaHC0 ₃ solution, optionally with water and saturated NaCl solution, the organic phase is dried over sodium sulfate, filtered, concentrated and purified by chromatography on silica gel, by preparative HPLC and / or by crystallization The purified compounds are optionally freeze-dried. Mass spectrometry (MS): El (electron impact ionization) M ⁺

FAB (Fast Atom Bombardment) (M + H) ⁺

ESI (electrospray ionization) (M + H) ⁺

APCI-MS (atmospheric pressure chemical ionization mass spectrometry) (M + H) ⁺

HPLC Methods:

Method A:

 Gradient: 4.2 min

 Flow: 2 ml / min 99:01 - 0: 100 water + 0.1% (vol.) TFA: acetonitrile + 0.1% (vol.) TFA

 0.0 to 0.2 min: 99:01

 0.2 to 3.8 min: 99:01 -> 0: 100

 3.8 to 4.2 min: 0: 100

 Column: Chromolith Performance RP18e; 100 mm long, inside diameter 3 mm

Wavelength: 220nm

Method B:

 Gradient: 5.5 min

 Flow: 2.75 ml / min 90:10 - 0: 100 water + 0.01% (vol.) TFA: acetonitrile +

 0.01% (Vol.) TFA

 0.0 to 3.5 min: 90:10 -> 0: 100

 3.5 to 4.3 min: 0: 100

 Column: Chromolith SpeedRod RP18e; 50 mm long, inside diameter 4.6 mm

Wavelength: 220nm

Method C:

 Gradient: 4.2 min

 Flow: 2 ml / min 99:01 - 0: 100 water + 0.05% (vol.) Formic acid: acetonitrile +

0.04% (by volume) of formic acid

 0.0 to 0.2 min: 99:01

 0.2 to 3.8 min: 99:01 -> 0: 100

 3.8 to 4.2 min: 0: 100

 Column: Chromolith Performance RP18e; 100 mm long, inside diameter 3 mm

Wavelength: 220nm

List of abbreviations and acronyms: AcOH acetic acid, wf. anhydrous, atm atmosphere (s), BOC tert-butoxycarbonyl CDI 1, 1'-carbonyldiimidazole, conc. concentrated, the day (s), Zers. Decomposition, DMAC Ν, Ν-dimethylacetamide, DMPU 1, 3-dimethyl-3,4,5,6-tetrahydro-2 (1 H) -pyrimidinone, DMF Ν, Ν-dimethylformamide, DMSO dimethylsulfoxide, DPPA

Diphenylphosphoryl azide, EDCI 1 - (3-dimethylaminopropyl) -3-ethylcarbodiimide, EtOAc ethyl acetate, EtOH ethanol (100%), Et ₂ 0 diethyl ether, Et ₃ N triethylamine, h (n), MeOH methanol, pet.-ether petroleum ether ( Boiling range 30-60 ° C), temp. Temperature, THF tetrahydrofuran, TFA trifluoro AcOH, Tf trifluoromethanesulfonyl, RT room temperature.

The content of all cited reference is incorporated herein by reference in its entirety. The invention is further illustrated by the following examples, but is not limited thereto.

Examples

I. Synthesis of Selected Compounds of the Invention

 The following compounds were synthesized and characterized. It is, however, one of skill in the art to otherwise prepare and characterize these compounds.

Preparation of Bromocarbonyl Compounds:

Preparation of 2-bromo-1 - {5,6,7,8-tetrahydro-naphthalen-2-yl) -ethanone:

25 g (143 mmol) of 1- (5,6,7,8-tetrahydro-naphthalen-2-yl) -ethanone were dissolved in 750 ml of THF, combined with 64.7 g (172 mmol) of phenyltrimethylammonium tribromide and stirred at room temperature for 15 h. The resulting precipitate was filtered and the filtrate was evaporated to dryness. The residue was taken up in ethyl acetate, washed with 2 x sat. Sodium bicarbonate solution and 1 x sat. Sodium chloride solution was washed, the organic phase was over

Dried sodium sulfate and evaporated to dryness.

 Yield: 62 g, white solid.

 HPLC: Rt. = 3.06 min.

Analogously to the above-mentioned instructions, the following compounds can be prepared. In some cases, a purification was by means of

Column chromatography on silica gel required:

 Rt.

 Synthetic

 Communications 2001,

31 (6), 877-892

 (Method A)

Journal of Organic

Chemistry 1984, 51 (26),

 Journal of Organic

Chemistry 1963, 29 (9),

 -2,255

 Journal of Organic

Chemistry 1963, 29 (9),

2248-2255

de A)

C)

Preparation of 2-bromo-1- {1,1-dimethyl-indan-5-yl) -ethanones:

 Stage a:

 3.72 g (16.5 mmol) of 5-bromo-1, 1-dimethylindane are dissolved in 100 ml of THF and degassed. Subsequently, 11.2 ml (33.05 mmol)

1 (ethoxyvinyl) tributyltin and 1.1 g (1.6 mmol) of bis (triphenylphosphine) palladium (II) dichloride. The reaction mixture was taken

Nitrogen atmosphere refluxed for 15 h. After cooling, a pH of 2 was adjusted with 2N HCl and stirred at RT for a further 15 h. The

The reaction mixture was diluted with water and extracted three times with ethyl acetate. The combined organic phases were washed with saturated NaHC0 ₃ solution and saturated NaCl solution, dried over Na ₂ S0 ₄ and evaporated. The residue was chromatographed on silica gel by column chromatography.

 Yield: 2.4 g, oil.

HPLC: Rt. = 3.22 min (Method A). Stage b:

 The α-bromination is carried out as described above

Phenyltrimethylammonium.

 Yield: 3.1 g, yellow oil.

 HPLC: Rt. = 3.41 min (Method A).

Preparation of 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine Hydrobromide:

 930 mg (3.0 mmol) of 2-bromo-1- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -ethanone and 778 mg (3.0 mmol) (1 -Thiocarbamoyl-piperidin-4-yl) -carbamic acid tert-butyl ester were suspended in 15 ml of ethanol and refluxed for 24 h. The precipitate was filtered off with suction and washed with ethanol and ether. The residue was dried in vacuo.

 Yield: 900 mg, solid. The product is available as hydrobromide.

 LCMS: 370 (M + H), HPLC: Rt = 2.89 min (Method A).

The following compounds can be prepared analogously to the abovementioned instructions. In some cases, purification by extraction, column chromatography on silica gel or preparative HPLC required:

 Starting material product Rt.

¹ H NMR (500 MHz, DMSO / deuterated

 TFA) δ 7.35 (d, J = 8.2, 1H), 7.29 (d, J = LCMS: 342 8.2, 1H), 7.22 (s, 1H), 4.05 (d, J = 13.6, 2H), M + H) 3.42 - 3.29 (m, 3H), 2.69 (t, J = 6.3, 2H),

 2.08 (d, J = 9.7, 2H), 1.77 - 1.65 (m, 4H),

 1.60 - 1.54 (m, 2H), 1.16 (s, 6H).

35 Analog can be produced:

1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazine:

Yield: 27 mg, oil. The product is present as trifluoroacetate.

 Rt = 3.04 min (Method A), LCMS: 356 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.75 (d, J = 1.5, 1H), 7.53 (dd, J = 8.2, 1.6, 1 H), 7.32 (d, J = 8.3, 1 H), 3.76-3.68 (m, 4H), 3.34-3.26 (m, 4H), 1.64 (s, 4H), 1.25 (d, J = 16.7, 12H). 4- (5,5-Dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -2-pyrrolidin-3-yl-thiazoles:

 The preparation is carried out as described above starting from 3-thiocarbamoyl-pyrrolidine-1-carboxylic acid tert-butyl ester. The cleavage of the Boc protective group is carried out as described with 4 N HCl in dioxane.

 Yield: 1.07 g, yellow solid. Product is available as hydrochloride.

 Rt = 2.82 min (Method A), LCMS: 313 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated δ 7.78 (d, J = 1.3, 1 H), 7.72 (d, J = 8.2, 1 H), 7.65 (s, 1 H), 7.42 (d, J = 8.2 , 1 H), 4.06 (p, J = 7.2, 1 H), 3.74 (dd, J = 11.7, 7.9, 1 H), 3.65 (dd, J = 11.7, 7.0, 1 H), 3.54 - 3.46 (m , 1 H), 3.44 - 3.36 (m, 1 H), 2.82 (t, J = 6.3, 2H), 2.52 (td, J = 13.6, 7.4, 1 H), 2.30 (dq, J = 14.9, 7.4, 1H), 1.86-1.79 (m, 2H), 1.72-1.66 (m, 2H), 1.29 (s, 6H). 1- [4- <5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] - [4,4'-bipiperidinyl:

Stage a:

 403 mg (0.50 mmol) of [4,4 '] bipiperidinyl-1-carboxylic acid tert-butyl ester were dissolved in 5 ml of THF and admixed with a solution of 310 mg (1.65 mmol) of thiocarbonylimidazole. The reaction mixture is stirred for 2 h at RT and then treated with 5 ml of 25% ammonia solution. The

The reaction mixture was irradiated for 3 hours at 60 ° C in the microwave. After cooling, the reaction mixture was concentrated, treated with water, the residue was filtered off with suction and washed with a little water.

 300 mg, white solid.

 Rt = 2.75 min (Method A), LCMS: 328 (M + H).

Stage b:

 The reaction with the bromocarbonyl compound is carried out as described above.

 Yield: 76 mg, oil. The product is available as hydrobromide.

 Rt = 3.14 min (Method A), LCMS: 438 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.78 (s, 1H), 7.54 (d, J = 8.2, 1H), 7.38 (d, J = 8.3, 1H), 3.91 (d, J = 13.2, 2H), 3.31 (d, J = 12.5, 2H), 3.03 (t, J 11.4, 2H), 2.83 (t, = 11.7, 2H), 1.81 (dd, J = 31.7, 12.4, 4H), 1.68 (s, 4H), 1.47 - 1.20 (m, 18H). 4- (2-pyrrole ^{"idin-1-yl-ethyl)} -1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol -2-yl] -piperidine:

 The preparation is carried out as described above starting from 4- (2-pyrrolidin-1-yl-ethyl) -piperidines.

 Yield: 76 mg, oil.

 Rt = 3.14 min (Method A), LCMS: 452 (M + H).

1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-4-carboxylic acid ethyl ester

 The preparation is carried out as described above starting from piperidine-4-carboxylic acid ethyl ester.

 Yield: 83 mg, white solid. The product is present as hydrochloride. Rt = 4.20 min (Method A), LCMS: 428 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ 7.64 (d, J = 1.4, 1H), 7.51-7.41 (m, 2H), 4.12 (q, J = 7.1, 2H), 4.02 (d, J = 13.2, 2H), 3.46 (t, J = 10.9, 2H), 2.80 - 2.69 (m, 1H), 2.06 (dd, J = 13.4, 3.1, 2H), 1.88 - 1.73 (m, 2H), 1.69 (s, 4H), 1.30 (d, J = 12.6, 12H), 1.22 (t, J = 7.1, 3H).

1- {1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} - pyrrolidin-3-ylamine:

 The preparation is carried out as described above starting from (1-piperidin-4-yl-pyrrolidin-3-yl) -carbamic acid tert-butyl ester. For the removal of the Boc protective group, 150 mg (0.28 mmol) of (H1- [4- (5,5,8,8-tetramethyl-5,6,7

, 8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} -pyrrolidin-3-yl) - tert-butyl carbamic acid added with 5 ml of 4N HCl in dioxane and 15 h at RT touched. The Niderschlag was filtered off, washed with dioxane and dried in vacuo.

 Yield: 119 mg, greenish solid. The product is present as hydrochloride.

 Rt = 2.73 min (Method A), LCMS: 439 (M + H).

C- {1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} - methylamine:

The preparation is carried out as described above starting from piperidine-4-ylmethyl-carbamic acid tert-butyl ester. The cleavage of the Boc protective group is carried out as described with 4 N HCl in dioxane.

 Yield: 32 mg, beige solid. The product is present as hydrochloride.

 Rt. = 3.03 min (Method A), LCMS: 384 (M + H).

1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -pyrrolidin-3-ylamine:

 The preparation is carried out as described above starting from pyrrolidin-3-yl-carbamic acid tert-butyl ester. The cleavage of the Boc protective group is carried out as described with 4 N HCl in dioxane.

 Yield: 123 mg, light green solid. The product is present as hydrochloride.

Rt = 2.69 min (Method A), LCMS: 356 (M + H). 2- {1- [4- <5,5,8,8-tetramethyl-5,6,7 _I 8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} - ethylamine:

 The preparation is carried out as described above starting from (2-piperidin-4-yl-ethyl) -carbamic acid tert-butyl ester. The cleavage of the Boc protective group is carried out as described with 4 N HCl in dioxane.

 Yield: 43 mg, light green solid. The product is present as hydrochloride.

Rt = 2.93 min (Method A), LCMS: 398 (M + H).

4- {1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} - morpholine:

The preparation is carried out as described above starting from 4-piperidin-4-yl-morpholines.

 Yield: 495 mg, light yellow solid.

 Rt. = 2.90 min (Method A), LCMS: 440 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.70 (d, J = 1.8, 1H), 7.52 (dd, J = 8.2, 1.8, 1H), 7.41 (d, J = 8.2, 1H) , 4.21 (d, J = 12.8, 2H), 4.05 (d, J = 11.3, 2H), 3.74 (t, J = 12.0, 2H), 3.64 - 3.55 (m, 1 H), 3.51 (d, J = 11.4, 2H), 3.31 (t, J = 12.0, 2H), 3.23 - 3.16 (m, 2H), 2.27 (d, J = 10.1, 2H), 1.91 - 1.82 (m, 2H), 1.70 (d, J = 6.7, 4H), 1.30 (d, J = 16.4, 12H).

1-methyl-4- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-4 yl} piperazines:

 The preparation is carried out as described above starting from 1-methyl-4-piperidin-4-yl-piperazine. Yield: 326 mg, yellow solid.

Rt. = 2.86 min (Method A), LCMS: 453 (M + H). 3- [4- <5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] - 3,9-diaza-spiro [5.5] undecane:

 The preparation is carried out as described above starting from 3,9-diazaspiro [5.5] undecane-3-carboxylic acid tert-butyl ester. The cleavage of the Boc protective group is carried out as described with 4 N HCl in dioxane.

 Yield: 31 mg, green solid. Product is available as hydrochloride.

 Rt. = 2.94 min (Method A), LCMS: 424 (M + H).

3- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine:

The preparation is carried out as described above starting from 3-carbamoyl-piperidine-1-carboxylic acid tert-butyl ester. The cleavage of the Boc protective group is carried out as described with 4 N HCl in dioxane. Product is available as hydrochloride.

 Yield: 3 mg.

 Rt = 3.08 min (Method A), LCMS: 341 (M + H).

1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-4-carboxylic acid (2-hydroxy ethyl) amides:

 , The preparation is carried out as described above starting from piperidine-4-carboxylic acid (2-hydroxyethyl) amides.

 Yield: 89 mg, beige solid.

Rt. = 2.94 min (method A), LCMS: 442 (M + H). 1 '- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] - [1, 4 "] bipiperidyl 3-ol:

The preparation is carried out as described above, starting from

[1, 4 '] bipiperidinyl-3-ol.

 Yield: 31 mg, light green solid. Product is available as hydrochloride.

 Rt. = 2.94 min (Method A), LCMS: 454 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.69 (s, 1H), 7.51 (dd, J = 8.2, 1.8, 1H), 7.36 (d, J = 8.3, 1H), 4.20 - 4.07 ( m, 3H), 3.56 (s, 1H), 3.46-3.35 (m, 1H), 3.30 (d, J = 12.0, 1H), 3.23 (d, J = 12.6, 2H), 3.10-3.01 (m, 1 H), 2.93 - 2.63 (m, 1 H), 2.15 (dt, J = 32.0, 17.1, 3H), 2.00 - 1.67 (m, 5H), 1.66 (s, 4H), 1.26 (d, J = 16.1 , 12H).

3- {1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} - propane-1-ol:

The preparation is carried out as described above starting from 3-piperidin-4-yl-propan-1-ol.

 Yield: 16 mg, beige solid. Product is available as hydrochloride. Rt. = 3.22 min (Method A), LCMS: 413 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.61 (d, J = 1.6, 1H), 7.49-7.42 (m, 2H), 4.07 (d, J = 12.6, 2H), 3.45 (t, J = 6.5, 2H), 3.38 (dd, J = 12.6, 10.4, 2H), 1.89 (d, J = 11.0, 2H), 1.70 (s, 4H), 1.68 - 1.47 (m, 3H), 1.38 - 1.24 (m , 16H).

 2- 1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-3-yl} -ethanol :

The preparation is carried out as described above starting from 2-piperidine-3-yl-ethanol.

 Yield: 69 mg, beige solid. Product is available as hydrochloride. Rt. = 3.12 min (Method A), LCMS: 399 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.62 (s, 1H), 7.48-7.43 (m, 2H), 3.97 (d, J = 12.8, 2H), 3.56 - 3.50 (m, 2H), 3.35 (t, J = 10.9, 1H), 3.16 - 3.06 (m, 1H), 1.91 - 1.81 (m, 4H), 1.69 (s, 4H), 1.68 - 1.36 (m, 4H), 1.29 (d, J = 15.0, 12H).

1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-3-carboxylic acid (2-hydroxy ethyl) amides:

 The preparation is carried out as described above starting from piperidine-3-carboxylic acid (2-hydroxy-ethyl) amides.

 Yield: 20 mg, beige solid. Product is available as hydrochloride. Rt = 2.96 min (method A), LCMS: 442 (M + H).

1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-3-carboxylic acid (3-hydroxy propyl) amides:

 The preparation is carried out as described above starting from piperidine-3-carboxylic acid (3-hydroxypropyl) amides.

 Yield: 60 mg, yellow solid. Product is available as hydrochloride.

 Rt. = 3.01 min (Method A), LCMS: 456 (M + H).

 H NMR (500 MHz, DMSO / deuterated TFA) δ 7.65 (d, J = 1.5, 1H), 7.48 (dd, J

= 8.2, 1.7, 1 H), 7.43 (d, J = 8.3, 1 H), 4.02 (d, J = 9.6, 1 H), 3.87 (d, J = 13.4, 1 H), 3.50 - 3.34 (m , 5H), 3.20 - 3.08 (m, 2H), 2.58 (dd, J = 9.0, 5.0, 1H), 2.00 - 1.92 (m, 1H), 1.84 (dd, J = 9.4, 4.2, 1H) , 1.75 - 1.62 (m, 6H), 1.62 - 1.54 (m, 2H), 1.29 (d, J = 15.8, 12H). S-ilWS.See-tetramethyl-S. E.e.-tetrahydro-naphthalene ^ -y-thiazol-1-yl] -piperidin-3-yl} -propan-1-ol:

 The preparation is carried out as described above starting from 3-piperidin-3-yl-propan-1-ol.

 Yield: 18 mg, beige solid. Product is available as hydrochloride. Rt = 3.19 min (Method A), LCMS: 413 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.65 (d, J = 1.5, 1H), 7.48 (dd, J = 8.2, 1.7, 1 H), 7.43 (d, J = 8.3, 1 H), 4.02 (d, J = 9.6, 1H), 3.87 (d, J = 13.4, 1H), 3.50 - 3.34 (m, 5H), 3.20 - 3.08 (m, 2H), 2.58 (dd, J = 9.0, 5.0, 1H), 2.00-1.92 (m, 1H), 1.84 (dd, J = 9.4, 4.2, 1H), 1.75-1.62 (m, 6H), 1.62- 1.54 (m, 2H), 1.29 ( d, J = 15.8, 12H).

(R) -1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphtha-en-2-yl) -thiazol-2-yl] -pyrrolidine-3 ylamine:

 The preparation is carried out as described above starting from (R) -pyrrolidin-3-yl-carbamic acid tert-butyl ester. The cleavage of the Boc protective group is carried out as described with 4 N HCl in dioxane.

 Yield: 250 mg, yellow solid. Product is available as hydrochloride.

 Rt = 2.72 min (Method A), LCMS: 356 (M + H).

(S) -1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -pyrrolidin-3-ylamine:

The preparation is carried out as described above starting from (S) -pyrrolidin-3-yl-carbamic acid tert-butyl ester. The cleavage of the Boc protective group is carried out as described with 4 N HCl in dioxane. Yield: 136 mg, yellow solid. Product is available as hydrochloride.

 Rt = 2.73 min (Method A), LCMS: 356 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ 7.63 (d, J = 1.5, 1H), 7.52-7.44 (m, 2H), 4.16 (d, J = 5.4, 1H), 4.01 (dd, J = 12.1, 5.9, 1H), 3.92-3.72 (m, 3H), 2.57-2.45 (m, 1H), 2.39-2.26 (m, 1H), 1.71 (s, 4H), 1.31 (d, J = 12.2, 12H ).

3- {4- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazine-1-yl} - propane-1,2-diol:

 The preparation is carried out as described above starting from 3-piperazin-1-yl-propane-1, 2-diol.

 Yield: 41 mg, beige solid. Product is available as hydrochloride.

Rt. = 3.02 min (Method A), LCMS: 430 (M + H).

 1H NMR (400 MHz, DMSO / deuterated TFA) δ 7.79 (d, J = 1.9, 1H), 7.58 (dd, J

= 8.2, 1.9, 1H), 7.38 (d, J = 8.3, 1H), 4.27-4.10 (m, 2H), 4.07-3.99 (m, 1H), 3.66 (d, J = 35.1, 4H), 3.52 ( dd, J = 11.1, 4.8, 1H), 3.46-3.30 (m, 4H), 3.20 (dd, J = 13.1, 10.4, 1H), 1.70 (s, 4H), 1.30 (d, J = 14.5, 12H) ,

Dimethyl {1- [4- {5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} - amine:

The preparation is carried out as described above starting from dimethylpiperidin-4-yl-amines.

 Yield: 53 mg, yellow solid. Product is available as hydrochloride.

 Rt. = 3.00 min (Method A), LCMS: 398 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ 7.71 (d, J = 1.9, 1H), 7.53 (dd, J = 8.2, 1.9, 1H), 7.39 (d, J = 8.3, 1H), 4.18 ( d, J = 13.4, 2H), 3.56-3.46 (m, 1H), 3.25 (t, J = 11.7, 2H), 2.82 (s, 6H), 2.16 (d, J = 10.6, 2H), 1.87 - 1.74 (m, 2H), 1.68 (s, 4H), 1.28 (d, J = 12.8, 12H). 4- [4-5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -cyclohexylamine

The preparation is carried out as described above starting from (4-carbamoylcyclohexyl) -carbamic acid tert-butyl ester. The cleavage of the Boc protective group is carried out as described with 4 N HCl in dioxane.

 Yield: 225 mg, yellow solid. Product is available as hydrochloride.

 Rt = 3.12 min (Method A), LCMS: 369 (M + H).

2- {4- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazin-1-yl} - cyclohexanol:

 The preparation is carried out as described above starting from 2-piperazine-1-yl-cyclohexanol.

 Yield: 42 mg, white solid. Product is available as hydrochloride.

 Rt. = 3.17 min (Method A), LCMS: 454 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.83 (d, J = 1.9, 1H), 7.58 (dd, J = 8.3, 1.9, 1H), 7.39 (d, J = 8.3, 1H) , 4.05 (dd, = 26.9, 12.7, 2H), 3.74 - 3.63 (m, 2H), 3.56 - 3.35 (m, 5H), 3.22 - 3.09 (m, 1H), 2.03 (t, J = 13.5, 2H ), 1.82 - 1.75 (m, 1H), 1.72 - 1.63 (m, 5H), 1.51 - 1.19 (m, 16H).

2-Pyrrolidin-3-yl-4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazoles:

The preparation is carried out as described above starting from 3-carbamoylpyrrolidine-1-carboxylic acid tert-butyl ester. The cleavage of the Boc protective group is carried out as described with 4 N HCl in dioxane. Yield: 30 mg, light yellow solid. Product is available as hydrochloride.

 Rt. = 2.99 min (Method A), LCMS: 341 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ 7.98 (s, 1H), 7.89 (d, J = 1.7, 1H), 7.70 (dd, J = 8.2, 1.8, 1H), 7.39 (i.e. , J = 8.3, 1H), 4.05 (p, J = 7.6, 1H), 3.74 (dd, J = 11.6, 8.0, 1H), 3.62 - 3.51 (m, 1H), 3.51 - 3.31 (m , 2H), 2.53 - 2.44 (m, 1H), 2.30 - 2.17 (m, 1H), 1.69 (s, 4H), 1.30 (d, J = 16.8, 12H).

1- [4- (5,5-Dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazine:

 The preparation is carried out as described above starting from piperazine 1-carboxylic acid tert-butyl ester. The cleavage of the Boc protective group is carried out as described with 4 N HCl in dioxane.

 Yield: 31 mg, light yellow solid. Product is available as hydrochloride.

 Rt = 2.89 min (Method A), LCMS: 328 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.59 (dd, J = 8.2, 1.7, 1H), 7.51 (d, J = 1.2, 1H), 7.38 (d, J = 8.2, 1H) , 3.78 - 3.72 (m, 4H), 3.34 - 3.29 (m, 4H), 2.77 (t, J = 6.2, 2H), 1.82 - 1.74 (m, 2H), 1.68 - 1.62 (m, 2H), 1.27 ( s, 6H).

2- (4- {1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-4- yl} -piperazin-1-yl) ethanol:

The preparation is carried out as described above starting from 2- (4-piperidin-4-yl-piperazin-1-yl) -ethanol.

 Yield: 310 mg, light yellow solid. Product is available as hydrochloride.

 Rt = 2.77 min (Method A), LCMS: 483 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated δ 7.66 (d, J = 1.5, 1H), 7.51-7.43 (m, 2H), 4.30 (d, J = 13.1, 2H), 3.96-3.36 (m, 15H ), 2.33 (d, J = 11.2, 2H), 2.00 (dd, J = 20.2, 11.7, 2H), 1.72 (s, 4H), 1.31 (d, J = 12.9, 12H). 1- [4- {1-Dimethyl-indan-5-yl) -thia-2-ol-2-yl] -piperidin-4-ylamine:

The preparation is carried out as described above starting from (1-thiocarbamoyl-piperidin-4-yl) -carbamic acid tert-butyl ester.

 Yield: 1.07 g, light green solid. Product is available as hydrochloride.

 Rt = 2.59 min (Method A), LCMS: 328 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated δ 7.61-7.53 (m, 2H), 7.27 (d, J = 7.8, 1H), 4.15 (d, J = 13.8, 2H), 3.44 (t, J = 1 1.6, 3H), 2.94 (t, J = 7.1, 2H), 2.14 (d, J = 10.2, 2H), 1.95 (dd, J = 12.5, 5.2, 2H), 1.85 - 1.70 (m, 2H), 1.27 (s, 6H).

2- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazine-1-yl} - ethanol:

75 mg (0.16 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazine trifluoroacetate were washed with 14 μΙ (0.19 mmol) of 2-chloroethanol in 6 ml of ethanol and 55 μΙ (0.39 mmol) of triethylamine for 2 h at 160 ° C in the microwave irradiated. The reaction mixture was evaporated and purified by preparative HPLC.

 Yield: 16 mg, oil. The product is present as trifluoroacetate.

 LCMS: 400 g / mol [M + H], HPLC: Rt. = 3.02 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.79 (d, J = 1.9, 1H), 7.58 (dd, J = 8.2, 1.9, 1H), 7.35 (d, J = 8.3, 1H), 4.12 (b, 2H), 3.86-3.79 (m, 2H), 3.60 (dd, J = 32.2, 19.3, 4H), 3.40-3.25 (m, 4H), 1.68 (s, 4H), 1.29 (d, J = 17.3, 12H).

Analog are produced:

 3- {4- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazine-1-yl} - propane-1-ol:

Yield: 34 mg, oil.

 LCMS: 414 g / mol [M + H], HPLC: Rt. = 3.10 min (Method A).

H NMR (400 MHz, DMSO / deuterated TFA) δ 7.76 (d, J = 1.8, 1H), 7.55 (dd, J = 8.2, 1.9, 1H), 7.32 (d, J = 8.3, 1H), 4.12 (i.e. , J = 13.1, 2H), 3.64 (d, J = 10.9, 2H), 3.51 (t, J = 5.9, 2H), 3.47 - 3.37 (m, 2H), 3.32 - 3.16 (m, 4H), 1.90 - 1.79 (m, 2H), 1.64 (s, 4H), 1.25 (d, J = 13.7, 12H). 4- {3- [4- {5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-1-yl} - propane-1-ol:

The preparation is carried out starting from 3- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine hydrobromide and Chloropropan-1-ol. The product is present as hydrochloride.

 Yield: 33 mg, solid.

 LCMS: 413 [M + H], HPLC: Rt. = 3.01 min (Method A).

4- {3- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-1-yl} - ethanol:

The product is available as TFA salt.

 Yield: 26 mg, solid.

 LCMS: 399 [M + H], HPLC: Rt. = 3.00 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.98 (d, J = 28.1, 1H), 7.90 (dd, J = 8.3, 1.8, 1H), 7.74 (ddd, J = 45.6, 8.3, 1.8 , 1H), 7.39 (d, J = 8.3, 1H), 3.97 (d, J = 10.6, 1H), 3.93 - 3.82 (m, 2H), 3.74 - 3.60 (m, 2H), 3.45 - 3.25 (m, 3H), 3.12 - 3.04 (m, 1H), 2.26 (d, J = 11.8, 1H), 2.06 - 1.98 (m, 2H), 1.85 - 1.75 (m, 1H), 1.70 (s , 4H), 1.30 (d, J = 21.1, 12H).

4- 4- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazin-1-yl} -butane -1-ol:

120 mg (0.34 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazine were mixed with 100 suspended μΙ_ (0.68 mmol) 4-bromobutyl acetate and 56 mg (0.41 mmol) of potassium carbonate in 3 mL of DMF and stirred overnight at 60 ° C. The reaction mixture was taken up in dichloromethane, washed once each with a concentrated sodium bicarbonate solution and a 1N hydrochloric acid solution. The organic phase was dried over sodium sulfate, filtered and evaporated. The splitting off of

Protecting group is carried out by means of a 1 N NaOH solution in methanol: Das

The reaction mixture was stirred at room temperature and then concentrated. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 Yield: 47 mg, yellow solid.

 LCMS: 428 [M + H], HPLC: Rt. = 3.13 min (Method A).

The following compounds were prepared analogously. In some cases further purification by preparative HPLC was not required. In some cases, the crude products were purified by column chromatography on silica gel, which was then partially converted to the hydrochloride with 4N HCl in dioxane or 1.25 M HCl in methanol:

4- 3- [4- (5,5-Dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -pyrrolidin-1-yl} -butan-1-ol :

The preparation is carried out starting from 4- (5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -2-pyrrolidin-3-yl-thiazole hydrobromide and 4-bromo-butyl acetate. The deprotection is carried out by means of a 1 N NaOH solution in Methanol. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 Yield: 11 mg, solid.

 LCMS: 385 [M + H], HPLC: Rt. = 2.85 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.80-7.76 (m, 1H), 7.66-7.62 (m, 1H), 7.57 (d, J = 4.9, 1H), 7.34 (d, J = 8.2, 1H), 4.20 - 3.92 (m, 2H), 3.73 - 3.59 (m, 1H), 3.45 (t, J = 6.1, 2H), 3.34 - 3.18 (m, 3H), 3.15 (s, 1 H), 2.74 (t, J = 6.3, 2H), 2.49 - 2.15 (m, 2H), 1.74 (dd, J = 12.4, 6.1, 4H), 1.64 - 1.58 (m, 2H), 1.49 (dq, J = 12.2, 6.0, 2H), 1.22 (s, 6H).

5- {3- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-1-yl} - pentane-1-ol:

 The preparation is carried out starting from 3- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine hydrobromide and Chloropentyl acetate. The deprotection is carried out by means of a 1 N NaOH solution in methanol. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 Yield: 16 mg, solid.

 LCMS: 441 [M + H], HPLC. Rt. = 3.05 min (method A).

4- {3- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-1-yl} - butane-1-ol:

 The preparation is carried out starting from 3- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine hydrobromide and Bromobutyl acetate. The deprotection is carried out as described by means of a 1 N NaOH solution in methanol. The product was purified by preparative HPLC and by treatment with methanolic HCl in the

Hydrochloride transferred. Yield: 12 mg, solid.

LCMS: 427 [M + H], HPLC: Rt. = 3.02 min (Method A).

Preparation of (2- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidine-1 yl} -ethyl) -carbamic acid-tert-butyl ester:

100 mg (0.23 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazine hydrobromide were washed with 7 ml THF and 200 μΙ

Glacial acetic acid. 47 mg (0.46 mmol) of 5-hydroxy pentanal were added and the mixture was stirred for 30 min. Subsequently, 97 mg (0.46 mmol) of sodium trisacetoxyborohydride were added and the reaction mixture was stirred at room temperature for 24 h. The reaction mixture was filtered, the

Mother liquor was evaporated and the residue by means of

Column chromatography on silica gel.

 Yield: 56 mg of solid.

 ESI: 442 (M + H), HPLC: 3.16 min (method A)

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.79 (d, J = 1.8, 1H), 7.58 (dd, J = 8.2, 1.8, 1H), 7.34 (d, J = 8.3, 1H), 4.14 (d, J = 13.5, 2H), 3.64 (d, J = 10.7, 2H), 3.50 - 3.38 (m, 4H), 3.29 - 3.15 (m, 4H), 1.72 (dt, J = 9.5, 6.6, 2H), 1.68 (s, 4H), 1.54 - 1.46 (m, 2H), 1.40 (t, J = 14.8, 7.2, 2H), 1.32 - 1.24 (m, 12H).

The following compounds were prepared analogously. In some cases, using ketones instead of aldehydes required an increase in the reaction temperature to 40 ° C or an increase in the reaction time:

(1H-imidazo -ylmethyl) - {1- [4- (5,5,8,8-tetramethyl-5 ₍ 6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] - piperidin-4-yl} -amine:

Yield: 20 mg, solid. The product is available as TFA salt.

 ESI: 450 (M + H), HPLC: 2.85 min (Method A)

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 9.19 (d, J = 1.2, 1H), 7.82 (s, 1H), 7.73 (d, J = 1.7, 1H), 7.54 (dd, J = 8.2, 1.7, 1 H), 7.39 (d, J = 8.3, 1 H), 4.44 (s, 2H), 4.15 (d, J = 13.5, 2H), 3.55 - 3.46 (m, 1H), 3.31 (t, J = 12.0, 2H), 2.26 (d, J = 10.2, 2H), 1.83 - 1.73 (m , 2H), 1.69 (s, 4H), 1.29 (d, = 16.3, 13H).

(3-Methyl-3H-imidazol-4-ylmethyl) -1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2 yl] -piperidin-4-yl} -amine:

 Yield: 38 mg, solid, product is the hydrochloride.

 LCMS: 464 [M + H], HPLC: Rt. = 2.85 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ 7.85 (d, J = 1.4, 1H), 7.74 (d, J = 1.6, 1 H), 7.55 (dd, J = 8.2, 1.7, 1 H), 7.38 (d, J = 8.3, 1H), 4.50 (s, 2H), 4.15 (d, J = 13.3, 2H), 3.95 (s, 3H), 3.59 (s, 1H), 3.29 (t, J = 12.0, 2H), 2.28 (d, J = 10.3, 2H), 1.84-1.72 (m, 2H), 1.68 (s, 4H), 1.29 (d, J = 13.1, 12H).

Bis (1H-pyrazol-3-ylmethyl) - {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazole-2-one] yl] -piperidin-4-yl} -amine:

 Yield: 52 mg, solid.

 LCMS: 530 [M + H], HPLC: Rt. = 3.08 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.82 (d, J = 2.2, 2H), 7.68 (d, J = 1.8, 1 H), 7.50 (dd, J = 8.2, 1.8, 1 H), 7.43 (d, J = 8.3, 1 H), 6.53 (d, J = 2.2, 2H), 4.49 (s, 4H), 4.22 (d, J = 13.2, 2H), 3.62 (t, J = 11.8, 1 H), 3.33 (t, J = 12.1, 2H), 2.39 (d, J = 11.6, 2H), 2.12 - 2.01 (m, 2H), 1.71 (s, 4H), 1.30 (d, J = 16.7, 12H ). 2- {1- [4- {5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} - ethanol:

The preparation is carried out starting from 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamine hydrobromide and (tert-butyl-dimethyl-silanyloxy) -acetaldehyde. The deprotection is carried out in THF with 5 equivalents of a 1 M TBAF-THF solution: Das

The reaction mixture was stirred for 2 h at room temperature and until

Residue is concentrated. The product was reversed-phase

Purified by chromatography. The fractions were basified, dried, filtered and concentrated.

 Yield: 120 mg, white solid.

 LCMS: 414 [M + H], HPLC: Rt. = 2.75 min (Method B).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ 7.70 (d, J = 1.5, 1 H), 7.52 (dd, = 8.2, 1.5, 1 H), 7.44 (d, J = 8.3, 1 H), 4.18 (d, J = 13.3, 2H), 3.79-3.71 (m, 2H), 3.55-3.43 (m, 1H), 3.38 (t, J = 12.0, 2H), 3.16-3.10 (m, 2H), 2.26 (d, J = 10.7, 2H), 1.82 (qd, J = 12.4, 4.4, 2H), 1.71 (s, 4H), 1.31 (d, J = 13.0, 12H).

3- {1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} - propane-1-ol:

 The preparation is carried out starting from 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamine hydrobromide and 3- (terf-butyl-dimethyl-silanyloxy) -propionaldehyde. The splitting off of

Protecting group is carried out as already described by means of a 1 M TBAF-THF solution. The product was purified by reversed-phase chromatography. The fractions were basified, dried, filtered and concentrated.

 Yield: 19 mg, white solid.

 LCMS: 428 [M + H], HPLC: Rt. = 2.70 min (Method B).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.73 (d, J = 1.8, 1H), 7.55 (dd, J = 8.2, 1.8, 1H), 7.42 (d, J = 8.3, 1H) , 4.15 (d, J = 13.3, 2H), 3.57 (t, J = 5.9, 2H), 3.51 - 3.40 (m, 1H), 3.32 (t, J = 11.8, 2H), 3.14 - 3.07 (m, 2H), 2.21 (d, J = 10.4, 2H), 1.87 - 1.72 (m, 4H), 1.71 (s, 4H), 1.31 (d, J = 16.2, 12H).

(R) -2-amino-3- {1- [4- <5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] piperidin-4-ylamino} -propan-1-ol:

 The preparation is carried out starting from 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamine hydrobromide and (S) - 4-formyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester. The

Cleavage of the protective group is carried out by means of a 4N HCI-dioxane solution: The reaction mixture was stirred for 2 h at room temperature and until

Residue is concentrated. The product is converted into the hydrochloride by treatment with methanolic HCl.

 Yield: 9 mg, white solid.

 LCMS: 443 [M + H], HPLC: Rt. = 2.74 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.67 (s, 1H), 7.51-7.43 (m, 2H), 4.22 (d, J = 13.8, 2H), 3.76 (ddd, J = 17.0, 11.7 , 4.9, 2H), 3.65 - 3.54 (m, 2H), 3.49 - 3.35 (m, 3H), 3.28 (dd, J = 13.5, 6.7, 1H), 2.34 - 2.23 (m, 2H), 1.94 - 1.82 (m, 2H), 1.72 (s, 4H), 1.31 (d, J = 15.9, 12H).

3- {1- [4- (1,1-Dimethyl-indan-5-yl) -thiazol-2-yl] -piperidin-4-ylamino} -propan-1-ol:

 The preparation is carried out starting from 1- [4- (1,1-dimethyl-indan-5-yl) -thiazol-2-yl] -piperidin-4-ylamine hydrochloride and 3- (te / t-butyl-dimethyl-silanyloxy ) - propionaldehyde. The cleavage of the protective group is carried out by means of a 1 M tetramethylammonium THF solution: The reaction mixture was stirred overnight at room temperature and then concentrated to dryness. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

Yield: 18 mg, solid. LCMS: 386 [M + H], HPLC: Rt. = 2.63 min (Method A).

2- {1- [4- (1,1-Dimethyl-indan-5-yl) -thiazol-2-yl] -piperidin-4-ylamino} -ethanol:

 The preparation is based on 1- [4- (1,1-dimethyl-indan-5-yl) -thiazol-2-yl] -piperidin-4-ylamine hydrochloride and (terf-butyl-dimethyl-silanyloxy) - acetaldehyde. The deprotection is carried out as already described by means of a 1M tetramethylammonium THF solution. The product was purified by preparative HPLC and converted to the hydrochloride.

 Yield: 6 mg, solid.

 LCMS: 372 [M + H], HPLC: Rt. = 2.61 min (Method A).

2 - ((2-hydroxy-ethyl) -1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl) -thiazol-2-yl] piperidin-4-yl} -amino) -ethanol:

The preparation is carried out starting from 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamine hydrobromide and (tert-butyl-dimethyl-silanyloxy) -acetaldehyde. The deprotection is carried out as already described by means of a 1M TBAF-THF solution. The product was purified by reversed-phase chromatography and analyzed for

Hydrochloride transferred.

 Yield: 23 mg, white solid.

 LCMS: 458 [M + H], HPLC: Rt. = 2.69 min (Method B).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.65 (d, J = 1.6, 1H), 7.50 - 7.43 (m, 2H), 4.26 (d, J = 13.0, 2H), 3.96 - 3.83 (m , 5H), 3.52 - 3.28 (m, 6H), 2.29 (d, J = 11.6, 2H), 2.08 - 1.96 (m, 2H), 1.72 (s, 4H), 1.31 (d, J = 16.3, 12H) , 2 - [{1- [4- (5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} - (2- hydroxyethyl) amino] ethanol:

The preparation is carried out starting from 1- [4- (5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamine and (tert- Butyl-dimethyl-silanyloxy) -acetaldehyde. The deprotection is carried out as already described by means of a 1M tetramethylammonium THF solution. The product was purified by preparative HPLC and converted to the hydrochloride.

 Yield: 4 mg, brown oil.

 LCMS: 430 [M + H], HPLC: Rt. = 2.72 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.41 (q, J = 8.2, 2H), 7.34 (s, 1H), 4.18 (d, J = 12.9, 2H), 3.78 (t, J = 5.1 , 3H), 3.44 - 3.20 (m, 6H), 3.15 (s, 2H), 2.74 (t, J = 6.2, 2H), 2.20 (d, J = 10.7, 2H), 1.99 - 1.88 (m, 2H) , 1.76 - 1.72 (m, 2H), 1.64 - 1.59 (m, 2H), 1.21 (s, 6H).

(R) -3- {1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-4 -ylamino} propanes-1,2-diol:

The preparation is carried out starting from 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamine hydrobromide and (S) - 2,2-dimethyl- [1,3] dioxolane-4-carbaldehyde. The deprotection is carried out by means of a 1.25 N HCl-methanol solution: The reaction mixture was stirred for 5 h at room temperature, concentrated to dryness and dried under high vacuum. The product was treated by treatment

methanolic HCl converted into the hydrochloride.

 Yield: 33 mg, green solid.

LCMS: 444 [M + H], HPLC: Rt. = 2.69 min (Method B). (Si-S-il-I ^ SSee-tetramethyl-SeTe-tetrahydro-naphthalene-1-yl) -thiazol-2-yl] -piperidin-4-ylamino} -propane-1,2-diol:

 The preparation is carried out starting from 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamine hydrobromide and (R) - 2,2-dimethyl- [1,3] dioxolane-4-carbaldehyde. The deprotection is carried out as described by means of a 1.25 N HCl-methanol solution. The product was converted to the hydrochloride.

 Yield: 30 mg, brown solid.

 LCMS: 444 [M + H], HPLC: Rt. = 2.64 min (Method B).

5- 3- [4- <5,5-Dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -pyrrolidin-1-yl} -pentan-1-ol :

 Yield: 21 mg, brown oil, product is the hydrochloride.

 LCMS: 399 [M + H], HPLC: Rt. = 2.88 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.91 (s, 1H), 7.71 (d, J = 7.9, 1H), 7.65-7.62 (m, 1H), 7.42 (d, J = 8.2 , 1 H), 4.27 - 3.95 (m, 2H), 3.85 - 3.50 (m, 2H), 3.47 (t, J = 6.3, 2H), 3.39 - 3.22 (m, 3H), 3.21 (s, 1 H) , 2.80 (t, J = 6.3, 2H), 2.41-2.25 (m, 1H), 1.83-1.77 (m, 2H), 1.76-1.70 (m, 2H), 1.67 (dd, J = 7.4, 4.1, 2H), 1.55 - 1.48 (m, 2H), 1.45 - 1.38 (m, 2H), 1.28 (s, 6H).

5- {4- [4- (5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazin-1-yl} -pentan-1 oil:

Yield: 17 mg, solid. Product is the hydrochloride.

 LCMS: 414 [M + H], HPLC: Rt. = 2.92 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.58 (dd, J = 8.2, 1.7, 1H), 7.50 (d, J = 1.4, 1H), 7.35 (d, J = 8.2, 1H) , 7.26 (s, 1H), 4.06 (d, J = 13.8, 2H), 3.58 (d, J = 11.9, 2H), 3.53 - 3.45 (m, 2H), 3.41 (t, J = 6.4, 2H), 3.20 - 3.08 (m, 4H), 2.74 (t, J = 6.3, 2H), 1.79 - 1.68 ( m, 4H), 1.65-1.61 (m, 2H), 1.50-1.43 (m, 2H), 1.38-1.30 (m, 2H), 1.25 (s, 6H).

5- {4- [4- (5,5-Dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazin-1-yl} -butan-1 oil:

The preparation is carried out starting from 1- [4- (5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazol-2-yl] piperazine hydrobromide and 4-bromo-butyl acetate. The deprotection is carried out as described by means of a 1 N NaOH solution in methanol. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 Yield: 12 mg, solid.

 LCMS: 400 [M + H], HPLC: Rt. = 2.86 min (Method A).

3 - {(S) -1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -pyrrolidine-3 -ylamino} propane-1-ol

 The preparation is carried out starting from (S) -1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -pyrrolidine 3-ylamines and 3- (tert-butyl-dimethyl-silanyloxy) propionaldehydes. The deprotection is carried out as already described by means of a 1 M TBAF-THF solution. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 Yield: 5 mg, colorless oil.

 LCMS: 414 [M + H], HPLC: Rt. = 2.71 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.62-7.58 (m, 1H), 7.47-7.39 (m, 2H), 7.18 (s, 1H), 4.10 (s, 1H), 3.98 ( dd, J = 12.0, 6.4, 1H), 3.94 - 3.85 (m, 1H), 3.84 - 3.74 (m, 1H), 3.74 - 3.64 (m, 1H), 3.52 (t, J = 5.9, 2H), 3.18 - 2.98 (m, 2H), 2.41-2.34 (m, 1H), 1.83-1.75 (m, 2H), 1.65 (s, 4H), 1.62-1.50 (m, 1H), 1.25 (d, J = 15.9, 12H).

3 - {(R) -1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -pyrrolidine-3 -ylamino} ethane-1-ol

The preparation is carried out starting from (R) -1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -pyrrolidine 3-ylamine and (tert-butyl-dimethyl-silanyloxy) acetaldehyde. The deprotection is carried out as already described by means of a 1M TBAF-THF solution. The product is purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 Yield: 11 mg, colorless oil.

 LCMS: 400 [M + H], HPLC: Rt. = 2.70 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ 7.67 (s, 1H), 7.53-7.39 (m, 2H), 7.23 (s, 1H), 4.13 (d, J = 4.8, 1H), 4.01 ( dd, J = 11.9, 6.5, 1H), 3.93-3.76 (m, 2H), 3.76-3.63 (m, 3H), 3.23-3.10 (m, 2H), 2.48-2.35 (m, 1H), 1.69 (s, 4H), 1.68 - 1.50 (m, 1H), 1.30 (d, J = 12.3, 12H).

(S) -Amino-S-il-^ -isSe.e.e-tetramethyl-S, .e-tetrahydro-naphthalen-yl) -thiazol-2-yl! -Piperidin-4-ylamino} -propan-1-ol:

 The preparation is carried out starting from 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamine hydrobromide and (R) -4-formyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester. The

 Cleavage of the protective group is carried out by means of a 4N HCI-dioxane solution: The reaction mixture was stirred for 2 h at room temperature and until

Residue is concentrated. The product was converted to the hydrochloride by treatment with methanolic HCl.

 Yield: 6 mg, beige solid.

LCMS: 443 [M + H], HPLC: Rt. = 2.76 min (Method A). ¹ H NMR (500 MHz, DMSO / deuterated TFA) ¹ H NMR (500 MHz, DMSO) δ.66 (s, 1H), 7.51-7.44 (m, 2H), 4.24 (d, J = 13.2, 2H) , 3.77 (ddd, J = 28.3, 11.7, .9, 2H), 3.62 (dt, J = 23.3, 8.5, 2H), 3.53 - 3.36 (m, 3H), 3.31 (dd, J = 13.4, 6.9, H ), 2.36-2.26 (m, 2H), 1.97-1.85 (m, 2H), 1.73 (s, 4H), 1.32 (d, J = 15.6, 12H)

Preparation of N- (1 - {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl) -thiazol-2-yl] -piperidine 4-yl} -pyrrolidin-3-yl) -acetamide:

150 mg (0.32 mmol) of 1- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidine 4-yl} -pyrrolidin-3-ylamines were dissolved in 1 ml of pyridine and treated with 90 μΙ acetic anhydride. The reaction mixture was stirred at RT for 15 h and then concentrated. The residue was taken up in ethyl acetate, washed with sat. NaHC0 ₃ solution, dried over Na ₂ S0 ₄ and concentrated. The resulting oil was stirred with ether and the resulting precipitate was filtered off with suction, washed with ether and dried.

 Yield: 21 mg, white solid.

 LCMS: 481 g / mol [M + H], HPLC: Rt. = 2.99 min (Method A).

 1H NMR (500 MHz, DMSO / deuterated TFA) δ 7.71 (s, 1H), 7.53 (d, J = 8.3,

1 H), 7.40 (d, J = 8.3, 1H), 4.34 (d, J = 6.9, 1H), 4.15 (d, J = 12.8, 2H), 3.90 - 3.02 (m, 7H), 2.42 - 1.70 (m, 6H), 1.87 (d, J = 2.4, 3H), 1.69 (s, 4H), 1.29 (d, J = 16.2, 12H).

S-il-I ^ S.S.e.e-tetramethyl-S.E.-tetrahydro-naphthalene ^ -y-thiazol-a-yl] -piperidin-4-ylamino} -propane-1,2-diol:

150 mg (0.41 mmol) of L - ^ - S.See tetramethyl-S.ey.e-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamine were dissolved in 2 ml of DMF and with 27.4 μΙ_ (0.41 mmol) of 2,3-epoxy-1-propanol. The reaction mixture was irradiated for 3 h at 120 ° C in the microwave and then stripped to residue. This was purified by flash chromatography on silica gel.

 5.7 mg solid, LCMS: 444 [M + H], HPLC: Rt. = 2.92 min (method A).

¹ H NMR (500 MHz, DMSO) δ 7.71 (d, J = 1.8, 1H), 7.52 (dd, J = 8.2, 1.9, 1H), 7.39 (d, J = 8.3, 1H), 4.13 ( d, J = 12.8, 2H), 3.87-3.79 (m, 1H), 3.56-3.22 (m, 5H), 3.16 (dd, J = 12.6, 2.9, 1H), 2.93 (dd, J = 12.6, 9.5, 1H), 2.30-2.13 (m, 2H), 1.86-1.72 (m, 2H), 1.69 (s, 4H), 1.29 (d, J = 16.3, 12H).

4- [2- {5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-4-yl] -piperidine:

Stage a:

 1 g (4.18 mmol) of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenecarboxylic acid was dissolved in 10 mL dioxane and treated with 1.62 g (8.35 mmol) EDCI, 582 mg (4.18 mmol ) HOBt and 936 pL (8.35 mmol)

 ethylmorpholine added. The reaction mixture was allowed to stand for 30 minutes

Room temperature stirred. Subsequently, 8.35 ml of a 0.5 M ammonia solution in dioxane were added. The mixture is added overnight

Room temperature stirred and then treated with water. The resulting residue was filtered off with suction, washed with water and by means of

Flash chromatography on silica gel.

 277 mg, Rt. = 3.08 min (Method A), LCMS: 232 (M + H).

Stage b:

 The product from step a (270 mg, 1.17 mmol) was dissolved in 8 mL DCM and 25 mL DME and then with 354 mg (0.87 mmol) 2,4-bis (4-methoxyphenyl) -2,4-dithioxo-1, 3,2,4-dithiadiphosphethane. The

The suspension was stirred at room temperature overnight, stripped to residue and purified by flash chromatography on silica gel.

259 mg, Rt. = 3.30 min (Method A), LCMS: 248 (M + H). Stage c:

 1 g (5.73 mmol) of 1- (4-acetylpiperidino) ethane-1-one was dissolved in 20 ml of methanol and slowly added at room temperature with 308 μΙ_ (6.02 mmol) of bromine. The reaction mixture was further stirred for 6 h and then added to

Deducted residue. This is taken up in ethyl acetate and extracted against saturated sodium bicarbonate solution. The organic phase was washed with a saturated sodium chloride solution, dried over sodium sulfate and concentrated to dryness.

 980 mg, Rt. = 1.88 min (Method A), LCMS: 249 (M + H).

A mixture of the product of Step b (100 mg, 0.40 mmol) and the product of Step c (125 mg, 0.40 mmol) of 1- (1-acetyl-piperidin-4-yl) -2-bromo-ethanone in 2 ml of ethanol was stirred overnight at 90 ° C, then to

Deducted residue. The residue was purified by flash chromatography on silica gel.

 123 mg, Rt. = 3.77 min (method A), LCMS: 397 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.87 (d, J = 1.9, 1H), 7.67 (dd, J = 8.2, 1.9, 1H), 7.46 (d, J = 8.3, 1H) , 7.36 (s, 1H), 4.54 (d, J = 12.8, 1H), 3.99 - 3.91 (m, 1H), 3.27 - 3.18 (m, 1H), 3.13 - 3.06 (m, 1H) , 2.77 - 2.68 (m, 1H), 2.14 - 2.02 (m, 5H), 1.74 - 1.64 (m, 5H), 1.62 - 1.51 (m, 1H), 1.31 (d, J = 16.0, 12H). Call e:

 The product from step d (100 mg, 0.25 mmol) was dissolved in 8 ml ethanol and treated with 212 mg (3.78 mmol) KOH and 1 ml water. The

The reaction mixture was stirred overnight at 60 ° C, then treated with water and ethyl acetate and extracted by shaking. The organic phase was washed with water, dried over sodium sulfate and concentrated. The residue was purified by preparative HPLC. The product is present as hydrochloride.

 58 mg, Rt. = 3.06 min (Method A), LCMS: 355 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.90 (d, J = 1.8, 1H), 7.67 (dd, J = 8.2, 1.7, 1H), 7.46 (d, J = 8.3, 1H) , 7.37 (s, 1H), 3.43 (d, J = 12.7, 2H), 3.21 - 3.06 (m, 3H), 2.24 (d, J = 12.1, 2H), 2.02 - 1.91 (m, 2H), 1.72 (s, 4H), 1.31 (d, J = 16.0, 12H). 4- [2- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -oxazol-5-yl] -piperidine

Stage a:

 5 g (23.44 mmol) 4-formyl-piperidine-1-carboxylic acid tert-butyl ester were dissolved in 40 mL THF and 40 mL terf-butanol. 2.63 g (23.44 mmol) of potassium tert-butoxide and 2.51 mL (46.89 mmol) of nitromethane were added and the reaction mixture was stirred for 2 h at room temperature. It was added 1.6 mL of acetic acid and the reaction mixture was diluted with ethyl acetate, washed 4 times with a saturated sodium chloride solution, dried over sodium sulfate, filtered and evaporated to dryness.

 7.2 g of yellow oil, Rt. = 2.91 min (Method A), LCMS: 275 (M + H).

Stage b:

The product of step a (6.4 mg, 23.33 mmol) was dissolved in 65 mL of methanol. 6.4 g of catalyst Pd-C-5% (50.5% water) was added. The The mixture was hydrogenated for 4.5 hours at room temperature and under normal pressure with 1.57 L of hydrogen 3.0. The reaction mixture was filtered off and concentrated.

 5.89 g of oil, LCMS: 245 (M + H).

Stage c:

 A mixture of the product of step b (612 mg, 2.50 mmol) and 300 mg (1.25 mmol) of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid 576 mg (3.76 mmol) HOBt and 720 mg (3.76 mmol) EDCI in 5 mL DMF was stirred at room temperature overnight. The reaction mixture was admixed with ethyl acetate and extracted with 15 ml each of a 1 N hydrochloric acid solution and a concentrated Natnumhydrogencarbonatlösung. The organic phase was dried over sodium sulfate, filtered and concentrated.

 738 mg of oil, Rt. = 3.40 min (Method A), LCMS: 359 (M + H - Boc).

Stage d:

 The product from step c (738 mg, 1.29 mmol) was dissolved in 10 mL dichloromethane. 8.02 mL (3.86 mmol) Dess-Martin periodinane was added. The reaction mixture was stirred for 1 h at room temperature, then treated with 15 ml of a saturated Natnumhydrogencarbonatlösung and 5 mL of a saturated sodium thiosulfate solution and stirred vigorously for 1 h. The organic phase was separated. The water phase was extracted again with dichloromethane. The combined organic phase was washed 1 time each with water and a 0.1 N hydrochloric acid solution, dried over sodium sulfate, filtered and concentrated to dryness. This was purified by flash chromatography on silica gel.

 153 mg, Rt. = 3.68 min (Method A), LCMS: 457 (M + H). Call e:

 The product from step d (75 mg, 0.16 mmol) was mixed with 78 mg (0.33 mmol) Burgess reagent, suspended in 5 mL THF and stirred at 60 ° C for several days.

 The reaction mixture was taken up in dichloromethane and once each with a saturated Natnumhydrogencarbonatlösung and a 1 N

 Washed hydrochloric acid solution. The organic phase was dried over sodium sulfate and concentrated.

84 mg, Rt. = 4.25 (Method A), LCMS: 439 (M + H). Stage f:

 The product of Step e (84 mg, 0.19 mmol) was added with 6 mL of a 4N hydrochloric acid-dioxane solution and stirred at room temperature. The

The reaction mixture was concentrated and purified by preparative HPLC. The product is present as hydrochloride.

 11 mg yellow solid, Rt. = 2.84 min (Method A), LCMS: 339 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.94 (d, J = 1.8, 1H), 7.73 (dd, J = 8.3, 1.8, 1H), 7.49 (d, J = 8.3, 1H), 7.15 (d, J = 0.8, 1H), 3.44-3.37 (m, 2H), 3.24-3.17 (m, 1H), 3.10 (dt, = 12.5, 2.7, 2H), 2.23 (dd, J = 14.1, 3.2, 2H), 1.96-1.85 (m, 2H), 1.72 (s, 4H), 1.31 (d, J = 13.3, 12H).

Preparation of 4,4-dimethyl-7- (4,4,5,5-tetramethyl- [1,2,2] dioxaborolan-2-yl) -3,4-dihydro-2H-naphthalene-1-one

 The preparation was carried out as previously described starting from 570 mg (1.98 mmol) of 7-bromo-4,4-dimethyl-3,4-dihydro-2H-naphthalene-1-one (preparation see Journal of Medicinal Chemistry, 1995, vol. 38, # 24 p 4764-4767) and 654 mg (2.58 mmol) of bis (pinacolato) diboron.

 338 mg, yellow solid, Rt. = 3.41 min (Method A), LCMS: 301 (M + H).

Preparation of 7- {2- [4- (2-hydroxy-ethylamino) -piperidin-1-yl] -thiazole-4-l} -4,4-dimethyl-3,4-dihydro-2H-naphthalene-1 one

 The preparation is carried out as described above, starting from 100 mg (0.27 mmol) of 2- [1- (4-bromo-thiazol-2-yl) -piperidin-4-ylamino] -ethanol (preparation as described above) and 88 mg ( 0.29 mmol) 4,4-dimethyl-7- (4,4,5,5-tetramethyl- [1,2,2] dioxaborolan-2-yl) -3,4-dihydro-2H-naphthalene-1-one. The product was purified by flash chromatography on silica gel.

 55 mg, yellow oil, LCMS: 400 (M + H), Rt. = 2.40 min (Method A).

1H NMR (500 MHz, DMSO / deuterated TFA) δ = 8.32 (d, J = 2.1, 1H), 8.02 (dd, J = 8.3, 2.1, 1H), 7.62 (d, J = 8.3, 1H) , 4.19 (d, J = 13.4, 2H), 3.79 - 3.72 (m, 2H), 3.52 - 3.42 (m, 1H), 3.33 (t, J = 11.9, 2H), 3.16 - 3.05 (m, 2H) , 2.78 - 2.70 (m, 2H), 2.25 (d, J = 10.4, 2H), 2.03 (t, J = 6.8, 2H), 1.83 (qd, J = 12.4, 4.3, 2H), 1.41 (s, 6H ). Preparation of 4- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino } butane-1-ol

 The preparation was carried out as described above starting from 120 mg (0.19 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2 -yl] - piperidin-4-ylamine hydrochloride (preparation previously described) and 57 μl (0.38 mmol) 4-bromo-butyl acetate. The deprotection was carried out by means of a 1 NaOH solution in methanol. The product was purified by preparative HPLC and is present as the hydrochloride.

 9 mg, solid, LCMS: 442 [M + H], HPLC: Rt. = 2.92 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.69 (d, J = 1.8, 1H), 7.50 (dd, = 8.2, 1.9, 1H), 7.43 (d, J = 8.3, 1H) , 4.17 (d, = 13.6, 2H), 3.53 - 3.34 (m, 5H), 3.07 - 3.00 (m, 2H), 2.23 (d, J = 10.7, 2H), 1.84 - 1.69 (m, 8H), 1.60 - 1.52 (m, 2H), 1.30 (d, J = 16.6, 12H).

Preparation of 5- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino } pentane-1-ol

 The preparation was carried out as described above via a reductive amination starting from 50 mg (0.08 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamine hydrochloride and 8 mg (0.08 mmol) 5-hydroxypentanal.

 5 mg, solid, LCMS: 456 [M + H], HPLC: Rt. = 2.94 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.72 (s, 1H), 7.53 (d, J = 8.2, 1H), 7.38 (d, J = 8.3, 1H), 4.12 (d, J = 13.4, 2H), 3.47-3.34 (m, 3H), 3.26 (t, J = 12.1, 2H), 3.03-2.93 (m, 2H), 2.18 (d, J = 10.6, 2H), 1.78- 1.58 (m, 9H), 1.52 - 1.35 (m, 5H), 1.28 (d, J = 13.1, 13H).

Preparation of 6- 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} hexane-1-ol

The preparation was carried out as described above, starting from 100 mg (0.16 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2 -yl] - piperidin-4-ylamine hydrochloride and 90 μΙ_ (0.32 mmol) (6-bromo-hexyloxy) -rert-butyl-dimethyl-silanes. The deprotection was carried out in THF with 7 equivalents of TMAF. The product was purified by preparative HPLC. The product is present as hydrochloride.

 4 mg, solid, LCMS: 470 [M + H], HPLC: Rt. = 2.97 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.52 (d, J = 1.7, 1H), 7.36 - 7.29 (m, 2H), 4.05 (d, J = 13.2, 2H), 3.37 - 3.26 ( m, 6H), 2.89-2.83 (m, 2H), 2.11 (d, J = 10.8, 2H), 1.73-1.50 (m, 11H), 1.40-1.32 (m, 3H), 1.29-1.22 (m, 5H), 1.21 - 1.14 (m, 15H).

Preparation of 6- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidin-1-yl } hexane-1-ol

 The preparation was carried out as described above, starting from 100 mg (0.26 mmol) of 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2 -yl] - piperidine hydrochloride and 92 mg (0.31 mmol) of (6-bromo-hexyloxy) -terf-butyl-dimethyl-silanes. The product was purified by flash chromatography on silica gel. The deprotection was carried out as already described with an HCl solution in dioxane. The product is present as hydrochloride.

 43 mg, white solid, LCMS: 455 [M + H], HPLC: Rt. = 3.07 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.79 (d, J = M, 1H), 7.72 (d, J = 23.8, 1H), 7.61-7.53 (m, 1H), 7.27 ( d, J = 8.3, 1H), 3.54 (d, J = 12.6, 2H), 3.41 - 3.28 (m, 3H), 3.07 - 2.96 (m, 4H), 2.26 (d, J = 14.4, 2H), 2.02 (dd, J = 23.4, 12.4, 2H), 1.67 - 1.55 (m, 6H), 1.43 - 1.34 (m, 2H), 1.33 - 1.23 (m, 4H), 1.18 (d, J = 19.9, 12H) ,

Preparation of 7- {4- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidin-1-yl } -heptan-1-ol

100 mg (0.26 mmol) of 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine hydrochloride were used in Dissolved 4 mL of ethanol and treated with 50 μΙ_ (0.31 mmol) of 7-bromo-heptan-1-ol and 107 μΙ_ (0.77 mmol) of triethylamine. The reaction mixture was heated at 150 ° C overnight, concentrated and the product was isolated from the crude mixture by preparative HPLC. The product is present as hydrochloride.

 15 mg, white solid, LCMS: 469 [M + H], HPLC: Rt. = 3.12 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.97-7.87 (m, 2H), 7.74-7.65 (m, 1H), 7.39 (d, J = 8.3, 1H), 3.66 (d, J = 12.4, 2H), 3.50 - 3.40 (m, 3H), 3.19 - 3.08 (m, 4H), 2.40 - 2.30 (m, 2H), 2.16 - 2.04 (m, 2H), 1.77 - 1.66 (m, 6H) , 1.52 - 1.42 (m, 2H), 1.34 (d, J = 19.8, 12H), 1.28 (s, 6H).

Preparation of (S) -3- {1- [4- (5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino } propanes-1,2-diol

 The preparation was carried out as previously described starting from 100 mg (0.27 mmol) of 1- [4- (5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl]. - piperidin-4-ylamine hydrochloride and 34 mg (0.27 mmol) of (R) -2,2-dimethyl- [1,3] dioxolane-4-carbaldehyde. The deprotection was carried out as described by means of a 1.25 N HCl-methanol solution. The product was converted to the hydrochloride.

 21 mg, solid, LCMS: 416 [M + H], HPLC: Rt. = 2.66 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.54-7.38 (m, 3H), 4.19 (d, J = 12.7, 2H), 3.92-3.84 (m, 1H), 3.58-3.35 (m, 5H), 3.25-3.13 (m, 1H), 2.97 (dd, J = 12.6, 9.5, 1H), 2.81 (t, J = 6.3, 2H), 2.33-2.22 (m, 2H), 1.94-1.78 (m, 4H), 1.73-1.64 (m, 2H), 1.29 (s, 6H).

Preparation of (S) -2-Amino-4-hydroxy-N- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -] thiazol-2-yl] -piperidin-4-yl} -butyramide

50 mg (0.12 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-4- ylamine hydrochloride and 44 mg (0.13 mmol) of (S) -2-tert-butoxycarbonylamino-4- (tert-butyl-dimethyl-silanyloxy) -butyric acid (preparation analogous to Tetrahedron, 2005, vol. 61, # 43 p.10277). 10284) were together with 50 μί (0.29 mmol) of N-ethyldiisopropylamine dissolved in 1 mL DCM and stirred at 0 ° C for 5 min. Then, 73 mg (0.14 mmol) of benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate and 50 μί (0.29 mmol) were added.

Ethyldiisopropylamine added. The mixture was further stirred for 1 h at 0 ° C, diluted with EA and shaken out with water and a saturated sodium bicarbonate solution and a saturated sodium chloride solution. The

organic phase was dried over sodium sulfate, filtered and concentrated. The residue was then treated with a 1.25 M HCl solution in methanol and stirred for 1 h. The methanolic solution was concentrated and the product was purified by preparative HPLC. The product is present as hydrochloride.

 4 mg, solid, LCMS: 471 [M + H], HPLC: Rt. = 2.86 min (Method A).

Preparation of (2S, 3R) -2-amino-3-hydroxy-N- {1 - [4- (5,5,8,8-tetramethyl-5,6,7-tetrahydro-naphthalen-2-yl) - thiazol-2-yl] -piperidin-4 yl} -butyramide-

 190 mg (0.47 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-4- Ylamines were dissolved in 5 mL THF and treated with 86 mg (0.56 mmol) 1-hydroxybenzotriazole hydrate, 239 μί (1.40 mmol) N-ethyldiisopropylamine, 108 mg (0.56 mmol) N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride and 113 mg (0.56 mmol) of N- (tert-butoxycarbonyl) -L-threonine were added. The

Mixture was stirred at room temperature overnight, dissolved in EA and 1N NaOH and extracted by shaking. The organic phase was washed with water, dried over sodium sulfate, filtered and concentrated. The splitting off of

Protecting group was carried out as previously described with HCl in dioxane. The product was purified by preparative HPLC and is present as the hydrochloride.

 16 mg, solid, LCMS: 471 [M + H], HPLC: Rt. = 2.74 min (Method A).

¹ H NMR (500 MHz, DMSG7 deuterated TFA) δ = 7.62 (s, 1H), 7.46 (q, J = 8.2, 2H), 4.13 - 4.04 (m, 3H), 4.01 - 3.94 (m, 3H), 3.67 - 3.56 (m, 3H), 3.25 (s, 3H), 2.07 (d, J = 12.8, 2H), 1.82 - 1.68 (m, 6H), 1.32 (d, J = 15.6, 12H), 1.24 (i.e. , J = 6.4,

3H).

Preparation of (2S, 3R) -2-amino-3-hydroxy-1- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl ) -thiazol-2-yl] -piperidin-1-yl} -butan-1-one

 The preparation was carried out analogously starting from 200 mg (0.47 mmol) of 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl ] -piperidine hydrochloride and 113 mg (0.52 mmol) N- (te / f-butoxycarbonyl) -L-threonine. The deprotection was carried out as already described with HCl in dioxane. The product was purified by preparative HPLC and is available as

Hydrochloride.

 8 mg, solid, LCMS: 456 [M + H], HPLC: Rt. = 2.97 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.91 (dd, J = 6.1, 1.7, 1H), 7.87-7.80 (m, 1H), 7.68 (d, J = 8.1, 1H), 7.40 (d, J = 8.2, 1 H), 4.66 - 4.54 (m, 1 H), 4.35 (dd, J = 25.3, 4.5, 1 H), 4.15 (t, J = 11.3, 1 H), 4.09 - 3.96 (m, 1H), 3.54 - 3.43 (m, 1H), 3.35 (t, J = 13.1, 1H), 3.24 (s, 1H), 3.03 - 2.90 (m, 1H), 2.35 - 2.20 (m, 2H), 1.95 - 1.82 (m, 1H), 1.81 - 1.67 (m, 5H), 1.38 - 1.29 (m, 12H), 1.28 - 1.24 (m, 3H).

Preparation of (2S, 3S) -3-Hydroxy-pyrrolidine-2-carboxylic acid {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl ) -thiazol-2-yl] -piperidin-4-yl} -amide

 The preparation was carried out analogously starting from 244 mg (0.50 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl ] -piperidin-4-ylamine and 116 mg (0.50 mmol) of (2S, 3S) -3-hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester. The deprotection was carried out analogously with HCl in dioxane. The product was purified by flash chromatography on silica gel

purified.

 158 mg, yellow oil, LCMS: 483 [M + H], HPLC: Rt. = 2.70 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.66 (s, 1H), 7.51-7.42 (m, 2H), 5.72-5.65 (m, 1H), 4.43 (dd, J = 5.6, 3.5 , 1H), 4.09 (d, J = 2.0, 1H), 4.07 - 3.97 (m, 3H), 3.58 - 3.50 (m, 2H), 3.49 - 3.34 (m, 3H), 2.06 - 1.92 (m, 5H), 1.77-1.65 (m, 7H), 1.29 (dd, J = 17.7, 8.9, 14H), 1.23-1.16 (m, 2H). Preparation of ((2S, 3S) -3-hydroxy-pyrrolidin-2-yl) - {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2 -yl) -thiazol-2-yl] -piperidin-1-yl} -methanone

 The preparation was likewise carried out starting from 150 mg (0.36 mmol) of 4- [4- (SSe-tetramethyl-SeyS-tetrahydro-naphthalene-1-thiazolyl-1-piperidine hydrochloride and 94 mg (0.40 mmol) (2S, 3S). 3-Hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-terf-butyl ester in DMSO The product was purified by flash chromatography on silica gel The deprotection was carried out analogously with HCl in methanol The product is present as the hydrochloride.

 145 mg, solid, LCMS: 468 [M + H], HPLC: Rt. = 3.05 min (Method A).

 1H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.93-7.87 (m, 2H), 7.69 (ddd, = 8.2, 3.4, 1.9, 1H), 7.39 (dd, J = 8.3, 1.7, 1H) , 4.64 - 4.40 (m, 3H), 4.14 (d, = 13.5, 1H), 3.54 - 3.33 (m, 5H), 3.06 - 2.94 (m, 1H), 2.33 - 2.17 (m, 3H), 1.91 ( dd, J = 34.3, 9.9, 3H), 1.78-1.65 (m, 5H), 1.30 (d, J = 15.9, 12H).

Preparation of (2R, 3S) -2- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazol-2-yl] piperidin-1-ylmethyl} -pyrrolidin-3-ol

 The preparation was carried out as already described with a 2N

 Lithium aluminum hydride solution in THF starting from 30 mg (0.06 mmol) of ((2S.3S) -3-hydroxy-pyrrolidin-2-yl) - {4- [4- (5,5,8,8-tetramethyl-5,6, 7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-1-yl} -methanone. The product was purified by preparative HPLC and is present as the hydrochloride.

 7 mg, solid, LCMS: 454 [M + H], HPLC: Rt. = 2.79 min (Method A).

 1H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.96 (s, 1H), 7.89 (d, = 1.8,

1 H), 7.68 (d, J = 8.4, 1H), 7.38 (d, J = 8.3, 1H), 4.26 - 4.19 (m, 1H), 3.86 - 3.74 (m, 2H), 3.71 - 3.62 (m, 1H), 3.56 - 3.47 (m, 3H), 3.44 - 3.35 (m, 3H), 2.40 (d, J = 11.9, 2H), 2.23 - 2.05 (m, 3H), 1.94 - 1.84 (m , 1H), 1.69 (s, 4H), 1.29 (d, J = 14.6, 13H). Preparation of (S) -3-hydroxy-2-methylamino-N- {1 - [4- <5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - thiazol-2-yl] -piperidin-4-yl} -propionamide

 The preparation was carried out analogously starting from 50 mg (0.12 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl ] -piperidin-4-ylamine hydrochloride and 33 mg (0.13 mmol) of (S) -2- (tert-butoxycarbonyl-methyl-amino) -3-hydroxy-propionic acid. The product was purified by flash chromatography on silica gel. The deprotection was carried out analogously with HCl in methanol.

 27 mg, solid, LCMS: 471 [M + H], HPLC: Rt. = 2.81 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.65 (d, J = 1.6, 1H), 7.51-7.42 (m, 2H), 4.09-3.98 (m, 3H), 3.93-3.86 (m, 1H), 3.85-3.79 (m, 2H), 3.60-3.44 (m, 6H), 2.09-1.97 (m, 2H), 1.75-1.64 (m, 6H), 1.30 (d, = 12.7, 13H).

Preparation of (S) -3-hydroxy-2-methylamino-1- {4- [4- (5,5,8,8-tetramethyl-5,6-tetrahydro-naphthalen-2-yl) thiazole-2 -yl] piperidin-1-yl} -propan-1-one

 The preparation was likewise carried out starting from 50 mg (0.12 mmol) of 4- [4- (SSe-tetramethyl-S. E.e.-tetrahydro-naphthalene) -cythiazolyl-1-piperidine hydrochloride and 30 mg (0.13 mmol) ( S) -2- (tert-butoxycarbonyl-methyl-amino) -3-hydroxy-propionic acid The product was purified by flash chromatography

Silica gel purified. The deprotection was carried out analogously with HCl in methanol. The product is present as hydrochloride.

 35 mg, solid, LCMS: 456 [M + H], HPLC: Rt. = 3.04 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.82 (d, J = 1.8, 1H), 7.75 (d, J = 5.8, 1H), 7.59 (d, = 8.0, 1H), 7.31 (d, = 8.2, 1H), 4.55 - 4.36 (m, 2H), 3.94 (d, = 10.8, 1H), 3.81 (dd, = 12.3, 3.9, 1H), 3.74 - 3.65 (m, 1 H), 3.44 - 3.34 (m, 1 H), 3.27 (t, J = 12.2, 1 H), 2.95 - 2.81 (m, 1 H), 2.63 - 2.54 (m, 2H), 2.25 - 2.10 (m, 2H), 1.85 - 1.58 (m, 6H), 1.22 (d, J = 20.4, 12H). Preparation of 4- {4- [2- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-4-yl] -piperidin-1-yl } butane-1-ol

 The preparation was carried out as described above starting from 100 mg (0.28 mmol) of 4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-4 -yl] - piperidine hydrochloride (preparation previously described) and 61 μΙ_ (0.42 mmol) of 4-bromo-butyl acetate. The deprotection was carried out by means of a 1 N NaOH solution in methanol. The product was purified by preparative HPLC and is present as the hydrochloride.

 33 mg, solid, LCMS: 427 [M + H], HPLC: Rt. = 3.03 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.83 (d, J = 1.9, 1H), 7.65-7.58 (m, 1H), 7.43-2.27 (m, 2H), 3.58 (d, J = 12.3, 2H), 3.49 - 3.41 (m, 2H), 3.16 - 3.00 (m, 5H), 2.24 (d, = 13.9, 2H), 2.05 - 1.91 (m, 2H), 1.80 - 1.69 (m, 2H ), 1.64 (s, 4H), 1.53 - 1.44 (m, 2H), 1.24 (d, J = 13.1, 12H).

Preparation of 5- {4- [2- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-4-yl] -piperidin-1-yl } pentane-1-ol

 The preparation was carried out as described above via a reductive amination starting from 100 mg (0.28 mmol) 4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-4-yl] -piperidine hydrochloride (prepared previously) and 58 mg (0.56 mmol) of 5-hydroxypentanal. The product was purified by preparative HPLC and is present as the hydrochloride.

 77 mg, solid, LCMS: 441 [M + H], HPLC: Rt. = 3.07 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.83 (d, J = 1.9, 1H), 7.65-7.55 (m, 1H), 7.43-2.25 (m, 2H), 3.57 (d, J = 12.3, 2H), 3.47 - 3.31 (m, 2H), 3.28 - 2.98 (m, 5H), 2.23 (d, J = 13.7, 2H), 2.07 - 1.91 (m, 2H), 1.77 - 1.59 (m, 6H), 1.52-1.41 (m, 2H), 1.40-1.30 (m, 2H), 1.23 (d, J = 13.6, 12H). Preparation of (S) -2-amino-3- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2-one] yl] -piperidin-1-yl} -propan-1-ol

 The preparation was carried out analogously via a reductive amination starting from 100 mg (0.26 mmol) of 4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole 4-yl] -piperidine hydrochloride and 55 μΙ_ (0.26 mmol) of (R) -4-formyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester. The product was purified by flash chromatography on silica gel. The deprotection was carried out analogously with HCl in methanol. The product is present as hydrochloride.

 16 mg, solid, LCMS: 428 [M + H], HPLC: Rt. = 2.75 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.93 (d, J = 1.5, 1H), 7.84 (s, 1H), 7.69 (d, J = 7.5, 1H), 7.41 (d, J = 8.3, 1H), 3.96-3.85 (m, 2H), 3.81-3.67 (m, 4H), 3.63-3.58 (m, 3H), 3.56-3.47 (m, 2H), 3.47-3.39 (m, 1 H), 3.38 - 3.21 (m, 2H), 2.43 (d, J = 1.5, 2H), 2.35 - 2.19 (m, 2H), 1.72 (s, 4H), 1.32 (d, J = 20.6, 12H ).

Preparation of (R) -2-amino-3- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2-one] yl] -piperidin-1-yl} -propan-1-ol

 The preparation was carried out analogously via a reductive amination starting from 100 mg (0.26 mmol) of 4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole 4-yl] -piperidine hydrochloride and 55 pL (0.26 mmol) of (S) -4-formyl 1-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester. The product was purified by flash chromatography on silica gel. The deprotection was carried out analogously with HCl in methanol. The product is present as hydrochloride.

 39 mg, solid, LCMS: 428 [M + H], HPLC: Rt. = 2.74 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.88-7.79 (m, 2H), 7.63 (d, J = 7.6, 1H), 7.33 (d, J = 8.3, 1H), 3.79 (s , 2H), 3.72-3.63 (m, 3H), 3.61-3.47 (m, 3H), 3.47-3.39 (m, 2H), 3.38-3.27 (m, 2H), 3.26-3.18 (m, 1H), 3.13 - 3.05 (m, 1H), 2.38 - 2.30 (m, 2H), 2.25 - 2.07 (m, 2H), 1.64 (s, 4H), 1.24 (d, J = 15.9, 12H). Preparation of 2- {1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazol-2-yl] -piperidin-4-ylamino } pentanes-1,5-diol

 Stage a:

 100 mg (0.25 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-4- ylamines (preparation described above) were together with 79 mg (0.30 mmol) of 2-bromo-pentanedioic acid diethyl ester

 (Preparation according to Synthesis, 1999, # 2 p 270-274) dissolved in 6 mL DMF and treated with 137 μΙ_ (0.99 mmol) of triethylamine. The reaction mixture was stirred for 3 days at room temperature, stirred into 12 ml of water and extracted twice with ΕΞΑ. The organic phase was dried over sodium sulfate, filtered, evaporated to dryness and purified by flash chromatography on silica gel.

 21 mg, residue, Rt. = 3.19 min (Method A), LCMS: 556 (M + H).

Stage b:

 4.3 mg (0.11 mmol) of lithium aluminum hydride were initially charged in 2 ml of THF and treated with 21 mg (0.04 mmol) of 2- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-) naphthalene-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} -pentanedioic acid diethyl ester from step a, pre-dissolved in 2 ml of THF slowly added. The reaction mixture was stirred overnight at room temperature, treated with 20 ml of water and extracted twice with EA. The organic phase was dried over sodium sulfate, filtered, evaporated to dryness and purified by preparative HPLC. The product is available as TFA salt.

 12 mg, solid, Rt. = 2.81 min (Method A), LCMS: 472 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.68 (d, J = 1.9, 1H), 7.50 (dd, J = 8.2, 1.9, 1H), 7.43 (d, J = 8.3, 1H ), 4.17 (d, = 12.9, 2H), 3.80 (dd, J = 12.2, 3.1, 1H), 3.67 - 3.57 (m, 2H), 3.55 - 3.47 (m, 2H), 3.47 - 3.29 (m, 3H), 2.25 (s, 2H), 1.91 - 1.69 (m, 8H), 1.68 - 1.48 (m, 2H), 1.31 (d, J = 13.0, 12H). 2- (3- {4- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazine-1 yl} -propyl) propanes-1,3-diol

 The preparation was carried out analogously as described above, starting from 200 mg (0.53 mmol) of 1 - ^ - (SSee-tetramethyl-Seye-tetrahydro-naphthalen ^ -y-thiazol ^ - yl] piperazines and 234 μΐ_ (0.1.06 mmol) 2 - (3-chloro-propyl) -malonic acid diethyl ester and subsequent reduction with lithium aluminum hydride The product is present as the hydrochloride.

 16 mg, solid, LCMS: 472 [M + H], HPLC: Rt. = 2.84 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ 7.75 (d, J = 1.8 Hz, 1H), 7.54 (dd, J = 8.2, 1.9 Hz, 1 H), 7.33 (d, J = 8.3 Hz, 1 H), 7.22 (s, 1H), 4.14 (b, 2H), 3.72 - 3.56 (m, 2H), 3.56 - 3.37 (m, 6H), 3.30 - 3.11 (m, 4H), 1.83 - 1.71 (m , 2H), 1.66 (s, 4H), 1.61 - 1.51 (m, 1H), 1.33 (dt, J = 12.1, 6.1 Hz, 2H), 1.26 (d, J = 13.8 Hz, 12H).

Preparation of [2 - ({1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazol-2-yl] -piperidine-4 -ylamino} -methyl) -cyclopropyl] -methanol

 Stage a:

 The preparation was carried out as described above via a reductive amination starting from 150 mg (0.37 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamine and 56 μΙ_ (0.41 mmol) of 2-formyl-cyclopropanecarboxylic acid ethyl ester. The product was using

Flash chromatography on silica gel.

 49 mg, yellow oil, Rt. = 3.10 min (Method A), LCMS: 496 (M + H).

Stage b:

 49 mg (0.10 mmol) of 2 - ({1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] - piperidin-4-ylamino} -methyl) -cyclopropanecarboxylic acid ethyl ester from step a were dissolved under nitrogen in 2 ml of THF. 475 μΙ_ of a 1 M diisobutylaluminum hydride solution in THF were added dropwise. The mixture was stirred overnight at 60 ° C, water and EA added, filtered through Celite, concentrated and purified by flash chromatography on silica gel.

 20 mg, yellow solid, Rt. = 2.88 min (Method A), LCMS: 454 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.66 (d, J = 1.7, 1H), 7.52 - 7.41 (m, 2H), 4.23 - 4.05 (m, 2H), 3.60 - 3.37 (m, 4H), 3.32-3.25 (m, 1H), 3.10-2.87 (m, 2H), 2.26 (d, J = 10.2, 2H), 1.88-1.76 (m, 2H), 1.72 (s, 4H), 1.35 - 1.26 (m, 13H), 1.16 - 1.08 (m, 1H), 1.06 - 0.97 (m, 1H), 0.65 - 0.54 (m, 2H).

Preparation of (2- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidine-1 ylmethyl} -cyclopropyl) -methanol

Stage a:

 The preparation was carried out analogously via a reductive amination starting from 100 mg (0.23 mmol) of 4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole 4-yl] -piperidine hydrobromide and 63 μΙ_ (0.46 mmol) of ethyl 2-formyl-1-cyclopropanecarboxylate. The product was purified by preparative HPLC

 purified.

 1 10 mg, lyophilisate, LCMS: 481 [M + H], HPLC: Rt. = 3.15 min (Method A).

Stage b:

 The reduction was carried out analogously starting from the product from stage a and a 1 M diisobutylaluminum hydride solution in THF. The product was purified by flash chromatography on silica gel and is present as the hydrochloride.

 22 mg, solid, Rt. = 3.01 min (Method A), LCMS: 439 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.97 (d, J = 25.6, 1H), 7.89 (d, J = 1.8, 1H), 7.72-7.65 (m, 1H), 7.38 ( d, J = 8.3, 1H), 3.78 (d, J = 12.5, 1H), 3.69 (d, = 12.2, 1H), 3.56 - 3.50 (m, 1H), 3.45 - 3.36 (m, 1 H), 3.25 - 3.10 (m, 4H), 3.02 - 2.94 (m, 1H), 2.39 - 2.28 (m, 2H), 2.13 - 2.02 (m, 2H), 1.68 (s, 4H), 1.33 - 1.23 (m, 13H), 1.15 - 1.06 (m, 1H), 1.04 - 0.96 (m, 1H), 0.65 - 0.50 (m, 2H). Preparation of 1 - [3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1,2,4] thiadiazol-5-yl] -piperazine

Stage a:

 10 g (35.55 mmol) of 6-bromo-1, 1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene were weighed together with 8.92 g (99.55 mmol) of copper (I) cyanide and admixed with NMP , The reaction mixture was stirred at 140 ° C overnight and stirred into 400 ml of water. The resulting precipitate was filtered off with suction, washed several times with water, suspended in EA, filtered off with suction and washed well with EA. The filtrate was washed with a saturated sodium bicarbonate solution. The organic phase was dried over sodium sulfate, filtered, evaporated to dryness and purified by flash chromatography on silica gel.

 4.50 g, yellow crystals, Rt. = 3.57 min (method A), LCMS: 241 (M + H).

Stage b:

 894 mg (4.19 mmol) of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carbonitrile from stage a were weighed together with hydroxylammonium chloride (1.46 g, 20.96 mmol) and mixed with 20 ml Ethanol and triethylamine (2.9 mL, 20.96 mmol). The reaction mixture was stirred at room temperature overnight and was evaporated to dryness. This was suspended in water and extracted 2 times with EA. The organic phase was dried over sodium sulfate, filtered and concentrated to dryness.

989 mg brown residue, Rt. = 2.48 min (Method A), LCMS: 247 (M + H). Stage c:

 989 mg (4.02 mmol) of N-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carboxamidines from stage b were dissolved in methanol and in the presence of glacial acetic acid and Raney nickel under normal pressure and at

Room heating hydrogenated. The reaction mixture was filtered, concentrated and purified by flash chromatography on silica gel.

 433 mg brown residue, Rt. = 2.50 min (Method A), LCMS: 231 (M + H).

Stage d:

 To a solution of 433 mg (1.45 mmol) of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carboxamidine from step c and 166 μl (1.45 mmol) of perchloromethyl mercaptan in 3 ml DCM was slowly added dropwise at -5 ° C a solution of 290 mg (7.25 mmol) of NaOH in 3 mL of water. The reaction mixture was stirred at -5 ° C. for 30 min, then warmed to room temperature, diluted with 60 ml of water and extracted 3 times with DCM. The organic phase was washed with a saturated sodium chloride solution, dried over sodium sulfate, filtered, concentrated to dryness and purified by flash chromatography on silica gel.

 181 mg of brown oil, Rt. = 4.13 min (Method A), LCMS: 307 (M + H).

Level e:

 181 mg (0.53 mmol) of 5-chloro-3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) - [1, 2,4] thiadiazole from step d, together with 109 mg (0.58 mmol) of tert-butyl 1-piperazinecarboxylate, 13.5 mg (0.03 mmol) of 1,3-bis (2,6-diisopropylphenyl) imidazolium chloride and 102 mg (1.06 mmol) of sodium weighed into tert-butoxide and treated with 10 mL of toluene. The reaction mixture was degassed, then treated with 14.6 mg (0.02 mmol) of tris (dibenzylideneacetone) dipalladium (0), stirred overnight at 85 ° C, filtered, evaporated to dryness and purified by flash chromatography on silica gel.

 169 mg light residue, Rt. = 4.09 min (Method A), LCMS: 457 (M + H).

Stage f:

 The deprotection was carried out as already described.

 The product is present as hydrochloride.

137 mg light solid, Rt = 2.89 min (method A), LCMS: 357 (M + H). Preparation of 5- {4- [3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) - [1,2,4] thiadiazol-5-yl ] -piperazin-1-yl} -pentan-1-ol

 The preparation was carried out as described above starting from 65 mg (0.17 mmol) of 1- [3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1, 2,4] thiadiazol-5-yl] -piperazine hydrochloride and 17 mg (0.165 mmol) of 5-hydroxypentanal.

 37 mg light oil, Rt. = 2.93 min (Method A), LCMS: 443 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 8.14 (d, J = 1.8, 1H), 7.90 (dd, J = 8.3, 1.8, 1H), 7.42 (d, J = 8.3, 1H ), 4.23 - 4.09 (m, 2H), 3.74 - 3.61 (m, 4H), 3.51 (t, = 6.3, 2H), 3.31 (s, 2H), 3.26 - 3.18 (m, 2H), 1.85 - 1.74 ( m, 2H), 1.72 (s, 4H), 1.60-1.50 (m, 2H), 1.49-1.38 (m, 2H), 1.31 (d, J = 10.5, 12H).

4- {4- [3- (5,5,8 _> 8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1,2,4] thiadiazol-5-yl] - piperazin-1-yl} -butan-1-ol

 The preparation was carried out as described above starting from 65 mg (0.16 mmol) of 1- [3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1, 2,4] thiadiazol-5-yl] -piperazine and 36 μΙ_ (0.25 mmol) 4-bromo-butyl acetate. The deprotection was carried out by means of a 1 N NaOH solution in methanol. The product was purified by preparative HPLC and is available as

Hydrochloride.

 21 mg, solid, LCMS: 429 [M + H], HPLC: Rt. = 2.83 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ 8.06 (d, J = 1.8 Hz, 1 H), 7.82 (dd, J = 8.3, 1.8 Hz, 1 H), 7.33 (d, J = 8.3 Hz, 1 H), 4.07 (d, J = 12.9 Hz, 2H), 3.61 (t, J = 13.8 Hz, 4H), 3.47 (t, J = 6.0 Hz, 2H), 3.31 - 3.11 (m, 4H), 1.77 (dt, J = 15.4, 7.6 Hz, 2H), 1.64 (s, 4H), 1.54 - 1.45 (m, 2H), 1.22 (d, J = 11.1 Hz, 12H). Preparation of 1 - [3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1,2,4] oxadiazol-5-yl] -piperazine

Stage a:

 1.24 g (4.79 mmol) of N-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carboxamidines (preparation already described) were dissolved in 15 ml of NMP and treated with 1.16 ml (14.38 mmol) of pyridine. To that

 To the reaction mixture was added ethyl chloroformate (502 μL, 5.27 mmol). The mixture was stirred overnight at 80 ° C, stirred into 200 mL of water and extracted 2 times with ΕΞΑ. The combined organic phases were washed with 100 ml of water, dried over sodium sulphate, stripped to the residue and purified by flash chromatography on silica gel.

 980 mg brown residue, Rt. = 3.25 min (Method A), LCMS: 273 (M + H).

Stage b:

 248 mg (0.63 mmol) of 3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -4H- [1,2,4] oxadiazol-5-one from stage a were dissolved in 5 mL DCM and treated with pyridine (101 pL, 1.25 mmol) and phosphoryl chloride (115 pL, 1.25 mmol). The reaction mixture was stirred for 2 days at room temperature, diluted with DCM and extracted with water. The organic phase was over

 Dried sodium sulfate and evaporated to dryness.

 201 mg brown oil, Rt. = 4.03 min (Method A).

Stage c: 67 mg (0.22 mmol) of 5-chloro-3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) - [1,2,4] oxadiazole from step b were dissolved in 3 mL THF and treated with 61 mg (0.33 mmol) ie / -butyl 1-piperazinecarboxylate and 36 μΙ_ (0.26 mmol) triethylamine. The reaction mixture was added overnight

Stirred room temperature, added with 40 mL of water and extracted with ΕΞΑ 2 times. The organic phase was dried over sodium sulfate and evaporated to dryness.

 133 mg, residue, Rt. = 4.02 min (Method A), LCMS: 441 (M + H). Stage d:

 The deprotection was carried out as already described with HCl in methanol.

 The product was purified by flash chromatography on silica gel.

31 mg, light solid, Rt. = 2.83 min (method A), LCMS: 341 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.84 (d, J = 1.7, 1H), 7.65 (dd, J = 8.2, 1.7, 1H), 7.46 (d, J = 8.3, 1H ), 3.90 - 3.80 (m, 4H), 3.35 - 3.26 (m, 4H), 1.69 (s, 4H), 1.28 (d, J = 2.6, 12H).

Preparation of 4- {4- [3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) - [1, 2,4] oxadiazol-5-yl ] -piperazin-1-yl} -butan-1-ol

 The preparation was carried out as described above starting from 20 mg (0.06 mmol) of 1- [3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1, 2,4] oxadiazol-5-yl] -piperazirie and 13 pL (0.09 mmol) 4-bromo-butylacetate. The deprotection was carried out by means of a 1N NaOH solution in methanol. The product was purified by preparative HPLC and is available as

Hydrochloride.

 2 mg, solid, LCMS: 413 [M + H], HPLC: Rt. = 2.85 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.92 (d, J = 1.7, 1H), 7.70 (dd, J = 8.2, 1.7, 1H), 7.46 (d, J = 8.3, 1H) , 4.30 (d, J = 15.0, 2H), 3.65 (t, J = 11.9, 4H), 3.54 (t, J = 6.0, 2H), 3.38 - 3.19 (m, 5H), 1.88 - 1.78 (m, 2H ), 1.72 (s, 4H), 1.61 - 1.52 (m, 2H), 1.30 (d, J = 5.4, 13H). Preparation of 3,3-dimethyl-5- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] piperazin-1-yl} pentanes-1,4-diol

Stage a:

 200 mg (0.53 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole]

2-yl] -piperazines were dissolved in DCM, treated with 277 mg (1.06 mmol) of 5-bromo-3,3-dimethyl-4-oxo-pentanoic acid ethyl ester and 220 .mu.l (1.59 mmol) of triethylamine, overnight stirred at room temperature. The reaction mixture was concentrated to residue and purified by flash chromatography on silica gel.

 90 mg, yellow oil, Rt. = 3.29 min (Method A), LCMS: 526 (M + H).

Stage b:

 90 mg (0.171 mmol) of 3,3-dimethyl-4-oxo-5- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-nap

 hthalen-2-yl) -thiazol-2-yl] -piperazin-1-yl} -pentanoic acid ethyl ester from step a was dissolved in 8 ml of THF. Under ice-cooling 1.71 mL (1.71 mmol) of a 1 M lithium aluminum hydride solution in THF was added dropwise. The mixture was stirred with cooling for 1 h, then stirred at room temperature and then overnight at 40 ° C, decomposed with cooling with a saturated sodium sulfate solution and extracted 2 times with EA. The organic phase was washed with a saturated sodium chloride solution, dried over sodium sulfate, filtered, concentrated to dryness and purified by preparative HPLC. The product is present as hydrochloride.

 31 mg light solid, Rt. = 3.03 min (Method A), LCMS: 486 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.79 (d, J = 1.9, 1H), 7.58 (dd, J = 8.2, 1.9, 1H), 7.37 (d, J = 8.3, 1H ), 4.25 - 4.04 (m, 2H), 3.79 - 3.52 (m, 7H), 3.45 - 3.15 (m, 5H), 1.70 (s, 4H), 1.62 - 1.52 (m, 1H), 1.50 - 1.40 (m , 1H), 1.34-1.25 (m, 13H), 0.93 (d, J = 4.9, 6H). Preparation of 2- {2- {4- [4- (5,5,8 ₎ -8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl-i-azine 1-l-ethyl) -butane-1,4-diol

stage a

 Stage a:

 The preparation was carried out analogously starting from 250 mg (0.66 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl ] -piperazines and 255 mg (1.32 mmol) of 3- (2-bromo-ethyl) -dihydro-furan-2-one.

 77 mg, beige solid, Rt. = 3.07 min (Method A), LCMS: 468 (M + H).

Stage b:

 The reduction was carried out analogously starting from 77 mg of 3- (2- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2 -yl] -piperazin-1-yl} -ethyl) - dihydro-furan-2-ones from step a. The product is available as Trifluracetat salt.

 21 mg of brown oil, Rt. = 2.77 min (Method A), LCMS: 472 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.77 (s, 1H), 7.56 (d, J = 8.2, 1H), 7.38 (d, J = 8.3, 1H), 4.27-4.14 ( m, 2H), 3.76-3.63 (m, 2H), 3.59-3.48 (m, 4H), 3.41-3.24 (m, 5H), 1.91-1.81 (m, 1H), 1.80-1.66 (m, 6H). , 1.60 - 1.52 (m, 1H), 1.51 - 1.42 (m, 1H), 1.30 (d, J = 17.1, 13H).

Preparation of 2- {4- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperazin-1-yl pentanedioic acid diethyl ester and 2- (2- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2-] yl] piperazine-1-yl} -ethyl) butanes-1,4-diol

Stage a:

 The preparation was carried out analogously starting from 200 mg (0.56 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl ] -piperazines and 180 mg (0.68 mmol) of 2-bromo-pentanedioic acid diethyl ester.

 172 mg, brown oil, Rt. = 3.51 min (Method A), LCMS: 542 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.79 (d, = 1.8, 1H), 7.57 (dd, J = 8.2, 1.8, 1H), 7.38 (t, J = 7.3, 1H), 4.37 - 4.28 (m, 3H), 4.17 - 4.09 (m, 2H), 3.89 (s, 4H), 3.68 - 3.57 (m, 2H), 3.55 - 3.43 (m, 2H), 2.61 - 2.52 (m, 4H ), 2.52 - 2.44 (m, 1H), 2.43 - 2.34 (m, 1H), 2.23 - 2.12 (m, 1H), 1.69 (s, 4H), 1.36 - 1.18 (m, 21H).

Stage b:

 The reduction was carried out analogously starting from 172 mg of 2- {4- [4- (5,5,8,8-)

Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazin-1-yl} - pentanedioic acid diethyl ester from step a.

50 mg of brown oil, Rt. = 2.92 min (Method A), LCMS: 458 (M + H). 1H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.64 (s, 1H), 7.44 (dd, J = 8.2, 1.3, 1H), 7.32 (d, J = 8.3, 1H), 4.27-3.98 (m, 2H), 3.89-3.82 (m, 1H), 3.71-3.40 (m, 8H), 3.36-3.38 (m, 1H), 1.85-1.7 (m, 1H), 1.76-1.66 (m , 1H), 1.65 - 1.52 (m, 5H), 1.52 - 1.40 (m, 1H), 1.21 (d, J = 16.4, 13H). Preparation of 4- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazol-2-yl] piperazine-1-yl } -butane-1, 3-diol

 Stage a:

 The preparation was carried out analogously starting from 250 mg (0.66 mmol) of 1- [4- (SSSe-tetramethyl-o-tetrahydro-naphthalene-y-thiazolyl-1-piperazine and 156 μΙ_ (1.32 mmol) of 4-chloro 3-oxo-butyric acid methyl ester.

 90 mg, yellow oil, Rt. = 3.10 min (Method A), LCMS: 470 (M + H).

Stage b:

 The reduction was carried out analogously starting from 90 mg of 3-oxo-4- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole]. 2-yl] -piperazin-1-yl} -butyric acid methyl ester from stage a.

 20 mg of brown oil, Rt. = 2.91 min (Method A), LCMS: 444 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.73 (d, J = 1.9, 1H), 7.53 (dd, J = 8.2, 1.8, 1H), 7.42 (d, J = 8.3, 1H ), 4.29 - 4.16 (m, 3H), 3.80 - 3.64 (m, 5H), 3.49 - 3.28 (m, 3H), 3.19 (dd, J = 13.0, 10.8, 1 H), 1.72 (s, 4H), 1.67 (dd, J = 12.1, 6.0, 2H), 1.31 (d, J = 15.8, 13H).

Preparation of 5- {4- [4- {5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazol-2-yl] piperazin-1-yl } -pentanoic acid

100 mg (0.17 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-yl) -thiazole

2-yl] -piperazine hydrobromide were dissolved in 1.5 ml NMP, mixed with 56 μΙ_ (0.35 mmol) 5-bromo-pentanoic acid ethyl ester, 340 mg (1.04 mmol) cesium carbonate and 26 mg (0.17 mmol) sodium iodide, overnight 1 10 ° C stirred. The reaction mixture was salted with water, extracted with EA. The organic phase was dried over sodium sulfate, filtered, concentrated to dryness and purified by flash chromatography on silica gel.

 60 mg, yellow oil, Rt. = 3.23 min (Method A), LCMS: 484 (M + H).

Stage b:

 60 mg of 5- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazin-1-yl } -Pentanoic acid ethyl ester from stage a was dissolved in 2.5 ml of THF, treated with 250 uΙ_ water and 11 mg (0.43 mmol) of lithium hydroxide and stirred overnight at room temperature. The reaction mixture was neutralized with a 1 N hydrochloric acid solution, concentrated to dryness and concentrated by means of

purified preparative HPLC. The product is available as Trifluracetat salt.

 9 mg light solid, Rt. = 3.04 min (Method A), LCMS: 456 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.68 (s, 1H), 7.47 (d, J = 8.3, 1H), 7.29 (d, J = 8.3, 1H), 4.10 (s, 2H), 3.53 (d, J = 39.8, 4H), 3.28 - 3.12 (m, 4H), 2.26 (t, = 7.1, 2H), 1.74 - 1.65 (m, 2H), 1.61 (s, 4H), 1.59 - 1.49 (m, 2H), 1.21 (d, J = 13.6, 12H).

Preparation of 4- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazol-2-yl] -piperazin-1-yl } -butyric acid

 The preparation was carried out analogously starting from_100 mg (0.17 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazine hydrobromide and 63 mg (0.35 mmol) of 4-bromo-butyric acid ethyl ester. The product is available as TFA salt.

 18 mg light solid, Rt. = 3.00 min (method A), LCMS: 442 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.75 (d, J = 1.8, 1H), 7.54 (dd, J = 8.2, 1.8, 1H), 7.32 (d, J = 8.3, 1H ), 4.12 (d, J = 12.7, 2H), 3.64 (d, J = 10.6, 2H), 3.50 - 3.34 (m, 2H), 3.33 - 3.15 (m, 4H), 2.36 (t, J = 7.1, 2H), 1.97 - 1.87 (m, 2H), 1.64 (s, 4H), 1.25 (d, = 17.3, 12H). Preparation of 2- (3- {4- [4- (5,5,8,8-Tetrannethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperazine 1 -yl} -propyl) -malonic acid diethyl

00 mg (0.53 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

2-yl] -piperazines were dissolved in 5 ml of NMP, 235 μΙ_ (1.06 mmol) of 2- (3-chloro-propyl) malonic acid diethyl ester and 220 μl (1.59 mmol) of triethylamine were added and the mixture was heated at 100 ° C. overnight touched. The reaction mixture was concentrated to the residue and purified by preparative HPLC. The product is available as TFA salt.

 89 mg of light solid, Rt. = 3.27 min (Method A), LCMS: 556 (M + H).

 H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.79 (d, = 1.9, 1H), 7.58 (dd, J = 8.2, 1.9, 1H), 7.35 (d, J = 8.3, 1H), 4.24 - 4.08 (m, 6H), 3.69 - 3.56 (m, 3H), 3.54 - 3.39 (m, 2H), 3.30 - 3.21 (m, 3H), 1.92 - 1.82 (m, 2H), 1.82 - 1.72 (m , 2H), 1.69 (s, 4H), 1.33 - 1.20 (m, 19H).

Preparation of 1-piperidin-4-yl-4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] - piperazine

 Stage a:

 The preparation was carried out via a reductive amination as already described starting from 300 mg (0.69 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl). -thiazol-2-yl] -piperazine hydrobromide and 137 mg (0.69 mmol) 4-oxo-piperidine-1-carboxylic acid tert-butyl ester.

 370 mg, yellow oil, Rt. = 3.32 min (Method A), LCMS: 539 (M + H).

Stage b: The deprotection was carried out as already described starting from the product from stage a with a 4N HCl solution in dioxane. The product is present as hydrochloride.

 360 mg of light solid, Rt. = 2.76 min (Method A), LCMS: 439 (M + H).

¹ H NMR (400 MHz, DMSO) δ = 7.78 (d, J = 1.7, 1H), 7.57 (dd, J = 8.2, 1.8, 1H), 7.35 - 7.29 (m, 1H), 3.66 - 3.35 (m, 8H), 3.01-2.89 (m, 2H), 2.28 (d, J = 13.0, 2H), 1.91-1.77 (m, 2H), 1.65 (s, 4H), 1.26 (d, = 13.3, 12H ).

Preparation of 2- (4- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl) -thiazol-2-yl] -piperazine 1-yl} -piperidin-1-yl) ethanol

 The preparation was carried out as described above via a reductive amination starting from 50 mg (0.11 mmol) of 1-piperidin-4-yl-4- [4- (5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazine and 24 mg (0.13 mmol) (tert-butyl-dimethyl-silanyloxy) -acetaldehyde. The deprotection was carried out as already described with a 4N HCl solution in dioxane. The product is present as hydrochloride.

 10 mg, solid, Rt. = 2.77 min (Method A), LCMS: 483 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.79 (d, J = 1.7, 1H), 7.57 (dd, J = 8.2, 1.8, 1H), 7.38 (d, J = 8.3, 1H ), 3.83-3.72 (m, 5H), 3.60-3.50 (m, 4H), 3.23 (s, 5H), 3.16-3.06 (m, 2H), 2.43-2.35 (m, 2H), 2.23-0.208 (m , 2H), 1.70 (s, 4H), 1.33 - 1.27 (m, 14H).

Preparation of 2- (2- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl) -thiazol-2-yl] -piperazine 1-yl} -ethoxy) -ethanol

 The preparation was carried out as described above, starting from 100 mg (0.28 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2 -yl] -piperazine and 36 L (0.33 mmol) 2- (2-chloro-ethoxy) -ethanol. The product is present as hydrochloride.

 21 mg, solid, Rt. = 2.99 min (Method A), LCMS: 444 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.64 (d, J = 1.7, 1H), 7.42 (dd, J = 8.2, 1.7, 1H), 7.26 (d, J = 8.3, 1H ), 4.07 (s, 1H), 3.76 - 3.71 (m, 2H), 3.66 - 3.54 (m, 3H), 3.54 - 3.49 (m, 3H), 3.49 - 3.43 (m, 3H), 3.37 - 3.31 (m, 3H), 1.58 (s, 4H), 1.20 - 1.15 (m, 13H).

Preparation of 2- (2- {4- [4- {5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl) -thiazol-2-yl] -piperidine 1-yl} -ethoxy) -ethanol

 The preparation was carried out as described above, starting from 100 mg (0.26 mmol) of 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2 -yl] - piperidine hydrochloride and 34 μΙ_ (0.31 mmol) 2- (2-chloro-ethoxy) -ethanol. The product is present as hydrochloride.

 18 mg, solid, Rt. = 3.00 min (Method A), LCMS: 443 (M + H).

 1H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.83 (d, J = 1.8, 1H), 7.75 (d, J = 21.8, 1H), 7.64-7.55 (m, 1H), 7.30 (i.e. , J = 8.3, 1H), 3.80 - 3.70 (m, 2H), 3.65 (d, J = 12.7, 2H), 3.57 - 3.45 (m, 4H), 3.41 - 3.25 (m, 3H), 3.20 - 3.06 (m, 2H), 2.29 (d, = 12.7, 2H), 2.17 - 2.04 (m, 2H), 1.62 (s, 4H), 1.22 (d, J = 20.4, 12H).

Preparation of 2- (2- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl) -thiazol-2-yl] -piperazine 1-yl} -ethyl-amino) -ethanol

 The preparation was carried out as described above, starting from 100 mg (0.28 mmol) of 1: SS-tetramethyl-6-ethyl-tetrahydro-naphthalene-1-thiazolyl-1-yl] -piperazine and 50 mg (0.34 mmol ) 3- (2-chloro-ethyl) -oxazolidin-2-one. The

Cleavage of the protective group was carried out with a 1 sodium hydroxide solution. The product is present as hydrochloride.

 19 mg, solid, Rt. = 2.79 min (Method A), LCMS: 443 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.66 (d, J = 1.7, 1H), 7.45 (dd, J = 8.2, 1.6, 1H), 7.30 (d, J = 8.3, 1H ), 3.95 - 3.84 (m, 4H), 3.72 - 3.65 (m, 2H), 3.57 - 3.48 (m, 6H), 3.45 (t, J = 6.1, 2H), 3.10 - 3.04 (m, 2H), 1.63 (d, J = 12.4, 4H), 1.24-1.16 (m, 14H).

Preparation of 2- (2- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl) -thiazol-2-yl] -piperidine 1-yl} -ethyl-amino) -ethanol

 The preparation was carried out as described above, starting from 100 mg (0.26 mmol) of 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2 -yl] - piperidine hydrochloride and 46 mg (0.31 mmol) of 3- (2-chloro-ethyl) -oxazolidin-2-one. Deprotection was carried out with a 1 N sodium hydroxide solution. The product is present as hydrochloride.

 41 mg, solid, Rt. = 2.76 min (Method A), LCMS: 442 (M + H).

 1H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.78 (d, J = 1.6, 1H), 7.70 (s,

1H), 7.54 (d, J = 8.0, 1H), 7.25 (d, J = 8.3, 1H), 3.69-3.60 (m, 3H), 3.45-3.29 (m, 5H), 3.20- 3.08 ( m, 2H), 3.02 (s, 2H), 2.29 (d, J = 13.5, 2H), 2.12 - 1.98 (m, 2H), 1.57 (s, 4H), 1.23 - 1.11 (m, 12H).

Preparation of 4- [3- {5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -isoxazol-5-yl] -piperidine

Stage a:

 1 g (5.31 mmol) of 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene was dissolved in DCM and cooled to 0 ° C. With vigorous stirring, 1.12 mL (9.56 mmol) tin (IV) chloride was added dropwise. Subsequently, 0.47 mL (5.31 mmol) of (dichloromethyl) methyl ether was added dropwise within 10 minutes. The

Reaction mixture was at 0 ° C for a further 10 min and then at

Stirred room temperature for 45 min, with cooling with 30ml ice / water. The water phase was separated. The organic phase was washed with a 2N HCl solution and with a saturated NaCl solution. The organic phase was dried and evaporated to dryness.

 1.01 g, Rt. = 3.51 min (Method A), LCMS: 217 (M + H).

Stage b:

 The product from step a (1.01 g, 3.94 mmol) was combined with 0.82 g (11.81 mmol) of hydroxylammonium chloride and 1.25 g (11.81 mmol).

Sodium carbonate mixed with 20 mL of ethanol. The reaction mixture was stirred overnight at 80 ° C and filtered with suction. The filtrate was removed to the residue. This was purified by flash chromatography on silica gel.

 672 mg, Rt. = 3.33 min (Method A), LCMS: 232 (M + H).

Stage c: The product from stage b (672 mg, 2.91 mmol) was dissolved in 5 mL DMF and treated with 1 mL of a saturated HCl solution in diethyl ether. To the solution was added 1.08 g (3 mmol) of 45% potassium monopersulfate. The

The reaction mixture was stirred for 4 h at room temperature and evaporated to dryness. This was dissolved in ΕΞΑ and washed with a 0.5N HCl solution, a saturated sodium bicarbonate solution and a saturated NaCl solution. The organic phase was dried and evaporated to dryness.

 665 mg, Rt. = 3.57 min (Method A), LCMS: 266 (M + H).

Stage d:

 69 mg (0.33 mmol) of 4-ethynyl-piperidine-1-carboxylic acid tert-butyl ester (preparation according to Journal of the American Chemical Society, 2003, vol. 125, # 13, pp. 3714-3715)

 were treated with a solution of L-sodium ascorbate (13 mg, 0.07 mmol), potassium carbinate (91 mg, 0.66 mmol) and copper (II) sulfate 5-hydrate (5.25 mg, 0.03 mmol) in 2 mL aliquots. Butanol and 2 mL of water. To the mixture was added the product from Step c (100 mg, 0.33 mmol). The reaction mixture was stirred at room temperature for 3h, diluted with water and extracted 3 times with EA. The organic phase was dried and to the residue

deducted. This was purified by flash chromatography on silica gel.

 50 mg, Rt. = 4.10 min (method A), LCMS: 383 (M + H-f-butyl).

Level e:

 The deprotection was carried out as already described with an HCl solution in methanol. The product was purified by preparative HPLC and is present as the hydrochloride.

 11 mg solid, Rt. = 2.94 min (Method A), LCMS: 339 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.79 (d, J = 1.8, 1H), 7.61 (dd, = 8.2, 1.8, 1H), 7.45 (d, J = 8.3, 1H) , 6.87 (d, J = 0.6, 1H), 3.46 - 3.37 (m, 2H), 3.31 - 3.21 (m, 1H), 3.12 (td, J = 12.6, 2.8, 2H), 2.30 - 2.21 (m , 2H), 2.00 - 1.87 (m, 2H), 1.71 (s, 4H), 1.31 (d, J = 13.0, 12H).

Preparation of 4- {4- [3- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -isoxazol-5-yl] -piperidin-1-yl } butane-1-ol The preparation was carried out as described above starting from 130 mg of 4- [3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -isoxazol-5-yl] - piperidine and 83 μΙ_ 4-bromo-butyl acetate. The deprotection was carried out by means of a 1 N NaOH solution in methanol. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 37 mg, solid, LCMS: 411 [M + H], HPLC: Rt. = 2.93 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.82-7.76 (m, 1H), 7.64-7.55 (m, 1H), 7.48-7.42 (m, 1H), 6.75 (s, 1H) , 3.67 (d, J = 12.5, 2H), 3.59 - 3.50 (m, 2H), 3.30 - 3.09 (m, 7H), 2.39 - 2.27 (m, 2H), 2.12 - 1.97 (m, 2H), 1.90 - 1.76 (m, 2H), 1.72 (s, 4H), 1.62 - 1.51 (m, 2H), 1.31 (d, J = 11.7, 12H).

Preparation of S ^ -p-iS.S.e.e-tetramethyl-S. E.e.-tetrahydro-naphthalen-2-yl) -isoxazol-5-yl] -piperidin-1-yl} -pentan-1-ol

 The preparation was carried out as described above starting from 130 mg of 4- [3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -isoxazol-5-yl] - piperidine and 79 mg 5-hydroxypentanal. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 55 mg, solid, LCMS: 425 [M + H], HPLC: Rt. = 2.96 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.74-7.69 (m, 1H), 7.56-7.49 (m, 1H), 7.40-7.34 (m, 1H), 6.73 (s, 1H ), 3.58 (d, J = 12.3, 2H), 3.46 - 3.37 (m, 2H), 3.22 - 3.11 (m, 2H), 3.1 1 - 2.99 (m, 4H), 2.30 - 2.17 (m, 2H), 2.03 - 1.89 (m, 2H), 1.75 - 1.59 (m, 6H), 1.51 - 1.40 (m, 2H), 1.39 - 1.29 (m, 2H), 1.27 - 1.20

(m, 12H).

Stage a:

 1 g (4.21 mmol) of 1- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) ethanone was dissolved in 20 mL THF and treated with 1.03 mL (8.422 mmol)

 Diethyl carbonate added. To the mixture was added 539 mg (13.48 mmol)

Sodium hydride added in portions. The mixture was stirred at room temperature over the weekend, diluted with 100ml EA, added with 20ml water, acidified with a 1N HCl solution and extracted with EA. The organic phase was dried, stripped to residue and

Flash chromatography on silica gel.

 1.51 g, Rt. = 3.57 min (Method A), LCMS: 303 (M + H).

Stage b:

 1.51 g (4.62 mmol) of 3-oxo-3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -propionic acid ethyl ester from stage a was in 20 mL of glacial acetic acid dissolved, treated with 327 mg (4.71 mmol) of hydroxylammonium chloride and refluxed for 1 h. The

The reaction mixture was removed to the residue and by means of

Flash chromatography on silica gel.

 1.15 g, Rt. = 3.39 min (Method A), LCMS: 272 (M + H).

Stage c: 1.22 g (3.60 mmol) of 3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -4H-isoxazol-5-one from step b was added in 6 ml Dissolved (65.35 mmol) of phosphoryl chloride and cooled to 0 ° C. 399 pL (2.88 mmol) triethylamine were added slowly dropwise at 0 ° C. The reaction mixture was refluxed for 2 days, stripped to residue, stirred in ice and extracted 2 times with diethyl ether. The organic phase was dried, stripped to residue and

Flash chromatography on silica gel.

 441 mg, Rt. = 3.92 min (Method A), LCMS: 290 (M + H).

Stage d:

 400 mg (1.38 mmol) of 5-chloro-3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -isoxazole from stage c were used together with 257 mg of 1.38 mmol) of tert-butyl-1-piperazinecarboxylate and admixed with 231 μΐ_ (1.52 mmol) of 1,8-diazabicyclo [5.4.0] undec-7-ene. The mixture was melted at 150 ° C, stirred for 40 min at 150 ° C, diluted with DCM and evaporated to dryness. This was purified by flash chromatography on silica gel.

 400 mg, Rt. = 3.92 min (Method A), LCMS: 440 (M + H).

Level e:

 The deprotection was carried out as described above with TFA in DCM starting from 27 mg (0.06 mmol) of 4- [3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-) yl) -isoxazol-5-yl] -piperazine-1-carboxyloxylic acid tert-butyl ester from stage d. The product is available as TFA salt.

 26 mg solid, Rt. = 2.84 min (Method A), LCMS: 340 (M + H).

Preparation of 5- {4- [3- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -isoxazol-5-yl] -piperazine-1-yl } pentane-1-ol

 The preparation was carried out as described above via a reductive amination starting from 26 mg (0.05 mmol) of 1- [3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -isoxazol-5-yl] -piperazine and 5 mg (0.05 mmol) 5

Hydroxypentanal. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 4 mg, solid, LCMS: 426 [M + H], HPLC: Rt. = 2.88 min (Method A).

¹ H NMR (400 MHz, DMSG7 deuterated TFA) δ = 7.70 (d, J = 1.8, 1H), 7.53 (dd, J = 8.2, 1.8, 1H), 7.42 (d, J = 8.2, 1H), 4.01 - 3.93 (m, 2H), 3.64 (d, J = 12.7, 2H), 3.50 (t, J = 6.3, 2H), 3.47-3.38 (m, 2H), 3.29-3.17 (m, 5H), 1.81-1.73 (m, 2H), 1.71 (s, 4H), 1.58-1.50 (m, 2H), 1.47-1.39 (m, 2H), 1.30 (d, J = 10.5, 13H).

Preparation of 4- {2 - [(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carbonyl) -amino] -acetyl} -piperidine-1-carboxylic acid tert- butyl ester

Stage a:

 1.25 g (5.12 mmol) of 5,5,8,8-tetramethyl-5,6,7,8-tertahydro-2-naphthalenecarboxylic acid was used together with 2.5 g (10.23 mmol) of 4- (2-amino-1-hydroxybenzoyl) ethyl) -piperidine-1-carboxylic acid tert-butyl ester (preparation according to Bioorganic & Medicinal Chemistry Letters, 2004, vol. 14, # 13 p 3419-3424), 1.96 g (10.23 mmol) N- (3-dimethylaminopropyl) Weighed -N'-ethylcarbodiimide hydrochloride and 783 mg (5.12 mmol) of 1-Hydroxybenzotriazolhydrat and suspended in 20 mL of DMF. The reaction mixture was treated with 844 g (7.67 mmol) of 4-methylmorpholine, stirred at room temperature overnight, stirred into 400 ml of water. The mother liquor was decanted off and the resulting solid was washed with water, dissolved in EA, dried over sodium sulfate, filtered, evaporated to dryness and purified by flash chromatography on silica gel.

 1.15 g, Rt. = 3.43 min (method A), LCMS: 403 (M + H-tert-butyl).

Stage b:

 1.15 g (2.51 mmol) of 4- {1-hydroxy-2 - [(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carbonyl) -amino] -ethyl} - piperidine-1-carboxylic acid tert-butyl ester from step a was dissolved in 20 mL DCM and treated with 15.61 mL (7.52 mmol) Dess-Martin periodinan. The reaction mixture was stirred for 30 min at room temperature, treated with 20 ml of a saturated sodium bicarbonate solution and 5 ml of a saturated sodium sulfate solution and stirred vigorously for 30 min. The organic phase was separated and the water phase was extracted again with DCM. The organic phases were combined, dried, stripped to the residue and purified by flash chromatography on silica gel.

800 mg, Rt. = 3.55 min (Method A), LCMS: 375 (M + H). Preparation of 4- [2- {5 ^ 8 _> 8-tetramethyl-5,6 _> 7,8-tetrahydro-naphthalen-2-yl) -oxazol-5-yl] -piperidine

Stage a:

 400 mg (0.88 mmol) of 4- {2 - [(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carbonyl) -amino] -acetyl} -piperidine-1 The carboxylic acid tert-butyl ester was dissolved in 20 ml of THF and treated with 417 mg (1.75 mmol) of Burgess reagent. The reaction mixture was stirred overnight at 60 ° C, stripped to residue, dissolved in DCM and washed with a 1 N hydrochloric acid solution and a saturated

 Sodium bicarbonate solution washed. The organic phase was dried and evaporated to dryness.

 395 mg, Rt. = 4.12 min (Method A), LCMS: 439 (M + H).

Stage b:

 The deprotection was carried out as already described with HCl in methanol starting from 395 mg of product from stage a.

 306 mg of oil, Rt. = 2.84 min (Method A), LCMS: 339 (M + H).

Preparation of 4- {4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) oxazol-5-yl] -piperidin-1-yl } butane-1-ol

The preparation was carried out as described above starting from 150 mg (0.44 mmol) of 4- [2- (5,5,8,8-tetramethyl-5 ₁ 6,7,8-tetrahydro-naphthalen-2-yl) -oxazole-5 -yl] - piperidine and 96 pL (0.67 mmol) 4-bromo-butyl acetate. The splitting off of

Protecting group was carried out by means of a 1N NaOH solution in methanol. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 57 mg, solid, LCMS: 411 [M + H], HPLC: Rt = 2.82 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.97-7.87 (m, 1H), 7.65 (d, J = 8.2, 1H), 7.40 (d, = 8.3, 1H), 7.31-7.09 (m, 1H), 4.31 (s, 1H), 3.90-3.76 (m, 2H), 3.55 (s, 2H), 3.48-3.26 (m, 2H), 3.06 (s, 5H), 2.20 (i.e. , J = 12.1, 2H), 1.98 - 1.85 (m, 2H), 1.79 - 1.68 (m, 2H), 1.67 - 1.55 (m, 4H), 1.50 - 1.39 (m, 1H), 1.20 (dd, J = 18.3, 14.2, 12H).

Preparation of 5- {4- [2- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) oxazol-5-yl] -piperidin-1-yl } pentane-1-ol

 The preparation was carried out as described above via a reductive amination starting from 150 mg (0.44 mmol) of 4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -oxazol-5-yl] -piperidine and 91 mg (0.89 mmol) 5-hydroxypentanal The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 70 mg, solid, LCMS: 425 [M + H], HPLC: Rt. = 2.87 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.97-7.91 (m, 1H), 7.76-7.69 (m, 1H), 7.49 (d, J = 8.3, 1H), 7.29-7.11 ( m, 1H), 3.67-3.59 (m, 2H), 3.50-3.41 (m, 2H), 3.20-3.06 (m, 5H), 2.33-2.18 (m, 2H), 2.00-1.89 (m, 2H) , 1.79 - 1.65 (m, 6H), 1.56 - 1.45 (m, 2H), 1.45 - 1.34 (m, 2H), 1.30 (d, J = 13.1, 12H).

Preparation of 4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-5-yl] -piperidine

Stage a:

 233 mg (0.51 mmol) 4- {2 - [(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carbonyl) -amino] -acetyl} -piperidine-1 Tertiary butyl carboxylic acid esters were dissolved in 5 ml of THF together with 310 mg (0.77 mmol) of 2,4-bis (4-methoxyphenyl) -2,4-dithioxo-1,3,2,4-dithiadiphosphethane and stirred for 10 minutes in the microwave irradiated at 100 ° C. The reaction mixture was removed to the residue, dissolved in DCM and washed with a 1 N HCl solution and a saturated

Washed sodium bicarbonate solution. The organic phase was dried, evaporated to dryness.

 512 mg.

Stage b:

 The deprotection was carried out as already described with HCl in methanol starting from 512 mg of product from stage a.

 160 mg of oil, Rt. = 2.90 min (Method A), LCMS: 355 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.96-7.89 (m, 2H), 7.68 (dd, J = 8.3, 2.0, 1H), 7.50 (d, = 8.3, 1H), 3.49 - 3.41 (m, 2H), 3.40 - 3.30 (m, 1H), 3.11 (td, J = 12.7, 2.5, 2H), 2.24 (d, J = 12.5, 2H), 2.00 - 1.89 (m, 2H), 1.73 (s, 4H), 1.30 (dd, = 19.1, 10.2, 12H).

Preparation of 4- {4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-5-yl] -piperidin-1-yl } -butane-1-ol

 The preparation was carried out as described above starting from 70 mg (0.20 mmol) of 4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-5 -yl] - piperidine and 43 μΙ_ (0.30 mmol) of 4-bromo-butyl acetate. The splitting off of

Protecting group was carried out by means of a 1 N NaOH solution in methanol. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 23 mg, solid, LCMS: 427 [M + H], HPLC: Rt. = 2.92 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.97-7.89 (m, 2H), 7.72-7.65 (m, 1H), 7.53-7.48 (m, 1H), 3.67 (d, J = 12.4 , 2H), 3.60 - 3.42 (m, 2H), 3.38 - 3.10 (m, 5H), 2.36 - 2.23 (m, 2H), 2.09 - 1.96 (m, 2H), 1.88 - 1.78 (m, 2H), 1.73 (s, 4H), 1.60 - 1.52 (m, 2H), 1.32 (d, J = 15.9, 12H). Preparation of S ^ -P ^ SSee-tetramethyl-S.SJ.e -tetrahydro-naphthalen-2-yl) -thiazol-5-yl] -piperidin-1-yl} -pentan-1-ol

 The preparation was carried out as described above via a reductive amination starting from 70 mg (0.20 mmol) 4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-5-yl] -piperidine and 40 mg (0.40 mmol) 5-hydroxypentanal. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 41 mg, solid, LCMS: 441 [M + H], HPLC: Rt. = 2.95 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.89 (d, J = 1.9, 1H), 7.81 (s, 1H), 7.69-7.62 (m, 1H), 7.50-7.45 (m, 1 H), 3.64 (d, = 12.5, 2H), 3.53 - 3.39 (m, 2H), 3.34 - 3.07 (m, 5H), 2.33 - 2.19 (m, 2H), 2.04 - 1.91 (m, 2H), 1.78-1.66 (m, 6H), 1.55-1.48 (m, 2H), 1.44-1.36 (m, 2H), 1.31 (d, J = 13.7, 12H).

Preparation of 4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -oxazol-4-yl] -piperidine

Stage a:

The preparation was carried out as described above with EDCI and HOBt in DMF starting from 1 g (4.26 mmol) of 5,5,8,8-tetramethyl-5,6,7,8-tertahydro-2-one. naphthalenecarboxylic acid and 1.25 g (5.11 mmol) of 4- (1-amino-2-hydroxy-ethyl) -piperidine-1-carboxylic acid tert-butyl ester (preparation analogous to US2002 / 183361 A1, 2002).

 2.89 g, oil, Rt. = 3.40 min (Method A), LCMS: 459 (M + H). Stage b:

 The preparation was carried out as already described with Dess-Martin periodinan starting from the product from stage a.

 954 mg, yellow oil, Rt. = 3.55 min (method A), LCMS: 357 (M + H-boc).

Stage c:

 The preparation was carried out as already described with Burgess reagent starting from the product from stage b.

 1.10 g of solid, Rt. = 4.17 min (Method A), LCMS: 439 (M + H).

 Stage d:

 The deprotection was carried out as already described with HCl in dioxane starting from the product from stage c. The product is available as

Hydrochloride.

 1.20 g, solid, Rt. = 2.93 min (Method A), LCMS: 339 (M + H).

Preparation of 4- {4- [2- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) oxazol-4-yl] -piperidin-1-yl } -butane-1-ol

 The preparation was carried out as described above starting from 200 mg (0.32 mmol) of 4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -oxazole-4 -yl] - piperidine hydrochloride and 94 μί (0.64 mmol) 4-bromo-butyl acetate. The deprotection was carried out by means of a 2N NaOH solution in methanol. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 6 mg, solid, LCMS: 41 l [M + H], HPLC: Rt. = 2.91 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 8.02-7.87 (m, 2H), 7.78-7.70 (m, 1H), 7.48 (d, J = 8.3, 1H), 3.63 (d, J = 12.4, 1H), 3.54 - 3.36 (m, 2H), 3.21 - 3.06 (m, 4H), 2.98 - 2.88 (m, 1H), 2.27 - 2.14 (m, 2H), 2.00 - 1.88 (m, 2H), 1.85-1.76 (m, 2H), 1.76-1.68 (m, 4H), 1.58-1.49 (m, 2H), 1.34-1.27 (m, 12H). Preparation of 5- {4- [2- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -oxazol-4-yl] -piperidin-1-yl } pentane-1-ol

The preparation was carried out as described above via a reductive amination starting from 200 mg (0.32 mmol) of 4- [2- (5,5,8 ₎ -8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl). -oxazol-4-yl] -piperidine hydrochloride and 65 mg (0.64 mmol) 5-hydroxypentanal. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 5 mg, solid, LCMS: 425 [M + H], HPLC: Rt. = 2.95 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.98-7.93 (m, 1H), 7.84 (s, 1H), 7.79-7.71 (m, 1H), 7.47 (d, J = 8.3, 1 H), 3.63 (d, J = 12.4, 2H), 3.54 - 3.38 (m, 2H), 3.23 - 3.06 (m, 4H), 2.99 - 2.90 (m, 1H), 2.23 (d, J = 12.1 , 2H), 2.04 - 1.92 (m, 2H), 1.81 - 1.67 (m, 6H), 1.58 - 1.49 (m, 2H), 1.47 - 1.38 (m, 2H), 1.31 (d, J = 12.8, 12H) ,

Preparation of 4- [N '- {5,5,8,8-tetramethyl-5 ₎ 6,7,8-tetrahydronaphthalene-2-carbonyl-hydrazinocarbonyl] -piperidine-1-carboxyloxylic acid tert-butyl ester

Stage a:

 2 g (8.18 mmol) of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid was used together with 1.08 g (8.18 mmol) of tert-butylcarbazate and 1.88 g (9.81 mmol). Dissolved N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride in 10 mL of DMF and stirred overnight at room temperature. The

The reaction mixture was poured onto 200 ml of water. The resulting precipitate was filtered off, washed with water, taken up in ether and washed several times with water. The organic phase was dried, evaporated to dryness.

 2.42 g, Rt. = 3.27 min (method A), LCMS: 291 (M + H-tert-butyl).

Stage b:

 The deprotection was carried out as already described starting from the product from stage a with a 4N HCl solution in dioxane. The

Reaction mixture was evaporated to residue. The product was present as hydrochloride.

 2.2 g residue, Rt. = 2.56 min (Method A), LCMS: 247 (M + H).

Stage c:

 2.2 g (6.22 mmol) of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid hydrazide from step b were used together with 1.43 g (6.22 mmol) 1 Boc-piperazine- 4-carboxylic acid (preparation analogous to Bioorganic & Medicinal

Chemistry Letters, 2001, vol. 11, # 24 p. 3161-3164), 2.41 g (12.45 mmol) of N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride and 867 mg (6.22 mmol) of 1-hydroxybenzotriazole hydrate suspended in 15 mL of DMF. The reaction mixture was treated with 1.40 mL (12.45 mmol) of 4-methylmorpholine, at room temperature stirred overnight, stirred in 350ml of water. The resulting precipitate was filtered off with suction, dissolved in DCM, dried, stripped to the residue and purified by flash chromatography on silica gel.

1.23 g, Rt. = 3.22 min (method A), LCMS: 402 (M + H-tert-butyl).

Preparation of 4- [5- {5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1,3,4] thiadiazol-2-yl] -piperidine

Stage a:

The ring closure was carried out as described above starting from 100 mg (0.22 mmol) of 4- [N ^, - (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-carbonyl) -hydrazinocarbonyl]. -piperidine-1-carboxylic acid tert-butyl ester and 133 mg (0.33 mmol) of 2,4-bis (4-methoxyphenyl) -2,4-dithioxo-1,3,2,4-dithiadiphosphethane.

 160 mg of oil, Rt. = 4.03 min (Method A), LCMS: 456 (M + H).

Stage b:

 The deprotection was carried out as already described with HCl in methanol starting from 160 mg of product from stage a.

 20 mg of oil, Rt. = 2.82 min (Method A), LCMS: 356 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.80 (d, J = 1.9, 1H), 7.59 (dd, J = 8.2, 1.9, 1H), 7.40 (d, J = 8.3, 1H ), 3.56 - 3.46 (m, 1H), 3.41 - 3.32 (m, 2H), 3.06 (td, J = 12.6, 2.9, 2H), 2.24 (dd, J = 14.3, 3.1, 2H), 2.08 - 1.94 (m, 2H), 1.64 (s, 4H), 1.22 (d, J = 10.3, 12H).

Preparation of 4- {4- [5- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) - [1,3,4] thiadiazol-2-yl ] -piperidin-1-yl} -butan-1-ol

The preparation was carried out as described above starting from 125 mg (0.35 mmol) of 4- [5- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1, 3,4] thiadiazol-2-yl] -piperidine and 76 μΐ_ (0.53 mmol) 4-bromo-butyl acetate. The deprotection was carried out by means of a 1 N NaOH solution in methanol. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 66 mg, solid, LCMS: 428 [M + H], HPLC: Rt. = 2.87 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.90 (d, J = 1.9, 1H), 7.72-7.65 (m, 1H), 7.53-7.48 (m, 1H), 4.49-4.41 (m, 1H ), 3.80 - 3.66 (m, 2H), 3.63 - 3.49 (m, 2H), 3.31 - 3.14 (m, 4H), 2.41 (d, J = 14.0, 2H), 2.24 - 2.12 (m, 2H), 1.92 - 1.80 (m, 3H), 1.73 (s, 4H), 1.61 - 1.52 (m, 1H), 1.32 (d, J = 12.9, 12H).

Preparation of 5- {4- [5- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) - [1, 3,4] thiadiazol-2-yl ] -piperidin-1-yl} -pentan-1-ol

 The preparation was carried out as described above via a reductive amination starting from 125 mg (0.35 mmol) 4- [5- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) - [1, 3,4] thiadiazol-2-yl] -piperidine and 72 mg (0.70 mmol) of 5-hydroxypentanal. The product was purified by preparative HPLC and converted into the hydrochloride by treatment with methanolic HCl.

 84 mg, solid, LCMS: 442 [M + H], HPLC: Rt. = 2.90 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.90 (d, J = 1.9, 1H), 7.72-7.65 (m, 1H), 7.53-7.48 (m, 1H), 4.47-4.39 ( m, 1H), 3.69 (d, J = 13.6, 2H), 3.62 - 3.46 (m, 2H), 3.23 - 3.11 (m, 4H), 2.44 - 2.36 (m, 2H), 2.21 - 2.09 (m, 2H), 1.86 - 1.69 (m, 7H), 1.58 - 1.37 (m, 3H), 1.32 (d, J = 12.7, 12H).

Preparation of 4- [5- (5,5,8 ₎ -8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1,3,4] oxadiazol-2-yl] -piperidine

400 mg (0.87 mmol) of 4- ^[N, - (5,5 ₁ 8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene- 2-carbonyl) -hydrazinocarbonyl] -piperidine-1-carboxylic acid tert butyl ester were dissolved in 4 mL phosphoryl chloride and stirred at 90 ° C for 1 h. The reaction mixture was tilted to 120 mL ice / water, made alkaline and washed 3 times

Extracted diethyl ether. The organic phase was dried and added to

Deducted residue.

124 mg, Rt. = 2.74 min (Method A), LCMS: 340 (M + H). Preparation of 4- {4- [5- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) - [1, 3,4] oxadiazol-2-yl ] -piperidin-1-yl} -butan-1-ol

 The preparation was carried out as described above starting from 75 mg (0.15 mmol) of 4- [5- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1, 3,4] oxadiazol-2-yl] -piperidine and 33 μΙ_ (0.23 mmol) 4-bromo-butyl acetate. The deprotection was carried out by means of a 1 N NaOH solution in methanol. The product was purified by preparative HPLC. The product is available as TFA salt.

 21 mg, solid, LCMS: 412 [M + H], HPLC: Rt. = 2.76 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.98-7.92 (m, 1H), 7.79-7.72 (m, 1H), 7.54 (d, J = 8.3, 1H), 3.68 (d, J = 12.5, 1H), 3.56 - 3.47 (m, 3H), 3.47 - 3.36 (m, 1H), 3.22 - 3.11 (m, 4H), 2.41 (d, J = 12.5, 2H), 2.19 - 2.06 (m, 2H), 1.87-1.69 (m, 6H), 1.60-1.47 (m, 2H), 1.32 (d, J = 8.6, 12H).

Preparation of 5- {4- [5- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) - [1, 3,4] oxadiazol-2-yl ] -piperidin-1-yl} -pentan-1-ol

 The preparation was carried out as described above via a reductive amination starting from 50 mg (0.10 mmol) 4- [5- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) - [1, 3,4] oxadiazol-2-yl] -piperidine and 21 mg (0.20 mmol) 5

Hydroxypentanal.

 13 mg, oil, LCMS: 426 [M + H], HPLC: Rt. = 2.78 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.96 (dd, J = 11.5, 1.8, 1H), 7.79-7.73 (m, 1H), 7.53 (d, J = 8.3, 1H), 3.73 - 3.57 (m, 2H), 3.55 - 3.35 (m, 3H), 3.26 - 3.08 (m, 4H), 2.41 (d, J = 12.9, 2H), 2.35 - 2.07 (m, 2H), 1.83 - 1.66 (m, 6H), 1.59 - 1.49 (m, 2H), 1.48 - 1.37 (m, 2H), 1.32 (d, J = 8.6, 12H). Preparation of 4- [3- {5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene) - [1,2,4] oxadiazol-5-yl] -piperidine

Stage a:

 The preparation was carried out as described above with EDCI and HOBt in DMF starting from 751 mg (3.05 mmol) of N-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalenes-2-carboxamidines ( Preparation described above) and 769 mg (3.35 mmol) of piperidine-1,4-dicarboxylic acid mono-tert-butyl ester.

 924 mg, oil, Rt. = 3.52 min (Method A), LCMS: 458 (M + H).

Stage b:

 The preparation was carried out as described above with Burgess reagent starting from 100 mg (0.18 mmol) of the product from stage b.

 37 mg solid, Rt. = 4.15 min (Method A).

Stage c:

 The deprotection was carried out as already described with HCl in methanol starting from the product from stage c. The product is available as

 Hydrochloride.

 7 mg, solid, Rt. = 2.91 min (Method A), LCMS: 340 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 8.00 (d, J = 1.8, 1H), 7.78 (dd, J = 8.2, 1.8, 1H), 7.50 (d, J = 8.3, 1H ), 3.57 - 3.47 (m, 3H), 3.44 (dt, J = 12.7, 3.6, 2H), 3.16 (td, J = 12.7, 3.0, 2H), 2.33 (dd, J = 14.4, 3.5, 2H), 2.20 - 2.05 (m, 2H), 1.73 (s, 4H), 1.31 (d, J = 6.8, 12H). Preparation of 4- {4- [3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) - [1, 2,4] oxadiazol-5-yl ] -piperidin-1-yl} -butan-1-ol

 The preparation was carried out as described above starting from 95 mg (0.25 mmol) of 4- [3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1, 2,4] oxadiazol-5-yl] -piperidine hydrochloride and 55 μΙ_ (0.38 mmol) 4-bromo-butyl acetate. The deprotection was carried out by means of a 1 NaOH solution in methanol. The product was purified by preparative HPLC and is present as the hydrochloride.

 55 mg, solid, LCMS: 412 [M + H], HPLC: Rt. = 2.91 min (Method A).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.96-7.89 (m, 1H), 7.76-7.67 (m, 1H), 7.49-7.43 (m, 1H), 3.62 (d, = 12.2 , 2H), 3.50 - 3.38 (m, 3H), 3.18 - 3.05 (m, 5H), 2.35 (d, J = 12.5, 2H), 2.13 - 1.99 (m, 2H), 1.78 - 1.63 (m, 6H) , 1.52 - 1.38 (m, 2H), 1.25 (d, J = 5.1, 12H).

Preparation of 5- {4- [3- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) - [1,2,4] oxadiazol-5-yl ] -piperidin-1-yl} -pentan-1-ol

 The preparation was carried out as described above via a reductive amination starting from 95 mg (0.26 mmol) of 4- [3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) - [1, 2,4] oxadiazol-5-yl] -piperidine hydrochloride and 52 mg (0.51 mmol) 5-hydroxypentanal.

 78 mg, solid, LCMS: 426 [M + H], HPLC: Rt. = 2.94 min (Method A).

H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.95-7.89 (m, 1H), 7.75-7.66 (m, 1H), 7.46-7.39 (m, 1H), 3.65- 3.55 (m, 2H ), 3.47 - 3.35 (m, 3H), 3.17 - 3.01 (m, 4H), 2.38 - 2.01 (m, 4H), 1.73 - 1.59 (m, 6H), 1.51 - 1.28 (m, 4H), 1.27 - 1.20 (m, 12H). Preparation of 4- [4-5,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-l] -piperidine

The preparation was carried out as described above starting from 1.09 g (2.05 mmol) of 2-bromo-1- (5,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -ethanone and 500 mg (2.05 mmol) mmol) of 4-thiocarbamoyl-piperidine-1-carboxylic acid terf-butyl ester. The product is available as hydrobromide.

 514 mg, solid, Rt. = 2.55 min (Method A), LCMS: 327 (M + H).

 H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.92 (s, 1H), 7.77 (d, J = 5.2, 1H), 7.74-7.64 (m, 1H), 7.25 (t, J = 8.7 , 1H), 3.50-3.40 (m, 3H), 3.19-3.04 (m, 2H), 2.99-2.81 (m, 2H), 2.29 (d, J = 11.7, 2H), 2.08-1.92 (m, 3H ), 1.91 - 1.79 (m, 1H), 1.67 - 1.53 (m, 1H), 1.52 - 1.40 (m, 1H), 1.36 - 1.22 (m, 6H).

Preparation of 4- {4- [4- (5,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-1-yl} -butane 1-ol

 The preparation was carried out as described above starting from 150 mg (0.37 mmol) of 4- [4- (5,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] - piperidine hydrobromide and 109 μΙ_ (0.74 mmol) 4-bromo-butyl acetate. The deprotection was carried out by means of a 1 N sodium hydroxide solution in methanol. The product was purified by preparative HPLC and is present as the hydrochloride.

 54 mg, white solid, LCMS: 399 [M + H], HPLC: Rt. = 2.86 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.92-7.83 (m, 1H), 7.79 (d, = 7.6, 1H), 7.75-7.66 (m, 1H), 7.26 (dd, J = 11.6, 8.2, 1H), 3.67 (d, J = 12.2, 2H), 3.54 - 3.39 (m, 3H), 3.22 - 3.11 (m, 4H), 2.99 - 2.84 (m, 2H), 2.38 (i.e. , J = 14.0, 2H), 2.13 (dd, J = 23.6, 12.5, 2H), 2.07 - 1.98 (m, 1H), 1.92 - 1.72 (m, 3H), 1.66 - 1.44 (m, 4H), 1.36 - 1.24 (m, 6H).

Preparation of 5- {4- [4- (5,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-1-yl} -pentane 1-ol

 The preparation was carried out as described above via a reductive amination starting from 100 mg (0.25 mmol) of 4- [4- (5,8-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazole-2 -yl] -piperidine hydrobromide and 50 mg (0.49 mmol) 5-hydroxypentanal. The product is present as hydrochloride.

 66 mg, white crystals, LCMS: 413 [M + H], HPLC: Rt. = 2.89 min (Method A). H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.89 (dd, J = 23.5, 1.2, 1H), 7.79 (d, = 6.6, 1H), 7.75-7.64 (m, 1H), 7.26 (dd , J = 11.5, 8.2, 1H), 3.66 (d, J = 12.5, 2H), 3.52 - 3.38 (m, 3H), 3.20 - 3.08 (m, 4H), 3.00 - 2.82 (m, 2H), 2.37 (d, = 13.3, 2H), 2.11 (dd, J = 23.4, 12.6, 2H), 2.05 - 1.97 (m, 1H), 1.92 - 1.82 (m, 1H), 1.81 - 1.67 (m, 2H) , 1.66 - 1.57 (m, 1H), 1.56 - 1.45 (m, 3H), 1.45 - 1.37 (m, 2H), 1.36 - 1.23 (m, 6H).

Preparation of 2- (4- {1- [4- (5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} piperazin-1-yl) ethanol

 The preparation was carried out as described above in 2 stages starting from 200 mg (0.80 mmol) 2- (4-piperidin-4-yl-piperazin-1-yl) -ethanol hydrochloride. In the 2nd stage, ring closure was carried out starting from the corresponding urea and 103 mg (0.37 mmol) of 2-bromo-1- (5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl) ethanone , The product was purified by preparative HPLC and is present as the hydrochloride.

 13 mg, solid, Rt. = 2.60 min (Method A), LCMS: 455 (M + H).

H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.64 (d, J = 8.2, 1H), 7.54 (s, 1H), 7.43 (d, J = 8.3, 1H), 4.11 (d, = 12.7, 2H), 3.86-3.79 (m, 4H), 3.76-3.35 (m, 3H), 3.44-3.36 (m, 3H), 3.19 (t, J = 12.4, 2H), 2.85-2.26 (m, 2H ), 2.21 (d, J = 10.4, 3H), 1.92 - 1.75 (m, 5H), 1.72 - 1.62 (m, 2H), 1.29 (s, 6H). Preparation of 4- [4- (8-ethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-1-yl] -piperidine-1-carboxylic acid tert-butyl ester

Stage a:

 The preparation was carried out as described above starting from 500 mg (2.05 mmol) of 2-bromo-1- (8-methyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -ethanone and 500 mg (2.05 mmol). 4-Thiocarbamoyl-piperidine-1-carboxylic acid ferric butyl ester. The product is available as hydrobromide.

 Solid, Rt. = 2.48 min (Method A), LCMS: 313 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.87 (d, J = 12.1, 1H), 7.83-7.61 (m, 2H), 7.19 (dd, J = 76.4, 8.0, 1H), 3.50 - 3.40 (m, 3H), 3.12 (t, J = 11.4, 2H), 2.99 - 2.87 (m, 1H), 2.84 - 2.70 (m, 2H), 2.29 (d, J = 13.7, 2H), 2.08 - 1.97 (m, 2H), 1.96-1.82 (m, 2H), 1.77-1.66 (m, 1H), 1.59-1.49 (m, 1H), 1.30 (dd, J = 18.0, 7.0, 3H).

 '

 Stage b:

 150 mg (0.38 mmol) of 4- [4- (8-methyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine from step a were dissolved in 3 mL of DMF , with 64 uΙ_ (0.46 mmol) of triethylamine and 98 μΙ_ di-tert-butyl dicarbonate and 2 h at

Room temperature stirred. The mixture was mixed with a 10%

 Citronsäurelösung and extracted with DCM 3 times. The organic phase was dried, filtered and evaporated to dryness.

 200 mg, brown oil, Rt. = 4.15 min (Method A), LCMS: 413 (M + H).

From the racemic mixture, 4 enantiomers by means of chiral

Chromatography isolated. For each enantiomer, the cleavage of the

Protecting group as previously described with HCl in methanol. The enantiomers are present as the hydrochloride.

4- [4 - ((S) -5-Methyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine

 2 mg, solid, Rt. = 2.73 min (Method A), LCMS: 313 (M + H).

4- [4 - ((R) -5-methyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine

 3 mg, solid, Rt. = 2.73 min (Method A), LCMS: 313 (M + H).

4- [4 - ((S) -8-Methyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine

 3 mg, solid, Rt. = 2.72 min (Method A), LCMS: 313 (M + H).

4- [4 - ((R) -8-methyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine

3 mg, solid, Rt. = 2.72 min (Method A), LCMS: 313 (M + H). Preparation of 1 - [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-4-carboxylic acid

Stage a:

 The preparation is carried out as described above starting from 4.9 g (11.56 mmol) of 2-bromo-1- (8-methyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -ethanone and 2.5 g (11.56 mmol) 1-Thiocarbamoyl-piperidine-4-carboxylic acid ethyl ester. The product is available as hydrobromide.

 4.5 g, green solid, Rt. = 3.56 min (Method A), LCMS: 427 (M + H).

Stage b:

 3.5 g (6.90 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-yl) -thiazole]

2-yl] -piperidine-4-carboxylic acid ethyl ester hydrobromide from step a were slurried in 25 ml of THF, with 21 ml of water and 843 mg (34.48 mmol)

Lithium hydroxide and stirred overnight at room temperature. The

The reaction mixture was concentrated by rotary evaporation, adjusted to pH = 1 with a 1-hydrochloric acid solution and then extracted twice with ΕΞΑ. The combined organic phases were dried over sodium sulfate, filtered and concentrated.

 2.7 g, green foam, Rt. = 3.09 min (Method A), LCMS: 399 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.60 (d, J = 1.7, 1H), 7.50-7.41 (m, 2H), 4.05 (d, J = 13.3, 2H), 3.60-3.48 ( m, 2H), 2.74 - 2.65 (m, 1H), 2.1 1 (dd, J = 13.7, 3.5, 2H), 1.93 - 1.80 (m, 2H), 1.72 (s, 4H), 1.31 (d, J = 12.7, 14H). Preparation of 2 - <{1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidine-4- ylmethyl} -amino) -ethanol

Stage a:

 200 mg (0.50 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-4- carboxylic acid are dissolved in 6 ml of DMF and admixed with 112 μΙ_ (1.00 mmol) of N-methylmorpholine, 194 mg (1.00 mmol) of N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride and 140 mg (1.00 mmol) of 1-hydroxybenzotriazole hydrate , The solution is stirred for 30 min at room temperature, then treated with 36 pL (0.60 mmol) of ethanolamine and stirred overnight at room temperature. The reaction mixture was treated with about 10 ml of a 1 N hydrochloric acid solution and extracted with ΕΞΑ. Subsequently, the water phase was made alkaline with a 1 M sodium hydroxide solution and extracted twice with ΕΞΑ. The last organic phases were combined, dried with sodium sulfate, filtered and concentrated. The product was purified by preparative HPLC and is present as TFA salt.

 126 mg, solid, LCMS: 442 [M + H], HPLC: Rt. = 2.87 min (Method A).

Stage b:

 The preparation was carried out as described above with 350 μl (0.35 mmol) of a 1N lithium aluminum hydride solution in THF starting from 126 mg (0.23 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8 tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-4-carboxylic acid

 (2-hydroxyethyl) amides from stage a. The product was purified by preparative HPLC and is present as TFA salt.

 36 mg, green oil, LCMS: 428 [M + H], HPLC: Rt. = 2.73 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.56 (s, 1H), 7.40 (s, 2H), 4.05 (d, J = 13.2, 2H), 3.72-3.62 (m, 2H), 3.35 (t, J = 11.5, 2H), 3.05 - 2.98 (m, 2H), 2.90 (d, J = 6.8, 2H), 2.12 - 2.02 (m, 1H), 1.93 (d, J = 11.2, 2H) , 1.65 (s, 4H), 1.47 - 1.36 (m, 2H), 1.24 (d, J = 15.2, 12H). Preparation of 2- <methyl {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-l) -thiazol-2-l] -piperidine 4-ylmeth-amino) -ethanol

 Stage a:

 The preparation was carried out analogously starting from 80 mg (0.20 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl ] -piperidine-4-carboxylic acid and 19 μΙ_ (0.24 mmol) 2-methylaminoethanol.

 114 mg, yellow oil, LCMS: 456 [M + H], HPLC: Rt. = 2.93 min (Method A).

Stage b:

 The reduction was carried out as described above with 375 μΙ_ (0.38 mmol) of a 1 N lithium aluminum hydride solution in THF starting from 14 mg (0.25 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7, 8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-4-carboxylic acid

 (2-hydroxy-ethyl) -methyl-amides from step a. The product was purified by preparative HPLC and is present as the hydrochloride.

 31 mg, gray oil, LCMS: 442 [M + H], HPLC: Rt. = 2.77 min (Method A).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.61 (d, J = 1.7, 1H), 7.50-7.42 (m, 2H), 4.14 (d, J = 13.0, 2H), 3.87- 3.78 ( m, 2H), 3.46 (t, J = 13.0, 2H), 3.39 - 3.30 (m, 1H), 3.27 - 3.18 (m, 2H), 3.10 - 3.02 (m, 1H), 2.91 (s, 3H ), 2.34 - 2.22 (m, 1H), 2.02 (dd, J = 41.6, 12.5, 2H), 1.72 (s, 4H), 1.57 - 1.44 (m, 2H), 1.31 (d, J = 15.1,

13H).

3 - ({1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylmethyl} amino) propane-1-ol:

 The preparation was carried out analogously to the methods described above.

16 mg, yellow oil, LCMS: 442 [M + H], HPLC: Rt. = 2.66 min (Method A). ¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.58 (s, 1H), 7.42 (s, 2H), 4.08 (d, J = 13.2 Hz, 2H), 3.54 (t, J = 5.8 Hz, 2H ), 3.40 (dd, J = 23.5, 8.6 Hz, 2H), 3.08 - 2.98 (m, 2H), 2.91 (d, J = 6.8 Hz, 2H), 2.07 (s, 1H), 1.95 (d, J = 11.7 Hz, 2H), 1.80 (dt, J = 12.5, 6.1 Hz, 2H), 1.67 (s, 4H), 1.45 (dd, J = 20.8, 11.8 Hz, 2H), 1.27 (d, J = 12.1 Hz , 12H).

Preparation of 4 - ((2-hydroxy-ethyl) - {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2 yl] -piperidin-4-yl} amino) butan-1-ol

Stage a:

 The preparation was carried out via a reductive amination (as already described), starting from 5 g (25.1 mmol) of 4-oxo-piperidine-1-carboxylic acid tert-butyl ester and 1.50 ml_ (25.1 mmol) of ethanolamine.

 4.15 g, residue, LCMS: 245 (M + H).

Stage b:

 The preparation was carried out as described above, starting from 400 mg (1.64 mmol) of 4- (2-hydroxyethylamino) -piperidine-1-carboxylic acid / butyl ester from stage a and 1.42 ml (9.8 mmol) of 4-bromo-butyl acetate ,

 1.65 g, residue, LCMS: 359 [M + H].

Stage c:

The deprotection was carried out as described above with HCl in dioxane starting from 758 mg (2.12 mmol) of 4 - [(4-acetoxy-butyl) - (2-hydroxy-ethyl) -]. amino] -piperidine-1-carboxylic acid tert-butyl ester from stage b. The product is present as hydrochloride.

 657 mg, residue, LCMS: 259 (+ H).

 Stage d:

 The preparation was carried out as described above starting from 500 mg (1.78 mmol) of acetic acid 4 - [(2-hydroxy-ethyl) -piperidin-4-yl-amino] -butyl ester

Hydrochloride from step c and 217 μΙ_ (1.78 mmol) ethoxycarbonyl isothiocyanate.

 1.08 g, residue.

Level e:

 The preparation was carried out as described above, starting from 800 mg (1.01 mmol) of 2-bromo-1- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - ethanone and 452 mg (1.01 mmol) of 4 - [(4-hydroxybutyl) - (2-hydroxy-ethyl) -amino] -piperidine-1-carbothioic acid amide from stage d. The product was purified by preparative HPLC and is present as the hydrochloride.

 6 mg, solid, Rt. = 2.89 min (Method A), LCMS: 486 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.63 (s, 1H), 7.50-7.41 (m, 2H), 4.32-4.19 (m, 2H), 3.97 (s, 1H), 3.83 (t , J = 5.0, 3H), 3.58 - 3.36 (m, 5H), 3.29 - 3.15 (m, 10H), 2.32 - 2.19 (m, 2H), 2.10 - 1.96 (m, 2H), 1.94 - 1.80 (m, 2H), 1.72 (s, 4H), 1.61 - 1.52 (m, 2H), 1.31 (d, J = 12.1, 12H).

Preparation of 4 - [{1- [5-bromo-4- {5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl) -thiazol-2-yl] - piperidin-4-yl} - (2-hydroxy-ethyl) -amino] -butan-1-ol

 The product is a by-product of the preparation of 4 - ((2-hydroxy-ethyl) - {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-one] yl) -thiazol-2-yl] -piperidin-4-yl} -amino) -butan-1-ol. The product was purified by preparative HPLC and is present as the hydrochloride.

 11 mg, solid, Rt. = 3.26 min (Method A), LCMS: 564 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.83 (d, J = 1.8, 1H), 7.60 (td, J = 8.6, 1.8, 1H), 7.40 (d, J = 8.3, 1H), 4.07 (d, J = 12.7, 2H), 3.80 (t, J = 5.1, 2H), 3.75 - 3.67 (m, 1H), 3.51 (t, J = 6.1, 2H), 3.44 - 3.33 (m, 1H) , 3.28 - 3.13 (m, 5H), 2.24 - 2.11 (m, 2H), 1.86 (dd, J = 26.3, 10.0, 4H), 1.71 (s, 4H), 1.59 - 1.48 (m, 2H), 1.34 1.27 (m, 12H).

10

 15

 20

 25

 30

35 Preparation of 5 - ((2-hydroxy-ethyl) - {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2 yl] -piperidin-4-yl} amino) pentan-1-ol

 The preparation was carried out as described above, starting from 460 mg (4.50 mmol) of 5-hydroxy-pentanal in step b. The product was purified by preparative HPLC and is present as the hydrochloride.

 8 mg, solid, Rt. = 2.93 min (Method A), LCMS: 500 (M + H).

 1H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.62 (d, J = 1.8, 1H), 7.49 (d, J = 8.3, 1H), 7.44 (dd, J = 8.2, 1.8, 1H) , 4.32 - 4.22 (m, 2H), 3.84 (t, J = 4.9, 3H), 3.59 - 3.48 (m, 4H), 3.25 - 3.14 (m, 3H), 2.28 (t, J = 13.7, 2H), 2.13 - 1.96 (m, 2H), 1.86 - 1.77 (m, 2H), 1.73 (s, 4H), 1.61 - 1.52 (m, 2H), 1.49 - 1.39 (m, 2H), 1.32 (d, = 11.8, 13H).

Preparation of 1 - [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ol

The thiourea was prepared as described above from 1 g (9.69 mmol) of piperidin-4-ol and 2 g (10.66 mmol) of 1,1'-thiocarbonyldiimidazole.

 1.4 g, beige solid, Rt. = 0.50 min (Method A), LCMS: 161 (M + H).

Stage b: The preparation was carried out as described above starting from 397 mg (0.94 mmol) of 2-bromo-1- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - ethanone and 100 mg (0.62 mmol) of 4-hydroxy-piperidine-1-carbothioic acid amide from step a. The product was purified by preparative HPLC and is present as the hydrochloride.

 17 mg, beige solid, Rt. = 3.01 min (Method A), LCMS: 371 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.61 (d, J = 1.7, 1H), 7.50 - 7.41 (m, 2H), 3.97 - 3.88 (m, 3H), 3.68 - 3.58 (m, 2H), 2.01-1.91 (m, 2H), 1.76-1.63 (m, 7H), 1.31 (d, J = 12.8, 12H).

Preparation of 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [-1-yl] -piperidine

Stage a:

 100 mg (0.44 mmol) of 6-ethynyl-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene (preparation as described above), 94 mg (0.44 mmol) of 4-azidopiperidine 1-carboxylic acid tert-butyl ester (preparation according to Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 13, p. 3564-3567), 3 mg (0.04 mmol) copper (finely powdered), 61 mg (0.44 mmol ) Triethylammonium chloride were suspended in 300 pL of tert-butanol and 300 pL of water and overnight

Room temperature stirred. The reaction mixture was filtered off and treated with water and DCM. The phases were separated. The organic phase was dried over sodium sulfate, filtered and concentrated.

 120 mg, brown oil, Rt. = 3.82 min (Method A), LCMS: 439 (M + H).

Stage b:

The deprotection was carried out as described above with HCl in dioxane starting from 120 mg (0.27 mmol) of 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-one] yl) - [1,2,3] triazol-1-yl] -piperidine-1-carboxylic acid tert-butyl ester from stage a. The product was purified by preparative HPLC and is present as the hydrochloride.

 11 mg, white solid, Rt. = 2.82 min (Method A), LCMS: 339 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 8.62 (s, 1H), 7.82 (d, J = 1.8, 1H), 7.63 (dd, J = 8.2, 1.8, 1H), 7.40 ( d, J = 8.3, 1H), 4.94-4.82 (m, 1H), 3.50 (d, J = 13.4, 2H), 3.21 (t, J = 11.0, 2H), 2.45 - 2.37 (m, 2H) , 2.36 - 2.23 (m, 2H), 1.70 (s, 4H), 1.30 (d, = 16.3, 12H).

Preparation of 4- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) - [1,2,3] triazol-1-yl ] -piperidin-1-yl} -butan-1-ol

 The preparation was carried out as described above starting from 24 mg (0.06 mmol) of 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1, 2,3] triazol-1-yl] -piperidine hydrochloride and 13 μΙ_ (0.11 mmol) acetic acid 4-chloro-butyl ester.

The deprotection was carried out by means of a 1 N sodium hydroxide solution in methanol. The product was purified by preparative HPLC and is present as the hydrochloride.

 10 mg, yellow oil, LCMS: 41 l [M + H], HPLC: Rt. = 2.79 min (Method A).

 1H NMR (500 MHz, DMSO) δ = 8.73-8.56 (m, 1H), 7.82 (d, J = 1.7, 1H), 7.66-7.60 (m, 1H), 7.41 (dd, J = 8.2, 4.3, 1H), 5.00 - 4.82 (m, 1H), 3.73 (d, J = 12.3, 1H), 3.57 - 3.45 (m, 3H), 3.31 - 3.15 (m, 6H), 2.50 (d, J = 13.3, 1H), 2.43-2.31 (m, 2H), 1.85-1.75 (m, 2H), 1.70 (s, 4H), 1.59-1.50 (m, 2H), 1.29 (t, J = 14.7, 14H).

Preparation of (2R, 3R) -3-amino-4- {1 - [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole] 2-yl] -piperidin-4-ylamino} -butan-2-ol

Step 1 :

 190 mg (0.47 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine 4-ylamine, 113 mg (0.51 mmol) N- (tert-butoxycarbonyl) -L-threonine, 86 mg (0.56 mmol) HOBt, 108 mg (0.56 mmol) N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride, and 240 μΙ (1.40 mmol) DIPEA are dissolved in 5 ml THF and stirred for 18 h at room temperature. The crude product was mixed with water, extracted with ethyl acetate and

 purified by column chromatography and silica gel

 Yield: 280 mg, yellow oil. Rt. = 3.22 min (Method A), LCMS: 571 (M + H).

Level 2:

 281 mg (0.37 mmol) of ((IS 1 R 4 -hydroxy-HI-i-S-S-tetramethyl-S. E.e.-tetrahydro-naphthalen-2-yl) -thiazol-2-yl! -Piperidine-4 -ylcarbamoyl} -propyl) -carbamic acid tert-butyl ester are dissolved in 2 ml of methanol and treated with 1 ml of 4N HCl in dioxane. The reaction mixture is stirred for 12 h at room temperature,

 evaporated and purified by preparative HPLC. The product is converted into the hydrochloride with methanolic HCl.

 Yield: 180 mg, beige solid. Rt. = 2.74 min (method A), LCMS: 471 (M + H).

 Level 3:

 1 15 mg (0.18 mmol) of (2S, 3R) -2-amino-3-hydroxy-N- {1- [4- (5,5,8,8-tetramethyl-

5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} -butyramide was dissolved in 3 ml of THF and filtered under nitrogen atmosphere at 70 ° C with 272 μΙ (0.54 mmol) 2M borane dimethylsulfide solution in THF and then stirred at 70 ° C for 2 hours. To decompose the borane excess was added dropwise with 1 ml of MeOH. The reaction mixture was concentrated and the oily RS was treated with 1 ml of water and 1 ml of concentrated HCl. It was stirred for 2 h at room temperature, with 2 Alkaline NaOH made alkaline and extracted with ethyl acetate. The organic phase was dried and purified by column chromatography on silica gel.

 Yield: 10 mg, solid. Rt. = 2.63 min (Method A), LCMS: 457 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.64 (d, J = 1.9 Hz, 1 H), 7.46 (dd, J = 8.2, 1.9 Hz, 1 H), 7.39 (d, J = 8.3 Hz, 1H), 4.16 (d, J = 13.4 Hz, 2H), 3.96 -

3.89 (m, 1H), 3.57 - 3.47 (m, 1H), 3.41 - 3.31 (m, 4H), 3.21 (dd, J = 13.0, 6.8 Hz, 1 H), 2.22 (t, J = 12.9 Hz, 2H), 1.86 - 1.74 (m, 2H), 1.67 (s, 4H), 1.27 (t, J = 11.8 Hz, 12H), 1.22 (t, J = 8.0 Hz, 3H). Morpholine-2-carboxylic acid {1- [4- {5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazol-2-yl] piperidine-4 yl} amides

 Preparation as described above starting from - [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamine and

Morpholine-2,4-dicarboxylic acid 4-tert-butyl ester.

 Yield: 110 mg, solid. Rt. = 2.73 min (Method A), LCMS: 483 (M + H). H NMR (500 MHz, DMSO / deuterated TFA) δ 7.60 (s, 1H), 7.45-7.40 (m, 2H), 4.26 (dd, J = 10.7, 2.8 Hz, 1H), 4.10-3.98 (m, 4H ), 3.86 - 3.77 (m, 1H), 3.54 - 3.44 (m, 3H), 3.23 (d, J = 12.9 Hz, 1H), 3.11 - 2.97 (m, 2H), 1.98 - 1.85 (m, 2H) , 1.83 - 1.70 (m, 2H), 1.67 (s, 4H), 1.33 - 1.21 (m, 12H).

4- {1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} - butyric acid:

Step 1 :

120 mg (0.30 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine-4- ylamine, 107 mg (0.59 mmol) of methyl 4-bromobutyrate, 481 mg (1.47 mmol) of cesium carbonate and 44 mg (0.30 mmol) of sodium iodide are suspended in 2 ml of NMP and stirred at 110 ° C. for 18 h. The

 The reaction mixture is mixed with water and extracted several times with ethyl acetate, dried and evaporated. The product is using

 Column chromatography on silica gel.

 Yield: 45 mg. Rt = 2.89 min (method A), LCMS: 470 (M + H).

Level 2:

45 mg (0.08 mmol) of the ester prepared above are suspended in 2.5 ml of THF and 0.25 ml of water, and 10 mg (0.41 mmol) of lithium hydroxide are added and the mixture is stirred at room temperature for 24 h. The solution is neutralized, evaporated and prep. HPLC purified. The product is present as trifluoroacetate.

Yield: 5 mg, white solid. Rt. = 2.79 min (Method A), LCMS: 456 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.89-7.81 (m, 2H), 7.66 (d, J = 8.2 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.27 (d, J = 7.5 Hz, 1H), 7.10 (d, J = 8.6 Hz, 1H), 4.51 (d, J = 13.9 Hz, 2H), 3.66 (d, J = 11.9 Hz, 2H), 3.38 (t, J = 12.7 Hz, 2H), 3.25 - 3.09 (m, 4H), 2.31 (t, J = 7.2 Hz, 2H), 1.80 - 1.70 (m, 2H), 1.69 (s, 4H), 1.63 - 1.55 (m, 2H ), 1.29 (d, J = 16.8 Hz, 12H).

Analog are produced: 3- {4- [4- <5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazin-1-yl} - propionic acid

 Yield: 37 mg, white solid. The product is present as trifluoroacetate. Rt. = 2.91 min (Method A), LCMS: 428 (M + H).

 H NMR (500 MHz, DMSO / deuterated TFA) δ 7.73 (d, J = 1.8 Hz, 1H), 7.52 (dd, J = 8.2, 1.8 Hz, 1H), 7.36-7.31 (m, 1H), 4.30 - 3.20 (m, 10H), 2.82 (t, J = 7.2 Hz, 2H), 1.66 (s, 4H), 1.25 (d, J = 17.2 Hz, 12H).

{4- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperazin-1-yl} -acetic acid

 Yield: 53 mg, white solid. The product is present as trifluoroacetate. Rt. = 2.94 min (Method A), LCMS: 414 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.71 (d, J = 1.8 Hz, 1 H), 7.49 (dd, J = 8.2, 1.8 Hz, 1 H), 7.32 (d, J = 8.3 Hz, 1 H), 4.21 (s, 2H), 4.03 - 3.77 (m, 4H), 3.53 (s, 4H), 1.65 (s, 4H), 1.24 (d, J = 16.5 Hz, 12H).

{1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} -acetic acid

 Yield: 22 mg, white solid. The product is present as trifluoroacetate. Rt = 2.78 min (Method A), LCMS: 428 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ 7.60 (d, J = 1.7 Hz, 1H), 7.44-7.38 (m, 2H), 6.88 (s, 1H), 4.13 (d, J = 13.8 Hz, 2H), 3.97 (s, 2H), 3.47 (t, J = 11.4 Hz, 1H), 3.37 (t, J = 11.9 Hz, 2H), 2.23 (d, J = 10.4 Hz, 2H), 1.76-1.71 (m, 2H), 1.66 (s, 4H), 1.26 (d, J = 12.8 Hz, 12H).

3- {1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} - propionic acid

 Yield: 32 mg, white solid. The product is present as trifluoroacetate. Rt = 2.76 min (Method A), LCMS: 442 (M + H).

 H NMR (400 MHz, DMSO / deuterated TFA) δ 7.54 (d, J = 1.3 Hz, 1H), 7.42-7.33 (m, 2H), 6.87 (s, 1H), 4.12 (d, J = 13.7 Hz, 2H ), 3.49 - 3.34 (m, 3H), 3.21 (t, J = 6.6 Hz, 2H), 2.67 (t, J = 6.6 Hz, 2H), 2.21 (d, J = 10.4 Hz, 2H), 1.88 - 1.74 (m, 2H), 1.64 (s, 4H), 1.23 (d, J = 12.0 Hz, 12H).

5- {1- [4- {5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} - pentanoic acid

 Yield: 46 mg, white solid. The product is present as trifluoroacetate. Rt. = 2.81 min (Method A), LCMS: 470 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.63 (d, J = 1.8 Hz, 1H), 7.45 (dd, J = 8.2, 1.8 Hz, 1 H), 7.40 (d, J = 8.3 Hz, 1 H), 6.88 (s, 1H), 4.13 (d, J = 13.3 Hz, 2H), 3.46-3.31 (m, 3H), 3.04-2.93 (m, 2H), 2.29 (t, J = 7.0 Hz, 2H), 2.24 - 2.16 (m, 2H), 1.77 - 1.72 (m, 4H), 1.67 (s, 4H), 1.64 - 1.57 (m, 2H), 1.26 (d, J = 16.1 Hz, 12H).

(4-ethoxy-butyl) - {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidine -4-yl} -amine

 The preparation is carried out as described above starting from 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin 4-ylamine and 1-bromo-4-methoxybutane in ethanol and triethylamine.

 Yield: 17 mg, yellow solid. The product is present as hydrochloride. Rt. = 2.91 min (Method A), LCMS: 456 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ 7.55 (s, 1H), 7.38 (s, 2H), 4.13 (d, J = 13.6 Hz, 2H), 3.39 (t, J = 11.9 Hz, 3H ), 3.32 (t, J = 6.0 Hz, 2H), 3.21 (s, 3H), 2.95 (dd, J = 17.9, 10.0 Hz, 2H), 2.27 - 2.13 (m, 2H), 2.06 - 1.66 (m, 4H), 1.65 (s, 4H), 1.57 (dt, J = 12.9, 6.3 Hz, 2H), 1.24 (d, J = 15.2 Hz, 12H).

(2-methoxy-ethyl) - {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidine -4-yl} -amine

 The preparation is carried out as described above starting from 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin 4-ylamine and 2-bromoethyl methyl ether in ethanol and triethylamine.

 Yield: 49 mg, yellow solid. The product is present as hydrochloride. Rt. = 2.85 min (Method A), LCMS: 428 (M + H).

¹ H NMR (500 MHz, DMSO) δ 8.73 (s, 2H), 7.76 (d, J = 1.8 Hz, 1H), 7.56 (dd, J = 8.2, 1.8 Hz, 1H), 7.31 (d, J = 8.3 Hz, 1H), 7.21 (s, 1H), 4.04 (d, J = 13.2 Hz, 2H), 3.64 - 3.59 (m, 2H), 3.37 - 3.27 (m, 4H), 3.21 - 3.14 (m, 2H ), 3.14 - 3.03 (m, 2H), 2.14 (d, J = 10.8 Hz, 2H), 1.72 - 1.61 (m, 6H), 1.26 (d, J = 16.0 Hz, 12H).

4- {4- [5-Hydroxymethyl-4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperazine-1 -yl} -butan-1-ol

Step 1 :

 The preparation is analogous to Journal of the Chemical Society, Perkin

 Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1987, p. 317-332 starting from 1- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -ethanone.

 Yield: 930 mg, yellow oil. Rt. = 3.42 min (method A).

 Level 2:

 The oxidation of 3-oxo-3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -propionic acid ethyl ester with PTT is carried out as described above.

 Yield: 900 mg, light yellow oil. Rt. = 3.57 min (Method A), LCMS: 381/383 (M + H).

 Level 3:

The reaction of 2-bromo-3-oxo-3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -propionic acid ethyl ester and 2-bromo- 1- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -ethanone in ethanol was carried out at 80 ° C as described above. The Boc protecting group was cleaved with HCl in dioxane. Yield: 920 mg, light yellow oil. Rt = 2.96 min (Method A), LCMS: 428 (M + H).

 Level 4:

 750 mg (1.75 mmol) of 2-piperazin-1-yl-4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazole-5-carboxylic acid ethyl ester are dissolved in 8 ml of NMP, with 259 μΙ (1.75 mmol) of 4-bromobutyl acetate and 1.72 g (5.26 mmol) are stirred at 60 ° C for 5 h. The reaction mixture was filtered, treated with 30 ml of THF and 4.5 ml of 2M sodium hydroxide solution and stirred overnight at RT Das

The reaction mixture was treated with water and extracted several times with ethyl acetate. The organic phase was washed with water, dried and concentrated. The crude product is purified by column chromatography on silica gel

Yield: 485 mg, yellow oil. Rt. = 2.98 min (Method A), LCMS: 500 (M + H).

Level 5:

 The preparation was carried out as already described starting from 2- [4- (4-hydroxy-butyl) -piperazin-1-yl] -4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro -naphthalen-2-yl) -thiazole-5-carboxylic acid ethyl ester by reduction with a

Lithium aluminum hydride solution in THF.

 56 mg, LCMS: 458 [M + H], HPLC: Rt. = 2.65 min (Method A).

¹ H NMR (400 MHz, DMSO) δ 7.56 (s, 1H), 7.41-7.32 (m, 2H), 5.42 (t, J = 5.3 Hz, 1H), 4.57 (d, J = 5.3 Hz, 2H ), 4.44 (b, 1 H), 3.44 (dd, J = 1.1, 6.6 Hz, 6H), 2.51 (d, J = 5.0 Hz, 4H), 2.37 (t, J = 6.9 Hz, 2H), 1.70 (s, 4H), 1.58 - 1.43 (m, 4H), 1.30 (d, J = 3.3 Hz, 12H).

2- [4- (4-Hydroxy-butyl) -piperazin-1-yl] -4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - thiazole-5-carboxylic acid dimethylamide

 The product is prepared by lithium hydroxide-mediated saponification of the ester in THF at 60 ° C and subsequent EDC / HOBt coupling with dimethylamine in THF.

5 mg, LCMS: 499 [M + H]. H NMR (400 MHz, DMSO / deuterated TFA) δ 7.46-7.37 (m, 3H), 3.47 (dt, J2, 5.2 Hz, 6H), 3.32 (s, 1H), 2.81 (s, 6H), 2.55 ( superimposed, 6H), 1.70 (s, 4H), - 1.43 (m, 4H), 1.27 (d, J = 18.0 Hz, 12H).

Preparation of 2- {1- [4- (5,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} -ethanol

 The preparation is carried out as described starting from 104 mg (0.26 mmol) of 1- [4- (5,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine -4- ylamine hydrochloride and 55 μΙ_ (0.26 mmol) (tert-butyl-dimethyl-silanyloxy) - acetaldehyde. The deprotection is carried out with a 4N HCl solution in dioxane. The purification is carried out by preparative HPLC. The product is present as hydrochloride.

 17 mg, light solid, LCMS: 386 (M + H), HPLC: Rt. = 2.49 min (Method

B).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.58 (d, J = 5.8, 1H), 7.54-7.46 (m, 1H), 7.31 (t, J = 8.3, 1H), 4.20 ( d, J = 13.3, 2H), 3.76 (s, 2H), 3.42 (t, J = 12.7, 2H), 3.13 (s, 2H), 3.00 - 2.86 (m, 2H), 2.28 (d, J = 11.9 , 2H), 2.03 (d, J = 7.7, 1H), 1.91 - 1.82 (m, 2H), 1.67 - 1.55 (m, 1H), 1.49 (d, J = 8.0, 1H), 1.37 - 1.22 (m, 8H).

Preparation of 4- {1- [4- (5,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} -butane 1-ol

 The preparation is carried out as described starting from 218 mg (0.58 mmol) of 1- [4- (5,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine 4-ylamine and 126 pL (0.58 mmol) 4-bromo-butyl acetate. The splitting off of

Protecting group is carried out by means of a 1 N NaOH solution in methanol. The product is present as hydrochloride.

 24 mg light solid, Rt. = 2.57 min (Method B), LCMS: 414 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.52 - 7.46 (m, 1H), 7.45 - 7.38 (m, 1H), 7.22 (t, J = 8.5, 1H), 4.12 (d, J = 12.3, 2H), 3.48-3.30 (m, 5H), 3.02-2.22 (m, 2H), 2.91-2.76 (m, 2H), 2.18 (d, J = 10.6, 2H), 1.98-1.91 (m , 1H), 1.84-1.62 (m, 5H), 1.59-1.45 (m, 3H), 1.44-1.35 (m, 1H), 1.28-1.15 (m, 6H). Preparation of 4- {1 - [4 - ((5R, 8S) -5,8-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazol-2-yl] -piperidine-4 -ylamino} butane-1-ol

 The enantiomer was isolated from the racemic mixture by chiral chromatography. The product is present as hydrochloride.

 13 mg light resin, Rt. = 2.39 min (Method B), LCMS: 414 (M + H).

Preparation of 4- {1- [4 - ((5S, 8S) -5,8-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazol-2-yl] -piperidine-4 ylamino} butan-1-ol

 The enantiomer was isolated from the racemic mixture by chiral chromatography. The product is present as hydrochloride.

 16 mg light resin, Rt. = 2.39 min (Method B), LCMS: 414 (M + H)

Preparation of 2- {1- [4- (5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} -ethanol

 The preparation is carried out as described starting from 60 mg (0.16 mmol) of 1- [4- (5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine -4- ylamine hydrochloride and 34 μΙ_ (0.16 mmol) (te / f-butyl-dimethyl-silanyloxy) - acetaldehyde. The deprotection is carried out with a 4N HCl solution in dioxane. The purification is carried out by preparative HPLC. The product is available as formate.

 18 mg, white solid, LCMS: 386 (M + H), HPLC: Rt. = 2.50 min (Method

B).

¹ H NMR (400 MHz, DMSOV deuterated TFA) δ = 7.53 (dd, J = 8.2, 2.0, 1H), 7.48-7.42 (m, 2H), 4.16 (d, = 13.5, 2H), 3.77- 3.69 ( m, 2H), 3.52 - 3.40 (m, 1H), 3.34 (t, J = 11.9, 2H), 3.16 - 3.08 (m, 2H), 2.80 (t, J = 6.2, 2H), 2.23 (d, J = 11.1, 2H), 1.86 - 1.73 (m, 4H), 1.70 - 1.63 (m, 2H), 1.28 (s, 6H). Preparation of 4- {1- [4- (5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} -butane 1-ol

 The preparation is carried out as described starting from 60 mg (0.16 mmol) of 1- [4- (5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine -4- ylamine hydrochloride and 22 μΙ_ (0.16 mmol) 4-bromo-butyl acetate. The deprotection is carried out by means of a 2N NaOH solution in methanol. The product is available as formate.

 19 mg light solid, Rt. = 2.55 min (Method B), LCMS: 414 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.54 - 7.41 (m, 3H), 4.19 (d,, = 13.5, 2H), 3.52 (t, J = 6.0, 2H), 3.48 - 3.41 (m , 2H), 3.09 - 2.99 (m, 2H), 2.81 (t, J = 6.3, 2H), 2.25 (d, J = 10.4, 2H), 1.87 - 1.66 (m, 9H), 1.61 - 1.52 (m, 2H), 1.29 (s, 6H).

Preparation of 4- [4- (5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine

The preparation is carried out as described starting from 8 g (31.6 mmol) of 2-bromo-1- (5,6,7,8-tetrahydro-naphthalen-2-yl) -ethanone and 8 g (32.7 mmol) of 4-thiocarbamoyl-piperidine -1-carboxylic acid tert-butyl ester.

 9 g, white crystals.

 H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.80 (d, J = 1.2, 1H), 7.70-7.63 (m, 2H), 7.13 (d, J = 7.8, 1H), 3.50- 3.43 ( m, 3H), 3.15 (td, J = 12.4, 2.6, 2H), 2.79 (d, J = 17.3, 4H), 2.32 (dd, J = 14.0, 2.8, 2H), 2.15 - 2.02 (m, 2H) , 1.84 - 1.75 (m, 4H).

Preparation of 4- {4- [4- (5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-1-yl} -butan-1-ol

The preparation is carried out as described starting from 39 mg (0.13 mmol) of 4- [4- (5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine and 30 μί (0.20 mmol) 4-bromo-butyl acetate. The deprotection is carried out by means of a 2N NaOH solution in methanol. The product is present as hydrochloride.

 28 mg white solid, Rt. = 2.24 min (Method B), LCMS: 371 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.74 (s, 1H), 7.64-7.56 (m, 2H), 7.05 (d, J = 7.8, 1H), 3.60 (d, J = 12.6 , 2H), 3.48 - 3.42 (m, 2H), 3.42 - 3.31 (m, 1H), 3.15 - 3.03 (m, 4H), 2.79 - 2.65 (m, 4H), 2.35 - 2.25 (m, 2H), 2.13 - 1.99 (m, 2H), 1.81 - 1.65 (m, 6H), 1.53 - 1.42 (m, 2H).

Preparation of 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine

6.12 g (12.28 mmol) 2-bromo-1- (5 ₎ 5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -ethanone and 3 g (12.28 mmol) 4 Thiocarbamoyl-piperidine-1-carboxylic acid tert-butyl ester were suspended in 50 ml of ethanol and refluxed overnight. The reaction mixture was cooled and concentrated. The residue was eingeteigt with little EA and PE, digested and filtered with suction. The solid was suspended in 180 mL EA, washed with 60 mL saturated sodium bicarbonate solution. The organic phase was dried over sodium sulfate, filtered and concentrated.

 3.70 g, brown oil. LCMS: 355 (M + H), HPLC: Rt. = 2.65 min (Method B).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.95-7.88 (m, 2H), 7.69 (dd, J = 8.2, 1.8, 1H), 7.39 (d, J = 8.3, 1H), 3.51 - 3.40 (m, 3H), 3.19 - 3.05 (m, 2H), 2.36 - 2.24 (m, 2H), 2.10 - 1.95 (m, 2H), 1.70 (s, 4H), 1.30 (d, J = 15.7, 12H).

Preparation of the racemates (SR) -2,2-dimethyl-4 - ((RS) -4-oxo-1-triethylsilanyloxy-butyl) -oxazolidine-3-carboxylic acid tert-butyl ester and (SR) -2,2 -Dimethyl-4 - ((SR) -4-oxo-1-triethylsilanyloxy-butyl) -oxazolidine-3-carboxylic acid tert-butyl ester

Stage a: 4- (1-Hydroxy-pent-4-envn-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester

5 g (21.81 mmol) racemate (SR) -4-formyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester are dissolved in 33 mL THF, placed under argon and cooled to -78 ° C. Add 43.62 mL (21.81 mmol) of a 0.5 M 3-butenylmagnesium bromide solution in THF dropwise. The mixture is stirred overnight at room temperature. After checking the DC, the mixture is mixed with approx. 90 mL of a saturated NH ₄ Cl solution while cooling, stirred overnight and diluted with approx. 50 mL of water. The phases are separated and the aqueous phase is extracted twice more with EA. The combined organic phases are dried over sodium sulfate, filtered and concentrated. The oily residue is flash chromatographed on silica gel.

 4.89g, colorless oil.

Stage b:

 2,2-Dimethyl-4- (1-triethylsilanyloxy-pent-4-enyl) -oxazolidine-3-carboxylic acid tert-butyl ester

 4.89 g (17.14 mmol) of the product from stage a are dissolved in 200 ml of DCM, placed under nitrogen and cooled to 0 ° C. 2.58 g (17.14 mmol) of chlorotriethylsilane and 209 mg (1.71 mmol) of 4- (dimethylamino) -pyridine are added. The reaction solution is further stirred at 0 ° C. for 15 minutes. Subsequently, 4.75 mL (34.27 mmol) of triethylamine are added. You leave the mixture on

Return to room temperature and stir overnight. After checking the DC, the reaction mixture is admixed with about 200 ml of a saturated NH ₄ Cl solution. The phases are separated and the aqueous phase is extracted twice more with EA. The combined organic phases are dried over sodium sulfate, filtered and concentrated. The residue is flash chromatographed on silica gel.

 Clear colorless oil, 5.02 g.

Stage c:

 (SR) -2,2-Dimethyl-4 - ((RS) -4-oxo-1-triethylsilanyloxy-butyl) -oxazolidine-3-carboxylic acid tert-butyl ester and (SR) -2.2-dimethyl-4 - ((SR ) -4-oxo-1-triethylsilanyloxy-butyl) -oxazolidine-3-carboxylic acid tert-butyl ester

 5.02 g (12.56 mmol) of product from stage b are dissolved in 140 mL DCM and cooled to -78 ° C. At this temperature, 2.1 1 g (25.12 mmol)

Sodium hydrogen carbonate is added and ozone is passed through the mixture for 2.5 h until the solution turns blue. After DC control, oxygen is then passed through the mixture for 1.5 h until complete decolorization. Subsequently, triphenylphsophin (3.30 g, 12.56 mmol) is added. The mixture is stirred at room temperature overnight and then filtered off. The filtrate is concentrated on a rotary evaporator to the residue. The 2 products are separated by flash chromatography on silica gel.

 Racemat 1: clear colorless oil, 1.21 g.

 Racemat 2: clear colorless oil, 1.83 g.

Preparation of the racemates (SR) -2,2-dimethyl-4 - ((RS) -3-oxo-1-triethylsilanyloxy-propyl) -oxazolidine-3-carboxylic acid tert-butyl ester and (SR) -2,2 -Dimethyl-4 - ((SR) -3-oxo-1-triethylsilanyloxy-propyl) -oxazolidine-3-carboxylic acid tert-butyl ester

The preparation is carried out as described above starting from 5 g of racemate (21.81 mmol) (SR) -4-formyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester and 21.81 mL (21.81 mmol) of a 1 M allylmagnesium bromide solution in diethyl ether.

 Racemat 3: clear colorless oil, 323 mg.

 Racemate 4: clear colorless oil, 329 mg.

Preparation of the racemates (SR) -2,2-dimethyl-4 - ((SR) -2-oxo-1-triethylsilanyloxy-ethyl) -oxazolidine-3-carboxylic acid tert-butyl ester and (SR) -2,2 -Dimethyl-4 - ((RS) -2-oxo-1-triethylsilanyloxy-ethyl) -oxazolidine-3-carboxylic acid tert-butyl ester

The preparation is carried out as described above starting from 5.01 g of racemate (21.85 mmol) (SR) -4-formyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester and 24.0 mL (24.0 mmol) of a 1 M vinylmagnesium bromide solution in THF.

 Racemat 5: clear colorless oil, 1.92g.

Racemat 6: clear colorless oil, 0.81g. Preparation of the racemate (2SR, 3RS) -2-amino-6- {4- [4- (5,5,8,8-tetramethyl-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine -1-yl} -hexanes-1,3-diol

 Stage a:

 (SR) -2,2-Dimethyl-4 - ((RS) -4- (4-r4- (5.5.8.8-tetramethyl-5.6.7.8-tetrahydronaphthalene-2-yl) -thiazol-2-yl-1-piperidine 1-ylVl-triethylsilanyloxy-butyl) -oxazolidine-3-carboxylic acid tert-butyl ester

 97 mg (0.249 mmol) of 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole

2-yl] -piperidine hydrochloride and 100 mg (0.249 mmol) racemate 1 were suspended with 4.3 ml of THF and treated with 175 μΙ glacial acetic acid. The reaction mixture was stirred at room temperature for 30 minutes. Subsequently, 106 mg (0.50 mmol) of sodium triacetoxyborohydride were added. The reaction mixture was stirred overnight at room temperature, stripped to residue, suspended with EA, washed with a saturated sodium bicarbonate solution and a saturated brine. The organic phase was dried over sodium sulfate, filtered, concentrated to dryness and by means of

 Purified by flash chromatography on silica gel.

 21 mg, clear oil, Rt. = 3.93 min (Method B), LCMS: 741 (M + H).

Stage b:

 Preparation of the racemate (2SR.3RS) -2-amino-6- (4-r4- (5.5.8.8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2-vn-piperidine 1-yl) -hexanes-1,3-diol

The intermediate from stage a was admixed with 1 ml of a 4N HCl solution in dioxane and stirred at room temperature overnight. The reaction mixture is concentrated and separated by flash-Chropmatographie on C18 silica gel. The product is present as hydrochloride.

 10 mg light solid, Rt. = 2.34 min (Method B), LCMS: 486 (M + H).

 H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.83 (d, J = 1.8, 1H), 7.74 (s, 1H), 7.66-7.56 (m, 1H), 7.31 (d, J = 8.3 , 1H), 3.66 - 3.57 (m, 4H), 3.56 - 3.50 (m, 1H), 3.47 - 3.34 (m, 1H), 3.14 - 3.04 (m, 4H), 2.96 - 2.87 (m, 1 H), 2.31 (d, J = 15.2, 2H), 2.09 (q, J = 12.3, 2H), 1.91 - 1.69 (m, 2H), 1.63 (s, 4H), 1.59 - 1.49 (m, 1H) , 1.48 - 1.38 (m, 1H), 1.22 (d, J = 20.0, 12H).

Preparation of the racemate (2SR, 3SR) -2-amino-6- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole -2-yl] -piperidin-1-yl} -hexanes-1,3-diol

 The preparation is analogous starting from 97 mg (0.249 mmol) 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl ] -piperidine hydrochloride and 100 mg (0.249 mmol) racemate 2. The product is available as

Hydrochloride.

 50 mg light solid, Rt. = 2.28 min (method B), LCMS: 486 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.93-7.87 (m, 2H), 7.74-7.65 (m, 1H), 7.40 (d, J = 8.3, 1H), 3.82-3.73 (m , 2H), 3.72 - 3.60 (m, 3H), 3.52 - 3.43 (m, 1H), 3.20 - 3.10 (m, 4H), 2.43 - 2.33 (m, 3H), 2.20 - 2.07 (m, 2H), 1.98 - 1.87 (m, 1H), 1.85 - 1.76 (m, 1H), 1.70 (s, 4H), 1.60 - 1.44 (m, 2H), 1.30 (d, J = 15.5, 12H).

Preparation of the enantiomeric pair (2R, 3S) -2-amino-5-4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - thiazol-2-yl] -piperidin-1-yl} -pentanes-1,3-diol and (2S, 3R) -2-amino-5- {4- [4- (5,5,8,8-tetramethyl -5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-1-yl} -pentane-1,3-diol

The preparation is analogous starting from 357 mg (0.914 mmol) 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl ] -piperidine hydrochloride and 322 mg (0.831 mmol) racemate 3. The 2 enantiomers were subsequently separated from the racemic mixture by means of chiral chromatography. The products are available as hydrochloride.

 Enantiomer 1: 47 mg light resin, Rt. = 2.28 min (Method B), LCMS: 472

(M + H).

¹ H NMR (500 MHz, DMSG7 deuterated TFA) δ = 7.83 (d, J = 1.8, 1H), 7.76 (s, 1H), 7.66-7.56 (m, 1H), 7.31 (d, J = 8.3, 1H), 3.76-3.70 (m, 1H), 3.65-3.55 (m, 3H), 3.48-3.34 (m, 2H), 3.29-3.22 (m, 1H), 3.21-3.17 (m, 1H), 3.15 - 3.07 (m, 2H), 3.02 - 2.96 (m, 1H), 2.32 (d, J = 15.0, 2H), 2.14 - 2.03 (m, 2H), 2.02 - 1.93 (m, 1H), 1.88 - 1.77 (m, 1H), 1.63 (s, 4H), 1.23 (d, J = 19.9, 12H).

Enantiomer 2: 50 mg light resin, Rt. = 2.29 min (Method B), LCMS: 472

¹ H NMR (500 MHz, DMS07 deuterated TFA) δ = 7.84 (d, = 1.8, 1H), 7.78 (s, 1H), 7.68 - 7.57 (m, 1H), 7.31 (d, J = 8.3, 1 H), 3.76-3.70 (m, 1H), 3.66-3.54 (m, 3H), 3.43-3.35 (m, 1H), 3.30-3.15 (m, 3H), 3.15-3.07 (m, 2H), 3.02 - 2.96 (m, 1H), 2.32 (d, J = 15.0, 2H), 2.15 - 2.03 (m, 2H), 2.01 - 1.93 (m, 1H), 1.89 - 1.79 (m, 1H), 1.63 ( s, 4H), 1.23 (d, J = 19.9, 12H).

Preparation of Enantiomeric Pair (2S, 3S) -2-amino-5- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl ) -thiazol-2-yl] -piperidin-1-yl} -pentane-1,3-diol and (2R, 3R) -2-amino-5- {4- [4- (5,5,8,8 -tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-1-yl} -pentane-1,3-diol

The preparation is analogous starting from 360 mg (0.923 mmol) 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl ] -piperidine hydrochloride and 325 mg (0.839 mmol) racemate 4. The 2 enantiomers were then separated from the racemic mixture by chiral chromatography. The products are available as hydrochloride.

 Enantiomer 3: 44 mg light solid, Rt = 2.30 min (Method B), LCMS: 472 (M + H).

¹ H NMR (500 MHz, DMSG7 deuterated TFA) δ = 7.83 (d, J = 1.6, 1H), 7.76 (s, 1H), 7.67-7.56 (m, 1H), 7.31 (d, J = 8.3, 1 H), 3.85 - 3.77 (m, 1H), 3.75 - 3.67 (m, 1H), 3.65 - 3.52 (m, 3H), 3.45 - 3.34 (m, 1H), 3.30 - 3.22 (m, 1 H), 3.19 - 3.06 (m, 4H), 2.32 (d, J = 14.9, 2H), 2.09 (q, J = 13.5, 2H), 1.99 - 1.90 (m, 1H), 1.89 - 1.78 (m, 1H), 1.63 (s, 4H), 1.22 (d, = 20.0, 12H).

Enantiomer 4: 50 mg light solid, Rt. = 2.27 min (Method B), LCMS: 472 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.84 (d, J = 1.8, 1H), 7.78 (s, 1H), 7.67-7.57 (m, 1H), 7.32 (dd, J = 8.2, 3.2, 1H), 3.84 - 3.77 (m, 1H), 3.75 - 3.68 (m, 1H), 3.58 (ddd, = 18.3, 13.2, 6.0, 3H), 3.45 - 3.35 (m, 1 H ), 3.29 - 3.21 (m, 1H), 3.20 - 3.07 (m, 4H), 2.32 (d, J = 14.5, 2H), 2.15 - 2.03 (m, 2H), 2.00 - 1.90 (m, 1H), 1.88 - 1.76 (m, 1H), 1.63 (s, 4H), 1.23 (d, J = 19.9, 12H).

Preparation of the racemate (2SR, 3SR) -2-amino-4- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole -2-yl] -piperidin-1-yl} butanes-1,3-diol

 The preparation is analogous starting from 100 mg (0.256 mmol) 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl ] -piperidine hydrochloride and 144 mg (0.385 mmol) racemate 6. The product is in the form of formate.

 4 mg light solid, LCMS: 456 (M + H).

Preparation of the racemate (2SR, 3RS) -2-amino-6- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole -2-yl] -piperazin-1-yl} -hexanes-1,3-diol

 The preparation is analogous starting from 160 mg (0.450 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl ] -piperazine and 204 mg (0.249 mmol) racemate 1. The product is present as formate.

 29 mg light solid, Rt. = 2.33 min (Method B), LCMS: 487 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 8.13 (s, 1H), 7.79 (d, J = 1.8, 1H), 7.58 (dd, J = 8.2, 1.8, 1H), 7.33 ( d, J = 8.3, 1H), 4.21 - 4.08 (m, 2H), 3.68 - 3.59 (m, 4H), 3.50 - 3.40 (m, 2H), 3.31 - 3.15 (m, 4H), 3.01 - 2.93 ( m, 1H), 1.92-1.71 (m, 2H), 1.67 (s, 4H), 1.61-1.38 (m, 3H), 1.27 (d, J = 13.4, 13H). Preparation of the racemate (2SR, 3SR) -2-amino-6- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole -2-yl] -piperazin-1-yl} -hexanes-1,3-diol

 The preparation is analogous starting from 140 mg (0.394 mmol) 4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl ] -piperidine hydrochloride and 190 mg (0.473 mmol) racemate 2. The product is present as formate.

 59 mg of light solid, Rt. = 2.33 min (Method B), LCMS: 487 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.73 (s, 1H), 7.51 (d, J = 8.0, 1H), 7.30 (d, J = 8.3, 1H), 4.12 (s, 1 H), 3.74 - 3.39 (m, 7H), 3.32 - 3.12 (m, 4H), 3.11 - 3.03 (m, 1H), 1.94 - 1.81 (m, 1H), 1.79 - 1.67 (m, 1H ), 1.63 (s, 4H), 1.56 - 1.33 (m, 2H), 1.23 (d, J = 13.8, 13H).

Preparation of 1 - [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] - [1, 4] diazepane

Stage a:

 Preparation of 4-thiocarbamoyl [1,4-diazepane-1-carboxylic acid tert-butyl ester

 1.37 g (6.85 mmol) of [1,4] diazepane-1-carboxylic acid tert-butyl ester and 1.12 g (6.85 mmol) of benzoyl isothiocyanate were dissolved in 13 ml of THF and stirred at 50 ° C. for 2 h. Subsequently, the solvent was distilled off and the residue was taken up in 34 mL of methanol and 3.4 mL of water and treated with 1.89 g of potassium carbonate. The mixture was refluxed overnight and then filtered off. The filtrate was concentrated, slurried in 80 ml of water and extracted 3 times with 20 ml of EA each time. The organic phase was over

 Dried sodium sulfate, filtered, concentrated, digested with a little PE and EA and filtered with suction.

 1.12g white crystals, Rt. = 1.92 min (Method B), LCMS: 260 (M + H).

Stage b unc c:

 Preparation of 1-r4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl-f 1.41diazepane

 The preparation is carried out as described above starting from 1.12 g (4.55 mmol) of 4-thiocarbamoyl- [1,4] diazepane-1-carboxylic acid tert-butyl ester from stage a and 1.93 g (6.25 mmol) of 2-bromo-1- ( 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -ethanone.

 888 mg yellow solid, Rt. = 2.63 min (Method B), LCMS: 370 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.50 (d, J = 1.7, 1H), 7.38 (d, J = 8.2, 1H), 7.33 (dd, J = 8.2, 1.8, 1H ), 4.03 - 3.98 (m, 2H), 3.71 (t, J = 5.7, 2H), 3.43 - 3.38 (m, 2H), 3.30 - 3.24 (m, 2H), 2.21 - 2.13 (m, 2H), 1.62 (s, 4H), 1.23 - 1.19 (m, 12H).

Preparation of 4- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl) -thiazol-2-yl] - [1, 4] diazepan-1-yl} -butan-1-ol

 The preparation is carried out as described above starting from 79 mg (0.214 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2 -yl] - [1,4] diazepane and 47 μΙ_ (0.321 mmol) 4-bromo-butyl acetate. The deprotection is carried out by means of a 1 N NaOH solution in methanol. The product is present as hydrochloride.

 45 mg light solid, Rt. = 2.69 min (Method B), LCMS: 442 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.66 (d, J = 1.7, 1H), 7.52-7.43 (m, 2H), 4.33-4.22 (m, 1H), 4.12-4.02 (m , 1 H), 3.82 - 3.62 (m, 4H), 3.53 - 3.47 (m, 3H), 3.35 (t, J = 11.6, 1 H), 2.46 - 2.26 (m, 2H), 1.80 (dt, J = 15.9, 7.9, 2H), 1.71 (s, 4H), 1.56 - 1.48 (m, 2H), 1.37 - 1.25 (m, 14H).

Preparation of 3- {4- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl) -thiazol-2-yl] - [1, 4] diazepan-1-yl} -propane-1-ol

 The preparation is carried out as described above starting from 95 mg (0.244 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2 -yl] - [, 4] diazepane and 30 μΙ_ (0.321 mmol) of 3-chloro-propan-1-ol. The product is present as hydrochloride.

 85 mg light solid, Rt. = 2.69 min (Method B), LCMS: 428 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.64 (s, 1H), 7.51 - 7.43 (m, 2H), 4.34 - 4.21 (m, 1H), 4.19 - 4.06 (m, 1H) , 3.87 - 3.65 (m, 4H), 3.62 - 3.48 (m, 3H), 3.44 - 3.26 (m, 3H), 2.45 - 2.22 (m, 2H), 1.97 - 1.88 (m, 2H), 1.72 (s, 4H), 1.32 (d, J = 11.3, 12H). Preparation of 1 - [4, 5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-3-ylamine

 The preparation is carried out analogously to the abovementioned protocol starting from 877 mg (4.38 mmol) piperidin-3-yl-carbamic acid tert-butyl ester.

 579 mg, yellow solid, Rt. = 2.65 min (Method B), LCMS: 370 (M + H).

 H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.69 (d, J = 1.8, 1H), 7.51 (dd, = 8.2, 1.9, 1H), 7.43 (d, J = 8.3, 1H), 4.06 (dd, J = 12.7, 3.2, 1H), 3.84 - 3.76 (m, 1H), 3.62 - 3.47 (m, 3H), 2.14 - 2.03 (m, 1H), 2.01 - 1.90 (m, 1 H), 1.83-1.74 (m, 2H), 1.71 (s, 4H), 1.31 (d, J = 14.2, 12H).

Preparation of 4- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazol-2-yl] -piperidin-3-ylamino } -butane-1-ol

 The preparation is carried out as described starting from 75 mg (0.20 mmol) of 1- ^ (SSSS-tetramethyl-S.ej.S-tetrahydro-naphthalen ^ -y -thiazol ^ -lyl-piperidin-S-ylamine and 45 μΙ_ (0.31 mmol ) 4-Bromo-butylacetate

 Protecting group is carried out by means of a 1 N NaOH solution in methanol. The product is present as hydrochloride.

 12 mg light solid, Rt. = 2.71 min (Method B), LCMS: 442 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.70 (s, 1H), 7.51 (d, J = 8.2, 1H), 7.42 (d, J = 8.3, 1H), 4.18 (dd, J = 13.2, 3.2, 1H), 3.83-3.75 (m, 1H), 3.70-3.61 (m, 1H), 3.54-3.44 (m, 4H), 3.09 (dd, J = 8.7, 6.0, 2H ), 2.21 - 2.13 (m, 1H), 2.00 - 1.92 (m, 1H), 1.86 - 1.73 (m, 4H), 1.70 (s, 4H), 1.61 - 1.54 (m, 2H), 1.30 (i.e. , J = 17.8, 12H). Preparation of 3- {1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidin-3-ylamino } propane-1-ol

 The preparation is carried out as described starting from 50 mg (0.11 mmol) of 1- [4 (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl ] -piperidin-3-ylamine and 14 μί (0.16 mmol) of 3-chloro-propan-1-ol. The product is present as hydrochloride.

 13 mg light solid, Rt. = 2.67 min (Method B), LCMS: 428 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.70 - 7.66 (m, 1H), 7.52 - 7.42 (m, 2H), 4.27 - 4.19 (m, 1H), 3.88 - 3.80 (m, 1 H), 3.75 - 3.66 (m, 1H), 3.66 - 3.59 (m, 2H), 3.58 - 3.48 (m, 2H), 3.19 (t, J = 7.5, 1H), 2.24 - 2.15 (m, 1 H), 2.04 - 1.94 (m, 2H), 1.93 - .85 (m, 2H), 1.84 - 1.75 (m, 2H), 1.72 (s, 4H), 1.31 (d, J = 13.7, 12H).

Preparation of 4- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazol-2-yl] -azepan-4-ylamino } butane-1-ol

Stage a:

 Preparation of 4- (4-hydroxy-butylamino) -azepane-1-carboxylic acid tert-butyl ester

 1.09 g (4.65 mmol) of 4-oxo-azepane-1-carboxylic acid tert-butyl ester and 864 μΙ_ (9.30 mmol) of 4-aminobutan-1-ol were suspended in 40 mL of ethanol, stirred for 40 minutes at room temperature, with 532 μΙ_ (9.30 mmol) of glacial acetic acid and stirred for 10 min. Sodium triacetoxyborohydride (1.97 g, 9.30 mmol) was added and the mixture was stirred at room temperature overnight and concentrated to dryness under vacuum. The residue was taken up in water and extracted 4 times with EA. The organic phase was dried over sodium sulfate, filtered and concentrated.

 1.39 g of clear oil, LCMS: 287 (M + H). Stage b:

 Preparation of 4- (azepan-4-ylamino) -butan-1-ol

 The cleavage of the Boc protective group is carried out as described with 4 N HCl in dioxane.

 1.09 g, yellow oil, LCMS: 187 (M + H).

Stage c:

 Preparation of 4- (4-hydroxybutylamino) -azepane-1-carbothioic acid amide The preparation is carried out as described above starting from 419 mg (2.25 mmol) of product from stage b and 401 mg (2.25 mmol) of thiocarbonylimidazole.

LCMS: 246 (M + H). Stage d:

 Preparation of 4 1-f 4 - (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl-1-azepan-4-ylamino) -butan-1-ol

The preparation is carried out as described above, starting from 508 mg (1.15 mmol) of 2-bromo-1- (5,5,8,8-tetramethyl-5,6 _l 7,8-tetrahydro-naphthalen-2-yl) -ethanone and the product from stage c. The purification was carried out by preparative HPLC. The product is present as hydrochloride.

 31 mg light solid, Rt. = 2.53 min (Method B), LCMS: 456 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.53 (s, 1H), 7.42-7.35 (m, 2H), 3.93- 3.85 (m, 1H), 3.77- 3.57 (m, 3H), 3.43 (t, = 6.1, 2H), 3.32 - 3.25 (m, 1H), 2.97 - 2.89 (m, 2H), 2.34 - 2.26 (m, 1H), 2.18 - 2.10 (m, 1H), 2.09 - 2.01 (m, 1H), 1.97 - 1.88 (m, 1H), 1.87 - 1.79 (m, 1H), 1.70 - 1.57 (m, 7H), 1.51 - 1.44 (m, 2H), 1.27 - 1.21 (m, 12H).

Preparation of 3- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazol-2-yl] -azepan-4-ylamino } propane-1-ol

 The preparation is carried out in 4 stages as described above starting from 3-amino-propan-1-ol. The product is present as hydrochloride.

 75 mg light solid, Rt. = 2.57 min (Method B), LCMS: 442 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 8.75 (s, 2H), 7.74 (d, J = 1.7, 1H), 7.55 (dd, J = 8.2, 1.7, 1H), 7.32 (i.e. , J = 8.3, 1H), 7.10 (s, 1H), 3.93 - 3.86 (m, 1H), 3.67 - 3.60 (m, 1H), 3.58 - 3.50 (m, 2H), 3.48 (t, J = 6.0, 2H), 3.25-3.18 (m, 1H), 3.02-2.22 (m, 2H), 2.35-2.26 (m, 1H), 2.19-2.10 (m, 1H), 2.08-1.99 ( m, 1H), 1.91 - 1.82 (m, 1H), 1.82 - 1.73 (m, 3H), 1.68 - 1.62 (m, 4H), 1.61 - 1.51 (m, 1H), 1.30 - 1.22 (m, 14H).

Preparation of 2- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) thiazol-2-yl] -azepan-4-ylamino } ethanol

 The preparation is carried out in 4 stages as described above starting from 2-aminoethanol. The product is present as hydrochloride.

 29 mg light solid, Rt. = 2.59 min (Method B), LCMS: 428 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 8.86 (s, 2H), 7.74 (d, J = 1.8, 1H), 7.55 (dd, J = 8.2, 1.8, 1H), 7.33 (i.e. , J = 8.3, 1H), 7.11 (s, 1H), 3.94 - 3.85 (m, 1H), 3.72 - 3.61 (m, 3H), 3.60 - 3.46 (m, 2H), 3.28 - 3.18 (m , 1 H), 3.05 - 2.96 (m, H), 2.39-2.28 (m, 1H), 2.22-2.12 (m, 1H), 2.09-1.98 (m, 1H), 1.94-1.81 (m, H), 1.81-1.69 (m, 1H), 1.69 - 1.63 (m, 4H), 1.63 - 1.52 (m, 1H), 1.31 - 1.22 (m, 3H).

Preparation of 2- {3,3-dimethylindan-5-yl) -4,4,5,5-tetramethyl [1,2,2] dioxaborolanes

500 mg (8.36 mmol) of 6-bromo-1,1-dimethyl-indane (preparation see WO 2005 / 66115A2) are dissolved in 5 ml of THF and treated with 733 mg (2.89 mmol) of bis (pinacolato) diboron and 654 mg (6.66 mmol ) Potassium acetate added. The reaction mixture is degassed several times, treated under nitrogen atmosphere with 78 mg (0.11 mmol) of bis (triphenylphosphine) palladium (II) dichloride and stirred overnight at 70 ° C. The reaction mixture is filtered and washed with 75 ml of EA. The filtrate is washed with 50 ml of water, over

Dried sodium sulfate, filtered and concentrated. The crude product is purified by flash chromatography on silica gel.

 140 mg of white solid, Rt. = 3.83 min (Method B), LCMS: 273 (M + H).

Preparation of 2- {8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -4,4,5,5-tetramethyl- [1,3,2] dioxaborolane

The preparation is analogous starting from 1g (4.18 mmol) 7-bromo-1,1-dimethyl-1, 2,3,4-tetrahydro-naphthalenes (preparation see WO2005 / 66115) and 1.38 g (5.44 mmol) bis (pinacolato) diboron.

 844 mg, yellow oil, Rt. = 3.91 min (method B), LCMS: 287 (M + H).

Preparation of 4,4,5,5-tetramethyl-2- (1,1,3,3-tetramethyl-indan-5-yl) - [1,3,2] dioxaborolane:

Step a:

 The bromination of 500 mg (2.87 mmol) of 1,1,3,3-tetramethylindane (see US 2005/148590) is carried out analogously to the instructions in Organic Synthesis, Collective Vol. 3, p. 138 (1995).

 732 mg, yellow oil, Rt. = 3.97 min (Method B).

Step b:

 The preparation is carried out analogously starting from 360 mg (1.42 mmol) of 5-bromo- 1, 1, 3,3-tetramethyl-indane from stage a and 469 mg (1.85 mmol).

 Bis (pinacolato) diboron.

 365 mg, yellow oil, Rt. = 4.07 min (Method B).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ 7.57 (dd, J = 7.5, 1.0, 1H), 7.50 (s, 1H), 7.17 (d, J = 7.2, 1H), 1.90 (s, 2H), 1.31 (s, 12H), 1.30 (s, 6H), 1.28 (s, 6H).

Preparation of 2- {1- [4- (3,3-dimethyl-indan-5-yl) -thiazol-2-yl] -piperidin-4-ylamino} -ethanol

 Step a

Preparation of 1- (4-Bromo-thiazol-2-yl) -piperidin-4-one 1 g (4.12 mmol) of 2,4-dibromo-thiazoles was dissolved in 10 ml of DMF, admixed with 1.06 g (7.82 mmol) of piperidin-4-one hydrochloride and 2.3 ml (16.47 mmol) of triethylamine and stirred at 80 ° C. for 3 days. The reaction mixture was stirred into 300 ml of water and extracted by shaking with EA. The organic phase was dried over sodium sulfate, filtered and concentrated. The purification was carried out by flash chromatography on silica gel.

 500 mg, yellow oil, Rt. = 2.23 min (Method A), LCMS: 262 (M + H).

Step b

 Preparation of 2-H - (4-Bromo-thiazol-2-yl) -piperidin-4-ylamino-ethanol

 100 mg (0.37 mmol) of 1- (4-bromo-thiazol-2-yl) -piperidin-4-one from stage a and 22 μΙ_ (0.37 mmol) of 2-aminoethanol were suspended in 7 ml of THF and stirred at room temperature for 1 h , with 21 μΙ_ (0.37 mmol) of glacial acetic acid and 164 mg (0.74 mmol) of sodium triacetoxyborohydride. The mixture was added overnight

Stirred room temperature, treated with water and EA, with a concentrated

NaOH solution adjusted to pH 12 and extracted by shaking with EA. The organic phase was dried over sodium sulfate, filtered and concentrated.

 122 mg brown residue, LCMS: 307 (M + H), Rt. = 1.78 min (Method A).

Step c

 Preparation of 2-Π -f4- (3,3-dimethyl-indan-5-yl) -thiazol-2-yl-piperidine-4-ylamino-ethanol

 130 mg (0.30 mmol) of 2- [1- (4-bromo-thiazol-2-yl) -piperidin-4-ylamino] -ethanol from step b, 92 mg (0.29 mmol) of 2- (3,3-dimethyl- indan-5-yl) -4,4,5,5-tetramethyl- [1,2,2] dioxaborolane, 92 mg (0.03 mmol)

Tetrakis (triphenylphosphine) palladium (0) and 125 mg (1.18 mmol)

 Sodium carbonate was weighed out, placed under nitrogen. With stirring, 2.5 mL of dioxane and 0.5 mL of water were added. The mixture was degassed, homogenized in an ultrasonic bath and heated for 30 min at 120 ° C in the microwave, diluted with about 20 mL EA and 20 mL of water and filtered off. The phases were separated and the water phase was extracted once more with EA. The organic phases were combined, dried over sodium sulfate, filtered and concentrated. The oily residue was purified by preparative HPLC. The product is present as hydrochloride.

19 mg, light solid, LCMS: 372 (M + H), Rt = 2.47 min (Method B). ¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.45-7.41 (m, 2H), 7.22 (d, J = 8.4, 1H), 4.13 (d, J = 13.6, 2H), 3.70- 3.65 ( m, 2H), 3.45 - 3.31 (m, 3H), 3.06 - 3.02 (m, 2H), 2.83 (t, J = 7.2, 2H), 2.20 (d, J = 10.7, 2H), 1.90 - 1.83 (m , 2H), 1.82 - 1.73 (m, 2H), 1.20 (s, 6H).

Preparation of 2- {1- [4- (1,1,3,3-tetramethyl-indan-5-yl) -thiazol-2-yl] -piperidin-4-ylamino} -ethanol

 The preparation is carried out as described above starting from 1 10 mg (0.29 mmol) 2- [1- (4-bromo-thiazol-2-yl) -piperidin-4-ylamino] -ethanol and 98 mg (0.29 mmol) 4.4 , 5,5-Tetramethyl-2- (1,1,3,3-tetramethylindan-5-yl) - [1,2,2] dioxaborolane. The product is available as formate.

 13 mg, white solid, LCMS: 400 (M + H), Rt = 2.74 min (Method B).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.56 (dd, J = 7.9, 1.7, 1H), 7.49 (d, J = 1.5, 1H), 7.28 (d, J = 7.9, 1H ), 4.22 (d, J = 13.5, 2H), 3.81 - 3.75 (m, 2H), 3.56 - 3.41 (m, 3H), 3.17 - 3.10 (m, 2H), 2.34 - 2.25 (m, 2H), 1.97 (s, 2H), 1.88 (qd, J = 12.6, 4.3, 2H), 1.34 (d, J = 10.6, 12H).

Preparation of 2- {1- [4- (8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} -ethanol

 The preparation is carried out as described above, starting from 100 mg (0.27 mmol) 2- [1- (4-bromo-thiazol-2-yl) -piperidin-4-ylamino] -ethanol and 98 mg (0.30 mmol) of 2- (8 , 8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -4,4,5,5-tetramethyl [1,2,2] dioxaborolane. The product is present as hydrochloride.

 16 mg, light solid, LCMS: 386 (M + H), Rt = 2.62 min (Method B).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.77 (d, J = 1.7, 1H), 7.50 (dd, J = 7.9, 1.8, 1H), 7.12 (d, J = 8.0, 1H ), 4.18 (d, J = 13.4, 2H), 3.76-3.70 (m, 2H), 3.50-3.40 (m, 1H), 3.38-3.27 (m, 2H), 3.14-3.07 (m, 2H), 2.76 (t, J = 6.2, 2H), 2.24 (d, J = 10.3, 2H), 1.85-1.74 (m, 4H), 1.70-1.64 (m, 2H), 1.33-1.29 (m, 6H). Preparation of 1- [4- {5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl-thiazol-2-yl] -piperidin-4-one

The preparation is carried out as described above via a Suzuki reaction starting from 339 mg (1.18 mmol) of 1- (4-bromo-thiazol-2-yl) -piperidin-4-one (preparation described above) and 449 mg (1.30 mmol ) 4,4,5,5-Tetramethyl-2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1, 3,2] dioxaborolane.

 208 mg, bright solid, Rt. = 3.55 min (Method B), LCMS: 369 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.68 (d, J = 1.9, 1H), 7.51 (dd, J = 8.2, 1.9, 1H), 7.44 (d, J = 8.3, 1H ), 4.01 (t, J = 6.3, 4H), 2.71 - 2.68 (m, 4H), 1.70 (s, 4H), 1.30 (d, J = 16.7, 12H).

Preparation of (1R, 2S, 3R) -3- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2-one yl] -piperidin-4-ylamino} -cyclopentane-1,2-diol

 24 mg (0.16 mmol) of (1R, 2S, 3R) -3-amino-cyclopentane-1,2-diol hydrochloride are dissolved in 1 ml of THF and 2 ml of DMF, and 27 μl (0.16 mmol) of DIPEA are added. 60 mg (0.16 mmol) of 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl] -piperidine-4- one are added. The mixture is stirred for 30 min at room temperature, admixed with 18 μΙ (0.32 mmol) of glacial acetic acid and stirred for a further 10 min. Subsequently, 70 mg (0.32 mmol)

 Sodium triacetoxyborohydride added. The reaction mixture is stirred overnight at room temperature, treated with a concentrated sodium bicarbonate solution and extracted 2 times with EA. The organic phase is dried over sodium sulfate, filtered and concentrated. The residue is purified by preparative HPLC. The product is present as hydrochloride.

46 mg, light solid, Rt. = 2.52 min (Method B), LCMS: 470 (M + H). ¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 7.63 (s, 1H), 7.50-7.43 (m, 2H), 4.28-4.18 (m, 2H), 4.13-4.06 (m, 1H), 4.05 - 4.00 (m, 1H), 3.69 - 3.58 (m, 2H), 3.57 - 3.43 (m, 3H), 2.42 - 2.21 (m, 3H), 2.08 - 1.80 (m, 5H), 1.75 - 1.64 ( m, 5H), 1.32 (d, J = 12.5, 13H).

Preparation of (1S, 2R, 3R) -3- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2-one yl] -piperidin-4-ylamino} -cyclopentane-diol

 The preparation is carried out analogously starting from 24 mg (0.16 mmol) of (1S, 2R, 3R) -3-amino-cyclopentane-1,2-diol hydrochloride and 60 mg (0.16 mmol) of 1- [4- (5,5, 8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-one. The product is present as hydrochloride.

 33 mg, light solid, Rt. = 2.50 min (Method B), LCMS: 470 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.44 (d, = 1.5, 1H), 7.33 (d, J = 8.3, 1H), 7.26 (dd, J = 8.2, 1.6, 1H) , 4.07 (d, J = 13.5, 2H), 4.01 - 3.93 (m, 2H), 3.50 - 3.43 (m, 1H), 3.42 - 3.31 (m, 3H), 2.21 (dd, J = 27.2, 12.1, 2H), 1.94-1.85 (m, 1H), 1.85-1.75 (m, 3H), 1.74-1.65 (m, 2H), 1.59 (s, 4H), 1.17 (d, J = 13.3, 12H).

Preparation of (R) -4- {1 - ^ - {SSe-tetramethyl-sec-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} -bu

 The preparation is carried out analogously starting from 22 mg (0.21 mmol) of (R) -4-amino-butane-1,2-diol and 80 mg (0.21 mmol) of 1- [4- (5,5,8,8-tetramethyl- 5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ones. The product is present as hydrochloride.

 52 mg, light resin, Rt. = 2.44 min (method B), LCMS: 458 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.45 (d, J = 1.7, 1H), 7.34 (d, J = 8.3, 1H), 7.27 (dd, J = 8.2, 1.7, 1H ), 4.09 (d, J = 13.6, 2H), 3.65 - 3.57 (m, 1H), 3.43 - 3.31 (m, 5H), 3.12 - 3.00 (m, 2H), 2.17 (d, J = 10.8, 2H ), 1.83-1.72 (m, 3H), 1.71-1.62 (m, 1H), 1.59 (s, 4H), 1.17 (d, J = 13.7, 12H). Preparation of (S) -4- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-l) -thiazol-2-yl] -piperidine -4-ylamino} -b

The preparation is carried out analogously starting from 22 mg (0.21 mmol) of (S) -4-amino-butane-1,2-diol and 80 mg (0.21 mmol) of 1- [4- (5,5,8,8-tetramethyl- 5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ones. The product is present as hydrochloride.

 72 mg, light resin, Rt. = 2.49 min (method B), LCMS: 458 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.69 (s, 1H), 7.50 (d, J = 8.2, 1H), 7.44 (d, J = 8.3, 1H), 4.20 (d, J = 13.4, 2H), 3.68-3.61 (m, 1H), 3.53-3.33 (m, 5H), 3.19-3.09 (m, 2H), 2.26 (d, J = 11.0, 2H), 1.96-1.78 ( m, 3H), 1.76-1.66 (m, 5H), 1.31 (d, J = 17.3, 12H).

Preparation of ((3aS, 4R, 7aR) -2,2-dimethyl-hexahydrobenzo [1,3] dioxol-4-yl) - {1- [4- {5,5,8,8-tetramethyl-5 , 6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} -amine

The preparation is carried out analogously in THF starting from 27 mg (0.16 mmol) of (3aS, 4R, 7aR) -2,2-dimethyl-hexahydro-benzo [1,3] dioxol-4-ylamine and 60 mg (0.16 mmol) of 1 - [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-one. The purification is carried out by flash chromatography on silica gel.

 45 mg, yellow resin, Rt. = 3.02 min (Method B), LCMS: 524 (M + H).

Preparation of (1R, 2S, 3R) -3- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2-one yl] -piperidin-4-ylamino} -cyclohexane-

45 mg ((3aS, 4R, 7aR) -2,2-dimethyl-hexahydro-benzo [1,3] dioxol-4-yl) - {1- [4- (5,5,8,8-tetramethyl-5 , 6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} -amine are mixed with 3 ml_ 1.25 N HCl in methanol and overnight Room temperature stirred. The reaction mixture is concentrated and dried under high vacuum. The product is present as hydrochloride.

 45 mg, light solid, Rt. = 2.55 min (Method B), LCMS: 484 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.61 (s, 1H), 7.43 (d, J = 8.2, 1H), 7.37 (d, J = 8.3, 1H), 4.16-4.08 (m, 2H ), 3.92 (d, J = 2.5, 1H), 3.64- 3.55 (m, 1H), 3.44 (dd, J = 10.1, 2.7, 1H), 3.34 (t, J = 12.8, 2H), 3.25 (td, J = 12.0, 4.0, 1H), 2.19 - 2.03 (m, 3H), 2.02 - 1.92 (m, 1H), 1.84 - 1.68 (m, 2H), 1.68 - 1.60 (m, 5H), 1.46 (i.e. , J = 13.5, 1H), 1.42-1.29 (m, 2H), 1.24 (d, J = 16.6, 12H).

Preparation of (S) -2-amino-3-hydroxy-N- {2- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -] thiazol-2-yl] -ethyl} -propionamide

Stage a

 Preparation of r4- (5,5,8,8-tetramethyl-5.6.7.8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl-acetonitriles

 The preparation is carried out as described above, starting from 576 mg (5.75 mmol) of 2-cyano-thioacetamide and 2 g (4.72 mmol) of 2-bromo-1- (5,5,8,8-tetramethyl-5,6,7,8 tetrahydro-naphthalen-2-yl) -ethanone.

 680 mg, brown oil, Rt. = 3.45 min (Method B), LCMS: 311 (M + H). 1H NMR (500 MHz, DMSO / deuterated TFA) δ = 8.03-8.00 (m, 1H), 7.91 (d, J = 1.8, 1H), 7.70 (dd, J = 8.2, 1.8, 1H), 7.40 (d, J = 8.2, 1H), 1.73-1.67 (m, 4H), 1.34-1.27 (m, 12H).

Stage b

 Preparation of 2-f4- (5.5.8.8-tetramethyl-5.6.7.8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl-ethylamines

680 mg (2.19 mmol) of [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -acetonitrile from step a are dissolved in Dissolved 10 mL of THF, placed under nitrogen, boiled to reflux and treated with 1.21 mL (2.41 mmol) of a 2M borane dimethyl sulfide complex solution in THF. The mixture is further refluxed for 40 minutes, after cooling with a 1.25 M HCl solution in methanol slowly added, concentrated on a rotary evaporator. The residue is in DCM taken up, washed with a saturated sodium bicarbonate solution. The organic phase is dried, filtered and concentrated. The brown oily residue is digested with a little ACN and filtered with suction.

 375 mg, beige crystals, Rt. = 2.48 min (Method B), LCMS: 315 (M + H). Stage c

 Preparation of ((S) -2-hydroxy-1 2-f 4 - (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -thiazol-2-yl-ethylcarbamoyl-dimethyl) -carbamic acid tert-butyl ester

The preparation is carried out as described above starting from 186 mg (0.59 mmol) of 2- [4- (5,5,8 _> 8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazole-2 -yl] - ethylamine from step b and 133 mg (0.65 mmol) of (S) -2-tert-butoxycarbonylamino-3-hydroxy-propionic acid.

 82 mg, brown oil, Rt. = 3.15 min (Method B), LCMS: 502 (M + H).

Stage d

 Preparation of (S) -2-amino-3-hydroxy-N- (2-r4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-vn-ethyl > -propionamide

 The deprotection is carried out as described above with HCl in dioxane starting from 82 mg (0.16 mmol) of ((S) -2-hydroxy-1- {2- [4- (5,5,8,8-tetramethyl-5, 6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -ethylcarbamoyl} -ethyl) -carbamic acid tert-butyl ester from step c. The product is purified by preparative HPLC and is available as formate.

 10 mg, solid, Rt. = 2.36 min (Method B), LCMS: 402 (M + H).

¹ H NMR (400 MHz, DMSO / deuterated TFA) δ = 8.12 (s, 1H), 7.94-7.88 (m, 2H), 7.69 (dd, J = 8.2, 1.9, 1H), 7.40 (dd, J = 8.2, 4.7, 1H), 3.87-3.75 (m, 2H), 3.75-3.67 (m, 2H), 3.65-3.55 (m, 1H), 3.30 (t, J = 6.8, 2H), 1.71 ( s, 4H), 1.31 (d, J = 17.5, 12H).

Preparation of morpholine-2-carboxylic acid [6- (5,5,8,8-tetramethyl-tetrahydro-naphthalen-2-yl) -pyridin-2-yl] -amide

Stage a

 Preparation of 6- (5.5.8.8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -pyridin-2-ylamines

 The preparation is carried out as described above starting from 2.30 g (13.0 mmol) of 6-bromo-pyridin-2-ylamine and 5.22 g (13.7 mmol) of 4,4,5,5-tetramethyl-2- (5,5,8,8 tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1, 3,2] dioxaborolane.

 4.49 g, light solid, Rt. = 2.43 min (Method B), LCMS: 281 (M + H).

¹ H NMR (500 MHz, DMSO / deuterated TFA) δ = 7.83 (dd, J = 8.8, 7.5, 1H), 7.63 (d, J = 1.8, 1H), 7.50-7.41 (m, 2H), 7.02 (d, J = 7.1, 1H), 6.91 (d, J = 8.8, 1H), 1.63 (s, 4H), 1.23 (d, J = 19.6, 12H).

Stage b

 Preparation of 2-r6- (5.5.8.8-tetramethyl-5.6.7.8-tetrahydro-naphthalen-2-yl) -pyridine

2-ylcarbamoyl-morpholine-4-carboxylic acid tert-butyl ester

82 mg (0.36 mmol) of morpholine-2,4-dicarboxylic acid 4-tert-butyl ester and 97 mg (0.39 mmol) of ethyl 2-ethoxy-1,2-dihydroquinoline-1-carboxylate (EEDQ) are dissolved in 2 ml of THF suspended and stirred for 20 min at room temperature. To that Mixture 100 mg (0.36 mmol) of β-iS.SSe-tetramethyl-S.ey.e-tetrahydro-naphthalen-2-yl) -pyridin-2-ylamines from step a are added. The mixture is further stirred overnight, added with water, adjusted to pH 9-10 with a 2N NaOH solution and extracted twice with ΕΞΑ. The combined organic phases are dried, filtered and concentrated (191 mg). The residue is removed by means of

Flash chromatography on silica gel.

 92 mg, white solid, Rt. = 3.97 min (Method B), LCMS: 494 (M + H).

Stage c

 Preparation of morpholine-2-carboxylic acid f6- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -pyridine-2-vn-amides

 The deprotection is carried out as described above with TFA in DCM starting from 92 mg (0.19 mmol) of 2- [6- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-) yl) -pyridin-2-ylcarbamoyl] -morpholine-4-carboxylic acid tert-butyl ester from stage b. The product is purified by preparative HPLC

purified and is present as TFA salt.

 23 mg, solid, Rt. = 2.63 min (Method B), LCMS: 394 (M + H).

¹ H NMR (400 MHz, DMSC7 deuterated TFA) δ = 8.22 - 8.09 (m, 2H), 7.96 (d, J = 2.0, 1H), 7.85 - 7.72 (m, 2H), 7.59 - 7.51 (m, 1 H), 4.68 (dd, J = 10.7, 2.8, 1H), 4.25 (d, J = 13.0, 1H), 4.11 - 3.98 (m, 1H), 3.71 - 3.64 (m, 1H), 3.40 - 3.16 (m, 3H), 1.75 (s, 4H), 1.34 (d, J = 17.6, 12H).

II. Biological assays

The compounds of formula (I) described in the Examples can be tested for kinase inhibitory activity in the assays described below. Other assays are known in the literature and could be readily performed by those skilled in the art (see, eg, Dhanabal et al., Cancer Res. 59: 189-197; Xin et al., J. Biol. Chem. 274: 9116-9121; Sheu et Biol. 38: 237-248; Gimbrone et al., J. Natt Cancer Inst 52: 413-427; Nicosia et al., Anticancer Res. 18: 4435-4441; Ausprunk et al., Dev. In Vitro 18: 538-549).

Tests for Inhibition of SphK1 Activity

test Description

Biochemical assay

 The kinase assay is performed as a 384-well flashplate assay.

5 nM modified SphK1, 800 nM omega-biotinyl-D-erythro-sphingosine and 1 μM ATP (with 0.3pCi ³³ P-ATP / well) are added in a total volume of 50 μM (25 mM HEPES, 5 mM MgCl ₂ , 1 mM dithiothreitol , 0.01% Brij35, 0.1% BSA (fatty acid-free), pH 7.4) with or without test substance (5-10 concentrations) for 120 min at 30 ° C. The reaction is stopped with 25 .mu.l 200 mM EDTA solution, aspirated after 30 min at room temperature and the wells washed 3 times with 100 .mu.l 0.9% NaCl solution. The unspecific portion of the kinase reaction (blank) is determined with 0.5 mM NaCl. Radioactivity is measured in the topcount. IC ₅ o values are calculated with RS1.

In addition to checking the activity of the substance on the purified SphK1 enzyme, it is necessary in the next step to investigate whether the substances SphK1 also in its physiological environment, i. in the cytoplasm of the cell. For this purpose, the formation of S1 P in U20S osteosarcoma cells, which overproduced the enzyme by introducing modified SphK1 cDNA, is measured by two different methods:

1. The cells are incubated with substances for 1 hour and then with tritiated sphingosine for 15 minutes. The radioactively labeled sphingosine is taken up by the cells during this time and converted from SphK1 to S1P. The cells are then washed and lysed with ammonia solution. Not around S1 P To separate reacted sphingosine, an extraction is carried out by adding a chloroform-methanol mixture. While sphingosine for the most part goes into the organic phase, S1 P accumulates in the aqueous phase and is quantified using a scintillation counter.

2. The cells are incubated with substances for 1 hour and then with sphingosine for 15 minutes. The sphingosine is released from the cells at this time

and converted from SphK1 to S1P. The cells are then washed and lysed with methanol. The methanol solution is then evaporated and the S1P taken up in lipid-free serum. The quantification of S1P is carried out using an S1P-specific antibody by means of a competitive ELISA assay. The biotin-linked S1P antibody is incubated with the sample solution and this mixture is transferred to a well whose bottom is coated with S1P. Only those antibodies which have not yet bound S1P from the sample solution bind to the S1P immobilized on the plate and can be coupled after a washing step by addition of horseradish peroxidase

Streptavidin can be quantified. For this purpose, the substrate TMB is added, which can be absorbed and measured after conversion by the peroxidase at a wavelength of 450 nm. A high signal thus corresponds to a low S1 P concentration in the sample solution and a low signal corresponding to a high S1P concentration.

Pharmacological data

SphK1 inhibition

 (IC50 ranges: A: <100 nM, B: 100 nM - 1000 nM, C:> 1000 nM)

Table 2

 Invention compound ICso

1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] -piperidin-4-ylamine

 l-K-iS.S.e.e-tetramethyl-S.ej.e-tetrahydro-naphthalen ^ -yl) -

B

 thiazol-2-yl] piperazines

 2- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] piperazine-1-yl} -ethanol

 3- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

thiazol-2-yl] piperazine-1-yl} -propan-1-ol 5- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] piperazin-1-yl} pentan-1-ol

 (1 H -imidazol-4-ylmethyl) - {1 - ^ - (SSe-tetramethyl-S.e.e.-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} amines

 4- (2-pyrrolidin-1-yl-ethyl) -1- [4- (5,5,8,8-tetramethyl-5,6,7,8-

B

 tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidine

 l - ^ - iS.S.e.e-tetramethyl-ö.ej.e-tetrahydro-naphthalen ^ -yl) -

B

 thiazol-2-yl] - [4,4 '] bipiperidinyl

 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

C

 thiazol-2-yl] -piperidine-4-carboxylic acid ethyl ester

 l-il - ^ - iS.S.e.e-tetramethyl-S.ey.e-tetrahydro-naphthalen ^ -yl) -

B

 thiazol-2-yl] -piperidin-4-yl} -pyrrolidin-3-ylamine

 C- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] -piperidin-4-yl} -methylamine

 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] -pyrrolidin-3-ylamine

 2- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] -piperidin-4-yl} -ethylamine

 4- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

C

 thiazol-2-yl] -piperidin-4-yl} -morpholines

l-MethyM-il - ^ - iS.S.e.e-tetramethyl-S.ej.S-tetrahydro-naphthalene

B

 2-yl) -thiazol-2-yl] -piperidin-4-yl} -piperazines

 3- {1- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -4-thiazol-2-yl] -piperidine-yl-amino} propanes-1,2-diol

 3- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] -3,9-diaza-spiro [5.5] undecane

 (3-methyl-3H-imidazol-4-ylmethyl) - {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-

B

 tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} -amine

 3- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] -piperidine

 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

C

 thiazol-2-yl] -piperidines-4-carboxylic acid (2-hydroxy-ethyl) -amides a ^. ^^ S ^^. e-tetramethyl-S.ey.S-tetrahydro-naphthalen ^ -yl) -

B

 thiazol-2-yl] piperazin-1-yl} -propane-1,2-diol

 Bis- (1H-pyrazol-3-ylmethyl) - {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-

B

 tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} -amine

 2- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

A

 thiazol-2-yl] -piperidin-4-ylamino} -ethanol

 r- -IS.S.S.e-tetramethyl-S. e.e.-tetrahydro-naphthalene-1-yl) -

B

 thiazole ^ -ylHI ^ Jbipiperidinyl-S-ol

 3-i1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -1-thiazol-2-yl] -piperidin-4-yl} -propane-ol

2- {1- [4- (5 _l, 5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

thiazol-2-yl] -piperidin-3-yl} -ethanol 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] -piperidine-3-carboxylic acid (2-hydroxy-ethyl) -amide

 1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

C

 thiazol-2-yl] -piperidine-3-carboxylic acid (3-hydroxypropyl) amides

3- {1- [4- (5 _I 5.8 _l 8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

C

 thiazol-2-yl] -piperidin-3-yl} -propan-1-ol

 (R) -1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] -pyrrolidin-3-ylamine

 (S) -1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] -pyrrolidin-3-ylamine

 DimethyK1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-

A

 yl) -thiazol-2-yl] -piperidin-4-yl} -amine

4- [4- ₍₅₎ 5,8,8-tetramethyl-5 ₁ 6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] -cyclohexylamine

 N-IHI K iS.S.e.S-tetramethyl-ö.ej.e-tetrahydro-naphthalene ^ yl) -

A

 thiazol-2-yl] -piperidin-4-yl} -pyrrolidin-3-yl) -acetamide

 2- {4- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] -piperazin-1-yl} -cyclohexanol

 2-pyrrolidin-3-yl-4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-

B

 naphthalen-2-yl) -thiazoles

 1- [4- (5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -

B

 piperazine

4- {4- [4- _{(5> 5-tetramethyl-i} 8.8 5.6 _I 7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] -piperazin-1-yl} -butan-1-ol

 1- [4- (5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -

B

 piperidin-4-ylamine

 1-I4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-4-yl] -piperidin-1-yl} -ethanone

2- (4- {1- [4- (5,5,8,8-Tetramethyl-5 _I 6.7 _l 8-tetrahydro-naphthalen-2-yl) -]

B

 thiazol-2-yl] -piperidin-4-yl} -piperazin-1-yl) ethanol

 4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-4-yl] -piperidine

 S-il - ^ - iS.S.e.S-tetramethyl-S.ej.e-tetrahydro-naphthalene ^ yl) -

A

 thiazol-2-yl] -piperidin-4-ylamino} -propan-1-ol

4- {4- [4- (5 _i 5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-

B

 yl] piperazin-1-yl} -butan-1-ol

 S ^ - ^^ S ^ -Dimethyl-S.ej.e-tetrahydro-naphthalene ^ -y-thiazole ^ -

C

 yl] -piperazin-1-yl} -pentan-1-ol

 (R) -2-amino-3- {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-

B

 naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} -propan-1-ol

2 - {(R) -1- [4- (5,5,8,8-tetramethyl-5,6 _l 7,8-tetrahydro-naphthalen-2-yl) -]

C

 thiazol-2-yl] -pyrrolidin-3-ylamino} -ethanol

 3 (S) -1- [4- (5,5,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -]

C

thiazol-2-yl] -pyrrolidin-3-ylamino} -propan-1-ol 2- {3- [4- (5,5,8,8-tetramethyl-5 ₁ 6 ₁ 7,8-tetrahydro-naphthalen-2-yl) -

B

 thiazol-2-yl] -piperidin-1-yl} -ethanol

3- {3- [4- _(5,5> 8 ₁ 8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

C

 thiazol-2-yl] piperidin-1-yl} -propan-1-ol

 - (5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -2-pyrrolidin-3-yl

B

 thiazoles

 4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

C

 oxazol-5-yl] -piperidine

 4- {3- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

C

 thiazol-2-yl] piperidin-1-yl} -butan-1-ol

5- {3- [4- (5 ₁ 5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -

C

 thiazol-2-yl] -piperidin-1-yl} -pentan-1-ol

 4- {3- [4- (5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-

B

 yl] -pyrrolidin-1-yl} -butan-1-ol

 543- [4- (5,5-Dimethyh5,6J, 8-tetrahydro-naphthalen-2-yl) -thiazol-2-

B

 y l] -pyrrolidin-1-yl} -pentan-1-ol

 (^ -S-il - ^ - iS.S.e.e-tetramethyl-S.ey.e-tetrahydro-naphthalene ^ yl) -

B

 thiazole-1-yl-piperidine-1-yl-aminol-propane-1-diol

 (SJ-S-il K iS.S.e.e-tetramethyl-S.ey.S-tetrahydro-naphthalene ^ yl) -

A

 thiazol-2-yl] -piperidin-4-ylamino} -propane-1,2-diol

 2 - [{1- [4- (5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-

B

 yl] -piperidin-4-yl} - (2-hydroxy-ethyl) -amino3-ethanol

 2 - ((2-hydroxy-ethyl) - {1- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-

B

 naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-yl} -amino) -ethanol

 1 - [4- (1,1-dimethyl-indan-5-yl) -thiazol-2-yl] -piperidin-4-ylamine B

2- {1- [4- (1,1-dimethyl-indan-5-yl) -thiazol-2-yl] -piperidin-4-ylamino} -

B

 ethanol

 3- {1- [4- (1,1-dimethyl-indan-5-yl) -thiazol-2-yl] -piperidin-4-ylamino} -

B

 propane-1-ol

 (S, ^ -Amino-S-il - ^ - iS.SSS-tetramethyl-S. E.e.-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -piperidin-4-ylamino} -propane-1 -oil

Claims

claims

1. Compounds according to the formula (I)

 in which, independently of one another, mean:

R1 D ² D ³ D ⁴ D ⁵ D ⁶ D ⁷ D ⁸ D ⁹ D ¹⁰ D ¹¹ , D Γχ ² , D Γ ¹³ , D ⁴ D ¹⁵ D ¹⁶ DH, D

(Deuterium), Α, OR ¹⁸ , CN, F, Cl and NR ¹⁸ R ¹⁸ ;

where R ¹ and R ² , R ³ and R ⁴ , R ⁵ and R ⁶ , R ¹⁰ and R ¹¹ , R ¹² and R ³ , R ¹⁴ and R ¹⁵ , R ¹⁶ and R ¹⁷ together are each also = 0 (carbonyl oxygen) can form;

wherein R ⁹ and R ¹ , R ¹ and R ² , R ² and R ³ , R ³ and R ⁴ , R ⁴ and R ⁵ , R ⁵ and R ⁶ , R ⁶ and R ⁷ , R ⁷ and R ⁸ , R ¹⁰ and R ¹¹ , R ¹¹ and R ¹² , R ¹² and R ¹³ , R ¹⁴ and R ¹⁵ , R ¹⁵ and R ¹⁶ , R ¹⁶ and R ¹⁷ together are each also cyclic alkyl having 3, 4, 5, 6 or 7 C. Atoms or Het with 3, 4, 5, 6 or 7 ring atoms can form;

wherein R ¹⁰ and R ¹⁹ when Y = CR ¹⁹ , R ¹¹ and R ¹² , R ¹³ and R ¹⁹ when Y ₂ =

CR ¹⁹ , R ¹⁴ and R ¹⁹ when Y = CR ¹⁹ , R ¹⁵ and R ¹⁶ , R ¹⁷ and R ¹⁹ when Y ₂ = CR ^{19 taken} together also each with the single bond and the C atoms to which they are attached , can form a C = C double bond;

R ^18, R ^{18 'is} H, D, or A;

, 18> 18 _D 1

R ¹⁹ R ^{19 '} H, D, A, OR ^1B , NR ^1B R ^1B 8', C (0) OR ¹ 1 ^B 8, C (O) NR> ¹ 1 ^B 8Ro ¹ 1 ^B 8 ·, F, Cl , Br, CN,

Het or A-Het;

ML M ₂ , M ₃ , CR ¹⁹ , N, S or O;

VC (R ¹⁹ ) (R ^{19 '} ), NR ¹⁹ or missing;

WC (R ¹⁹ ) (R ^{19 '} )] _p Z, CO- [C (R ⁹ ) (R ^9' )] _p Z, [C (R ⁹ ) (R ^{19 '} )] _P N (R ¹⁹ ) Z, CO-N (R ¹⁹ ) - [C (R ¹⁹ ) (R ^{19 '} )] _p Z, N (R ¹⁹ ) -CO- [C (R ¹⁹ ) (R ^19' )] _p Z, CO- 0- [C (R ¹⁹ ) (R ^{19 '} )] _p Z, C (0) OR ¹⁹ , OR ¹⁹ , H or D; where V, W and Y ₂ together are each also cyclic alkyl having 3, 4, 5, 6 or 7 C atoms, wherein preferably 1, 2, 3, 4, 5, 6 or 7 H atoms by F, Cl, Br , CN and / or OH, OR ¹⁹ , OC (O) R ¹⁹ , NR ¹⁹ C (O) OZ, C (O) OR ¹⁹ ,

C (O) N (R ¹⁹ ) (R ^{19 '} ) or N (R ¹⁹ ) (R ^19' ) may be replaced, or Het with 3, 4, 5, 6 or 7 ring atoms can form, wherein Het preferably a saturated , unsaturated or aromatic heterocycle having 1 to 4 N, O and / or S atoms, which is unsubstituted or mono-, di- or trisubstituted by Hal, F, Cl, Br, CN, A, OR ¹⁸ , W, SR ¹⁸ , N0 ₂ ,

N (R ⁹ ) (R ^{19 '} ), NR ⁸ COOZ, OCONHZ, NR ¹⁸ S0 ₂ Z, S0 ₂ N (R ¹⁸ ) Z, S (0) _m Z, COZ, CHO, COZ, = S, = NH , = NA, Oxy (-O) and / or = 0

 (Carbonyl oxygen) may be substituted;

 Z Het, Ar or A;

A is unbranched or branched alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, wherein 1, 2, 3, 4, 5, 6 or 7 H atoms by F, Cl , Br, CN and / or OH, OR ¹⁹ , OC (O) R ¹⁹ , NR ¹⁹ C (O) OZ, C (O) OR ¹⁹ ,

C (O) N (R ¹⁹ ) (R ^{19 '} ) or N (R ¹⁹ ) (R ^19' ) may be replaced;

and / or wherein one or two CH ₂ groups are represented by O, S, SO, SO ₂ , CO, COO, NR ¹⁸ , NR ¹⁸ CO, CONR ⁸ , cyclic alkyl having 3, 4, 5, 6 or 7 C atoms , CH = CH and / or CH = CH groups may be replaced;

or cyclic alkyl having 3, 4, 5, 6 or 7 C atoms, in which 1, 2, 3, 4, 5, 6 or 7 H atoms are represented by F, Cl, Br, CN and / or OH, OR ¹⁹ , OC (O) R ¹⁹ , NR ¹⁹ C (O) OZ, C (O) O ¹⁹ , C (O) N (R ¹⁹ ) (R ^{19 '} ) or N (R ¹⁹ ) (R ^19' ) may be replaced ;

Ar is mono-, di- or trisubstituted by Hal, F, Cl, Br, CN, A, OR ¹⁸ , W, SR ¹⁸ , NO ₂ , N (R ¹⁹ ) (R ^{19 '} ), NR ¹⁸ COOZ, OCONHZ, NR ⁽¹⁸ R) Z, S Z ¹⁸ S0 _2, S0 ₂ N (0) _m Z, COZ, CHO, COZ substituted phenyl, naphthyl or biphenyl,

 Het independently one, two or three nuclear

saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and / or S atoms which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, F, Cl, Br, CN, A, OR ¹⁸ , W, SR ¹⁸ , NO ₂ , N (R ⁹ ) (R ^{19 '} ), NR ¹⁸ COOZ, OCONHZ, NR ¹⁸ SO ₂ Z, SO ₂ N (R ⁸ ) Z, S (O) _m Z, COZ, CHO, COZ , = S, = NH, = NA, oxy (-0) and / or = 0 (carbonyl oxygen) may be substituted,

m 1, 2 or 3,

n, o is 0, 1 or 2,

p is 0, 1, 2, 3 or 4

with the proviso that compounds of formula (I) are excluded, wherein (a) M _! = N, M ₂ = CR ¹⁹ , M ₃ = S, and

(b) = CH and Y ₂ = N, and

 (c) n = 1 and o = 1;

 and their physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, including mixtures thereof in all

Conditions.

2. Compounds according to claim 1, wherein each independently of one another mean:

F, OR ¹⁸ or A;

where R ¹ and R ² , R ³ and R ⁴ , R ⁵ and R ⁶ , R ⁰ and R ¹¹ , R ¹² and R ¹³ , R ¹⁴ and R ¹⁵ , R ¹⁶ and R ¹⁷ together are each also = 0 (carbonyl oxygen) can form;

wherein R ⁹ and R ¹ , R ¹ and R ² , R ² and R ³ , R ³ and R ⁴ , R ⁴ and R ⁵ , R ⁵ and R ⁶ , R ⁶ and R ⁷ , R ⁷ and R ⁸ , R ⁰ and R ¹¹ , R ¹¹ and R ¹² , R ² and R ¹³ , R ¹⁴ and R ¹⁵ , R ¹⁵ and R ¹⁶ , R ¹⁶ and R ¹⁷ together are each also cyclic alkyl having 3, 4, 5, 6 or 7 C. Atoms or Het with 3, 4, 5, 6 or 7 ring atoms can form;

R ¹⁹ , R ¹⁹ H, A, OR ¹⁸ , C (O) OR ¹⁸ , C (O) NR ¹⁸ R ^{18 '} , A-Het;

M ₁ N, and M ₂ CR ¹⁹ and M ₃ S; or

Μτ N, and M ₂ S and M ₃ CR ¹⁹ ; or

M _n O, and M ₂ N and M ₃ CR ¹⁹ ; or

Mi N, and M ₂ O and M ₃ CR ¹⁹ ; or

MS, and M ₂ N and M ₃ N; or

M ₁ S, and M ₂ N and M ₃ CR ¹⁹ ; or

M _n O, and M ₂ N and M ₃ N; or

Mi N, and M ₂ N and M ₃ O; or

N, and M ₂ N and M ₃ S; or

M _n CR ¹⁹ , and M ₂ N and M ₃ O; or

M, CR ¹⁹ , and M ₂ O and M ₃ N; Υι Ν, and Υ ₂ CR ¹⁹ ; or

Υι Ν, and Υ ₂ Ν; or

Υι CR ¹⁹ , and Υ ₂ Ν; or

VC (R ¹⁹ ) (R ^{19 '} ), NR ¹⁹ or missing;

W [C (R ¹⁹ ) (R ^{19 '} )] _p Z, CO- [C (R ¹⁹ ) (R ^19' )] _p Z, CO-O- [C (R ¹⁹ ) (R ^{19 '} )] _p Z, CO-N (R ¹⁹ ) -

[C (R ¹⁹ ) (R ^{9 '} )] _p Z, [C (R ¹⁹ ) (R ^19' )] _P N (R ¹⁹ ) -Z, N (R ¹⁹ ) -CO- [C (R ⁹ ) (R ^{9 '} )] _p Z,

C (0) OR ¹⁹ , OR ¹⁹ or H;

where V, W and Y ₂ together are each also cyclic alkyl having 3, 4, 5, 6 or 7 C atoms, wherein preferably 1, 2, 3, 4, 5, 6 or 7 H atoms by F, Cl, Br , CN and / or OH, OR ¹⁹ , OC (O) R ¹⁹ , NR ¹⁹ C (O) OZ, C (O) OR ¹⁹ ,

C (O) N (R ¹⁹ ) (R ^{19 '} ) or N (R ¹⁹ ) (R ^19' ) may be replaced, or Het with 3, 4, 5, 6 or 7 ring atoms can form, wherein Het preferably a saturated , unsaturated or aromatic heterocycle having 1 to 4 N, O and / or S atoms, which is unsubstituted or mono-, di- or trisubstituted by Hal, F, Cl, Br, CN, A, OR ¹⁸ , W, SR ¹⁸ , NO ₂ , N (R ⁹ ) (R ^{19 '} ), NR ¹⁸ COOZ, OCONHZ, NR ¹⁸ S0 ₂ Z, SO ₂ N (R ¹⁸ ) Z, S (0) _m Z, COZ, CHO, COZ , = S, = NH, = NA, Oxy (-O) and / or = 0

 (Carbonyl oxygen) may be substituted;

 Z Het or A;

 m is 1 or 2;

 p is 0, 1, 2 or 3;

 and their physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, including mixtures thereof in all ratios.

3. compounds selected from the group consisting of:

 251

253

Ġ 10



257

259

262

5

264

265

266

267

268

270

271

272

274

276

277

4. A process for the preparation of compounds according to any one of claims 1 to 3 and their physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, characterized in that

wherein R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ R ⁷ , R ⁸ , R ⁹ and m have the meanings given in claim 1 and has the meaning given below, with a compound of formula (III)

wherein R ⁰ , R ¹¹ , R ¹² , R ³ , R ¹⁴ , R ¹⁵ , R ¹⁶ , R ¹⁷ , Y _{1 t} Y ₂ , V, n, and o have the meanings given in claim 1, L ₂ below Has meaning, "VH" is optionally provided with a protective group ("V-protection group"), and possibly still below specified connection steps are performed,

O

implements,

and

the compound of formula (IV) resulting from step (a)

wherein R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ R ⁷ , R ⁸ , R ⁹ , R ¹⁰ , R ¹¹ , R ¹² , R ³ , R ⁴ , R ⁵ , R ¹⁶ , R ¹⁷ , M ¹ M ² , M ³ , YL Y ₂ , V, m, n, and o and m are as defined in claim 1

meanings if necessary freed from the protective group ("V-protective group") and with a

 Compound of the formula (V)

 L-W (V)

 wherein W has the meaning given in claim 1 and L is Cl, Br, I or a free or reactively functionally modified OH group,

or

(c) releasing them from one of their functional derivatives (e.g., with protecting groups) by treatment with an acidic, basic, solvolyzing or hydrogenolysing agent,

and / or converting a base or acid of formula (I) into one of its salts.

Medicament comprising one or more compounds according to any one of claims 1 to 3 and their physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, including mixtures thereof in all ratios.

A pharmaceutical composition comprising one or more compounds according to any one of claims 1 to 3 and their physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers, including mixtures thereof in all ratios, for use in the treatment of diseases resulting from the inhibition of sphygmomania. Kinase 1 are influenced by the compounds according to any one of claims 1 to 3.

7. The pharmaceutical composition according to claim 6, wherein the diseases to be treated are selected from the group consisting of: "hyperproliferative Disease, inflammatory disease, angiogenic disease, fibrotic disease of the lung, kidney, liver and heart, cancer

(Tumor disease), atherosclerosis, restenosis, proliferative disease of the mesangial cells, psoriasis, squamous cell tumor, bladder, stomach, kidney, head and neck, esophagus,

Cervix, thyroid, intestine, liver, brain, prostate, genitourinary tract, lymphatic system, stomach, larynx, lungs, skin, monocytic leukemia, lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma, breast carcinoma, acute myeloid leukemia, chronic myeloid

Leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndrome, graft rejection, glomerulopathy, inflammatory

Intestinal disease, arthritis, asthma, allergies, inflammatory

Kidney disease, multiple sclerosis, chronic obstructive

Pulmonary disease, inflammatory skin diseases, Pardontal diseases, T cell-mediated immune disease, ulcerative colitis, Crohn's disease, indeterminate colitis, allergic encephalomyelitis, allergic neuritis, graft rejection, graft-versus-host reaction, myocarditis, thyroiditis, nephritis, systemic lupus erythematosus, insulin-dependent diabetes mellitus, rheumatoid arthritis, osteoarthritis, Caplan syndrome, Felty syndrome, Sjögren syndrome, ankylosing spondylitis, Still's disease

Chondrocalcinosis, metabolic arthritis, rheumatic fever, Reiter's syndrome, Wissler syndrome, glomerulonephritis, glomerular injury, nephrotic syndrome, interstitial nephritis, lupus nephritis, Goodpasture syndrome, Wegener's granulomatosis, renal vasculitis, IgA nephropathy, idiopathic glomerular disease, atopic dermatitis,

Contact sensitivity, acne, diabetic retinopathy, Kaposi's sarcoma, hemangioma, myocardial angiogenesis, atherosclerotic plaque neovascularization, angiogenic eye diseases, choroidal

Neovascularization, retrolental fibroplasia, macular degeneration, corneal graft rejection, rubeosis iridis, neuroscular glaucoma, Oster Webber syndrome ".

8. Medicament according to one of claims 5 to 7, wherein such a

Medicament contains at least one additional pharmacologically active substance (therapeutic, drug, ingredient).

9. Medicament according to one of claims 5 to 7, wherein the medicament is applied before and / or during and / or after treatment with at least one additional pharmacologically active substance.

A pharmaceutical composition comprising a therapeutically effective amount of at least one compound according to any one of claims 1 to 3.

Pharmaceutical composition according to claim 10 containing at least one additional compound selected from the group consisting of physiologically acceptable extenders, excipients, additives, thinners, carriers and / or additional

 pharmaceutically active substance except the compounds according to any one of claims 1 to 3.

A kit comprising a therapeutically effective amount of at least one compound according to any one of claims 1 to 3 and / or at least one pharmaceutical composition according to any one of claims 10 to 11 and a therapeutically effective amount of at least one further pharmacologically active substance other than the compounds according to any one of claims 1 to third

Compounds selected from the group consisting

25

 30

35

14. A method for the treatment of diseases according to any one of claims 6 or 7 comprising the administration of one or more compounds according to any one of claims 1 to 3 to a patient in need of such administration.